The extensive proliferation of human cancer cells with ever-shorter telomeres by Dagg, Rebecca Ann
1 
 
 
THE EXTENSIVE PROLIFERATION OF HUMAN 
CANCER CELLS WITH EVER-SHORTER TELOMERES 
 
 
Rebecca Dagg 
A thesis submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy 
 
Faculty of Medicine 
The University of Sydney 
2017
i 
 
Statement of Originality  
This is to certify that to the best of my knowledge, the content of this thesis is my own work. This 
thesis has not been submitted for any degree or other purposes. 
 
I certify that the intellectual content of this thesis is the product of my own work and that all the 
assistance received in preparing this thesis and sources have been acknowledged. 
 
 
Rebecca Dagg 
 
 
ii 
 
Abstract 
Cellular immortalisation is currently regarded as an essential step in malignant transformation and is 
consequently considered a hallmark of cancer. Acquisition of replicative immortality is achieved by 
activation of a telomere lengthening mechanism (TLM), either telomerase or the alternative 
lengthening of telomeres (ALT), to counter normal telomere attrition. However, a substantial 
proportion of glioblastomas, liposarcomas, retinoblastomas, and osteosarcomas are reported to be 
TLM-negative. The lack of serial untreated malignant human tumour samples over time has made it 
impossible to examine telomere length over time and therefore determine whether they are truly 
TLM-deficient, or whether this is the result of false-negative assays. Here we describe a subset (11%) 
of high-risk neuroblastomas (NB; MYCN-amplified or metastatic disease) that lack evidence of any 
significant TLM activity despite a 51% 5-year mortality rate. NB cell lines (COG-N-291 and LA-N-6) 
derived from such tumours proliferated for 500 population doublings (PDs) with ever-shorter 
telomeres (EST). COG-N-291 and LA-N-6 cells had exceptionally long and heterogeneous telomere 
lengths as measured by terminal restriction fragment (TRF) analysis (mean TRF of 31 and 37.8 kb, 
respectively) and telomere fluorescence in situ hybridisation. Both cell lines were telomerase negative 
during culturing and did not have elevated markers of ALT or associated gene mutations. The 
telomeres of these cells shortened by 80 and 55 bases/PD, consistent with telomere attrition due to 
normal cell division, but did not reach senescence after 500 PDs in culture. This is conclusive evidence 
that cells from highly malignant, lethal tumours are able to undergo continuous proliferation in spite 
of an EST phenotype. The EST phenotype was rescued by activation of telomerase (via transduction 
with hTERT expression constructs) or ALT (spontaneous occurrence of a nonsense TP53 mutation, 
followed by spontaneous activation of ALT after 100 PDs). We also found that NB EST cells are very 
sensitive to topoisomerase I inhibitors indicating the potential to target the EST phenotype with 
topoisomerase I inhibitors in high-risk NB.   
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Chapter 1: Introduction 
1.1. Telomere biology 
1.1.1. Telomeres and chromosome end-protection 
Chromosomes contain genetic material that must be conserved for correct cellular function. The linear 
chromosomes of mammalian cells terminate with 3-12 kilobases (kb) of tandem arrays of TTAGGG 
repeats (Moyzis et al., 1988), known as the telomere. The proximal 2 kb region of human telomeres 
consist of non-random arrays of variant (TCAGGG, TGAGGG, and TTGGGG) and canonical (TTAGGG) 
repeats (Allshire et al., 1989; Baird et al., 1995; Coleman et al., 1999). The telomere sequence is 
predominantly double-stranded with the terminal 100-200 bases on the G-rich strand ending in a 3’ 
single-stranded overhang (Makarov et al., 1997) (Figure 1.1.A). To prevent recognition of the telomeric 
3’ overhang as a double-stranded DNA (dsDNA) break which would lead to activation of a DNA damage 
response (DDR) at chromosome ends or chromosome end-to-end fusion, the telomere forms a protein-
DNA complex that can induce a unique chromatin structure at the telomere known as the T-loop (Griffith 
et al., 1999) (Figure 1.1.B). A T-loop is formed when the 3’ overhang invades the upstream duplex 
telomeric DNA forming a Holliday junction (HJ) (Liu and West, 2004) before annealing to the 
complementary C-rich strand inducing a displacement or D-loop (Figure 1.1.B). This sequesters the 
single-stranded telomeric DNA and provides a protective cap that defines the end of the chromosome, 
ultimately preventing it initiating a DDR (de Lange, 2004).  
  Telomeres provide specific binding sites for a number of proteins, of which the six-subunit 
protein complex known as shelterin is the best characterised. The shelterin complex is involved in the 
formation and stabilisation of the T-loop structure and is critical to preventing a DDR at the telomere 
(Liu et al., 2004a; Ye et al., 2004c) (Figure 1.1.C, D). The shelterin complex binds to telomeric DNA 
through three sequence-specific DNA binding proteins: telomeric repeat binding factor 1 (TRF1) and  
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Figure 1.1. Structure of the human telomere.  
(A) The human telomere is a predominantly double-stranded sequence of (TTAGGG)n repeats that 
ends in a 3’ single-stranded overhang of 100-200 bp on the G-rich strand. (B) The single-stranded 3’ 
overhang can invade the duplex sequence to form a T-loop. (C & D) The shelterin complex is able to 
bind telomeric DNA through TRF1 and TRF2 interaction with the dsDNA of the telomere and through 
POT1 binding to the ssDNA of the 3' overhang or the D-loop. TIN2 and TPP1 connect POT1 to TRF1 
and TRF2 and RAP1 binds directly to TRF2.   
 
telomeric repeat binding factor 2 (TRF2) which bind directly to double-stranded telomeric DNA 
(Benarroch-Popivker et al., 2016; Bilaud et al., 1997; Broccoli et al., 1997; Chong et al., 1995; van 
Steensel et al., 1998), and protection of telomeres 1 (POT1) which specifically binds to the single-
stranded telomeric DNA (Baumann and Cech, 2001; Loayza et al., 2004). TRF1 mediates T-loop formation 
by bending the dsDNA, and this allows the single-stranded overhang to invade the duplex telomere 
sequence and form a HJ, a process mediated by TRF2 (Griffith et al., 1999; Stansel et al., 2001). 
Telomeres represent a challenge to the DNA replication machinery and cells require TRF1 to ensure 
efficient telomere replication (Chastain et al., 2016; Martinez et al., 2009; Sfeir et al., 2009; Stewart et 
al., 2012). TRF2 prevents an ataxia telangiectasia mutated (ATM) dependent DDR (Celli and de Lange, 
2005; Denchi and de Lange, 2007; Karlseder et al., 2004) through two mechanisms: firstly the formation 
and stabilisation of the T-loop structure (Doksani et al., 2013; Griffith et al., 1999; Poulet et al., 2009) 
which prevents classical non-homologous end joining (NHEJ) at telomeres (Smogorzewska et al., 2002; 
van Steensel et al., 1998) or cleavage of the structure by resolvases (Poulet et al., 2009) and secondly, 
by direct inhibition of ATM (Okamoto et al., 2013). TRF2 recruits and binds the shelterin component 
repressor-activator protein 1 (RAP1) to the telomere, which aids in suppressing illegitimate 
recombination events at telomeres (Li et al., 2000; Martinez et al., 2010; Sfeir et al., 2010; Ye and de 
Lange, 2004). The fifth component of the shelterin complex, TRF1- and TRF2-interacting nuclear factor 
2 (TIN2), can bind both TRF1 and TRF2 and acts to stabilise the binding of these two proteins to the 
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telomere (Houghtaling et al., 2004; Kim et al., 2004; Kim et al., 1999; Liu et al., 2004a; Ye et al., 2004c). 
TPP1, the final component of the shelterin complex, directly binds to POT1 and with TIN2 mediates POT1 
interaction with TRF1 and TRF2 (Frescas and de Lange, 2014a; Frescas and de Lange, 2014b; Liu et al., 
2004b; Takai et al., 2011; Ye et al., 2004b). The TPP1/POT1 complex suppresses ataxia telangiectasia 
and Rad3 related (ATR) dependent DNA repair (Denchi and de Lange, 2007; Wu et al., 2006), likely 
through exclusion of the DDR protein replication protein A (RPA) from the single-stranded overhang 
(Gong and de Lange, 2010).  
In addition to the T-loop, telomeres can form G-quadruplex secondary structures. G-
quadruplexes are formed by G-rich DNA sequences which are able to associate with each other by 
Hoogsteen base pairing (Gellert et al., 1962; Gilbert and Feigon, 1999). G-quadruplexes have been 
detected in telomere sequence in vitro (Sen and Gilbert, 1988; Sundquist and Klug, 1989) and in vivo in 
organisms including ciliates (Paeschke et al., 2008; Paeschke et al., 2005) and humans (Biffi et al., 2013). 
Such structures can induce DNA damage at the telomere and hence must be unfolded by helicases 
including Bloom syndrome helicase (BLM) for correct cellular functions including DNA replication (Wu 
et al., 2015). 
1.1.2. Telomeric chromatin 
DNA is condensed into chromatin, a structure comprised of DNA bound to histone proteins, to allow all 
genetic material to fit into the nucleus of a cell. Chromatin also provides a mechanism to regulate DNA 
processes such as transcription. There are two types of chromatin; heterochromatin and euchromatin. 
Heterochromatin is a compact structure that renders the DNA transcriptionally inactive and is 
consequently associated with gene sparse regions of the chromosome (Pontecorvo, 1944). In contrast, 
euchromatin is less condensed and therefore found in regions of the genome that are transcriptionally 
active (Pontecorvo, 1944). The nucleosome is the basic subunit of chromatin and is comprised of 147 
base pairs (bp) of DNA wrapped tightly around a disc-shaped histone octamer (Kornberg, 1974; 
Kornberg and Thomas, 1974). A histone octamer contains two molecules each of H2A, H2B, H3 and H4 
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histones (Felsenfeld and Groudine, 2003; Kornberg, 1974; Kornberg and Thomas, 1974). Histones 
sterically prevent factors such as RNA polymerase from binding to the DNA, and chromatin remodelling 
is therefore required to allow transcription to occur. There are two methods of chromatin remodelling: 
nucleosomes can slide or be temporarily disassembled by adenosine triphosphate (ATP) dependent 
molecules (Cote et al., 1994; Lia et al., 2006; Saha et al., 2002; Saha et al., 2005), or the post-translational 
modification of histones (acetylation or methylation) can modulate DNA-histone binding or recruit other 
proteins to the nucleosome (Pogo et al., 1966; Schubeler et al., 2004).   
 Telomeric chromatin has features consistent with heterochromatin, including histone H3 tri-
methylation at lysine 9 (H3K9me3) and histone H4 tri-methylation at lysine 20 (H4K20me3) (Garcia-Cao 
et al., 2004). The histone methyltransferase (HMTase) Suv39h mediates trimethylation of H3K9 (Peters 
et al., 2001) which recruits heterochromatin protein-1 (HP1), necessary for chromatin compaction, to 
the telomere and subtelomere regions (Cheutin et al., 2003). HP1 then recruits the HMTase Suv4-20h 
resulting in trimethylation of H4K20 (Benetti et al., 2007b). Telomeric heterochromatin can also 
influence the chromatin structure of reporter genes in the subtelomere resulting in gene silencing 
through a process known as the telomere position effect (TPE) (Baur et al., 2001; Gottschling et al., 
1990). There is a low level of H3 and H4 acetylation at sub- and telomeric regions in mortal cells (Benetti 
et al., 2007a). Mammalian telomeres lack CpG sequences and hence are not methylated, compared to 
the sub-telomeric regions which may be highly methylated by the action of the DNA methyltransferases 
DNMT1, DNMT3a and DNMT3b (Brock et al., 1999; Gonzalo et al., 2006). Nucleosomes have been 
detected in human telomeres although they have an altered nucleosome structure compared to non-
telomeric regions of the genome (Ichikawa et al., 2014; Lejnine et al., 1995; Makarov et al., 1993; 
Tommerup et al., 1994). Repetitive sequences are predicted to be a difficult substrate to maintain 
packaged as a nucleosome, suggesting telomeres may also have rapid nucleosome turnover 
(Schneiderman et al., 2009).  
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1.1.3. Telomere replication 
Mammalian telomeres are replicated throughout S phase (Arnoult et al., 2010; Verdun and Karlseder, 
2006; Wright et al., 1999) from replication start sites largely originating in the subtelomere (Drosopoulos 
et al., 2012). However, there is emerging evidence that replication can also initiate in the telomere itself 
(Drosopoulos et al., 2012; Kurth and Gautier, 2010; Sfeir et al., 2009). Telomeric structures such as the 
T-loop, G-quadruplexes and heterochromatin present a barrier to replication forks (Paeschke et al., 
2011). Therefore, proteins that unwind structures within the telomere or restart stalled replication forks 
associate with the telomere during S or G2 phase (Chawla et al., 2011; Crabbe et al., 2004; Gu et al., 
2012; Sfeir et al., 2009; Uringa et al., 2012; Vannier et al., 2013; Ye et al., 2010). To facilitate replication 
of the telomere, telomeric structures must unfold either in response to the DNA polymerase or by active 
unwinding by helicases (Vannier et al., 2012). The helicases Werner syndrome ATP-dependent helicase 
(WRN), regulator of telomere elongation helicase 1 (RTEL1), and BLM are recruited to the mammalian 
telomere by TRF1, TRF2 and POT1 which subsequently remove T-loop and G-quadruplex structures to 
allow telomeric replication (Crabbe et al., 2004; Drosopoulos et al., 2015; Opresko et al., 2002; Sarek et 
al., 2015; Sfeir et al., 2009; Vannier et al., 2012; Wu et al., 2015; Zaug et al., 2005). There is evidence 
that during telomere replication single-stranded DNA (ssDNA) becomes exposed and induces the 
formation of a structure similar to the stalled replication fork (Verdun and Karlseder, 2006). This is 
detected by MRE11 and RPA which trigger an ATR/ATM-dependent response that leads to the 
completion of replication (Verdun and Karlseder, 2006).     
 Upon completion of replication, there is a small 3’ overhang caused by the inability of the 
replicating DNA to fill the terminal RNA primer during lagging strand synthesis (Levy et al., 1992). This 
generates an ATM-dependent DNA damage response, indicated by the localisation of MRE11 and ATM 
to the telomere during G2/M (Verdun and Karlseder, 2006). Consequently, the end of the telomere is 
processed by Apollo, Exo1, the CST (CTC1-STN1-TEN1) complex and POT1 (Chow et al., 2012; Huang et 
al., 2012; Lam et al., 2010; Stewart et al., 2012; Wu et al., 2012b; Wu et al., 2010) to generate a long 3’ 
overhang before the shelterin proteins and recombination proteins including RAD51, RAD52 and XRCC3 
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(X-Ray Repair Cross Complementing 3 protein) reform the T-loop at the end of the telomere (Amiard et 
al., 2007; Doksani et al., 2013; Stansel et al., 2001; Verdun and Karlseder, 2006).   
1.1.4. Telomere transcription 
Telomeres are transcribed into long non-coding RNA termed TERRA (telomere repeat-containing RNA) 
by RNA polymerase II from transcription initiation sites in the subtelomere (Azzalin et al., 2007; 
Nergadze et al., 2009; Schoeftner and Blasco, 2008). TERRA transcripts consist of UUAGGG repeats 
ranging in size from 100 bases to 9 kb (Azzalin et al., 2007) and about 7% of human TERRA transcripts 
have a poly-A tail (Azzalin and Lingner, 2008; Porro et al., 2010). Initial reports suggested approximately 
25% of telomeres in human cells transcribe TERRA from specific transcription start sites defined by CpG 
DNA islands (Nergadze et al., 2009; Porro et al., 2010), although, controversially, it has recently been 
proposed that only one or two subtelomeres are responsible for TERRA transcription (Lopez de Silanes 
et al., 2014; Montero et al., 2016). Cohesin, involved in regulating sister-chromatid cohesion, and CTCF, 
a chromatin organising factor, are components of human subtelomeres which are involved in the 
regulation of TERRA expression (Deng et al., 2012). DNMT3B, a DNA methyltransferase which regulates 
the methylation of repetitive sequences (Hansen et al., 1999), has also been implicated in the control of 
TERRA transcription (Yehezkel et al., 2008). Telomere length is involved in the regulation of TERRA levels 
via telomeric H3K9me3 density (Arnoult et al., 2012). Interaction between TRF1 and RNA polymerase II 
is also involved in regulating TERRA levels (Schoeftner and Blasco, 2008). TERRA expression is associated 
with the cell cycle, with levels peaking during early S phase before decreasing towards the end of S 
phase/G2 (Arnoult et al., 2012; Flynn et al., 2011; Porro et al., 2010). The low TERRA levels in late S phase 
facilitate DNA replication of the telomeres and as cells pass through mitosis and into the following G1 
phase TERRA expression increases again (Porro et al., 2010).  
 TERRA transcripts are retained at telomeres post-transcription (Azzalin et al., 2007; Ho et al., 
2008; Schoeftner and Blasco, 2008) and can form DNA-RNA hybrids due to the GC-rich nature of the 
sequences (Arora et al., 2014; Balk et al., 2013; Pfeiffer et al., 2013). Telomere DNA-RNA hybrids are 
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regulated by the RNA endonuclease RNaseH1 (Arora et al., 2014). TERRA is also able to form G-
quadruplex structures and can bind to telomere interacting proteins (Biffi et al., 2014; Xu et al., 2010). 
Heterogeneous nuclear ribonucleoproteins (hnRNPs) bind to telomeric ssDNA (Lopez de Silanes et al., 
2010), an interaction regulated by TERRA (Yamada et al., 2016). TERRA assists in T-loop formation by 
promoting POT1 binding to the telomeric ssDNA after DNA replication through its interaction with 
hnRNPA1 which will lead to RPA displacement from the ssDNA to allow POT1 binding (Flynn et al., 2011). 
Telomeric transcripts can bind to TRF1 and TRF2 (Azzalin et al., 2007; Deng et al., 2009; Schoeftner and 
Blasco, 2008) and telomeric heterochromatin formation is in part mediated by the interaction of TRF2 
and TERRA (Deng et al., 2009). This interaction also recruits the origin replication complex (ORC) to the 
telomere for the initiation of replication and formation of heterochromatin (Deng et al., 2009).  
1.2. Telomeres and replicative aging 
1.2.1. Senescence 
Normal somatic cells have a limited proliferative capacity in vitro (Hayflick, 1965; Hayflick and 
Moorhead, 1961). As proliferation ceases the cells undergo numerous biochemical and morphological 
changes as they enter a state of permanent growth arrest known as senescence. It was postulated by 
Olovnikov that the end replication problem was responsible for the initiation of senescence (Olovnikov, 
1971). The end replication problem refers to the inability of the DNA replication machinery to fully 
replicate the end of linear DNA molecules. DNA polymerases are unidirectional and require a primer to 
initiate synthesis therefore, the gap caused by the terminal RNA primer cannot be filled which ultimately 
results in the loss of telomeric sequence during each round of cell division (Levy et al., 1992). However, 
this process generates only a small overhang, which is converted to a 100-200 bp overhang by an 
exonuclease that acts in the 5’ to 3’ direction, shortening the C-rich telomere strand and thereby 
increasing the length of the G-rich single-stranded telomeric tail (Makarov et al., 1997). In fibroblasts 
telomere lengths decrease by 31-85 bp/population doubling (PD) (Harley et al., 1990) and mean 
telomere lengths decrease with age in the human population (Hastie et al., 1990; Lindsey et al., 1991). 
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Thus, the terminal telomere sequence is lost at the end of each cell division until the cell is prompted to 
exit the cell cycle. 
Cells require functional telomeres to form structures such as the T-loop to prevent chromosome 
end fusions or recognition of the end of the chromosome as a dsDNA break. However, as normal cell 
division erodes the telomere sequence the telomeres become critically short and dysfunctional. 
Depletion of shelterin proteins results in a dissociation between telomere length and the induction of 
senescence (Karlseder et al., 2002; van Steensel et al., 1998) implying that alterations to the telomere 
structure, and not just shorter telomere lengths, result in activation of senescence due to the DDR that 
forms at a subset of telomeres (d'Adda di Fagagna et al., 2003). This DDR is visualised by the localisation 
of DDR components such as p53-binding protein 1 (53BP1) or phosphorylated histone H2AX (γ-H2AX) to 
the telomere where they form a telomere dysfunction induced focus (TIF) (Takai et al., 2003). 
Visualisation of telomeres and γ-H2AX in metaphase spreads allow an accurate quantification of TIFs 
(Cesare et al., 2009; Thanasoula et al., 2010). In young primary human cells a very low frequency of TIFs 
is observed however, they accumulate in presenescent cells until at least five foci are present in 
senescent nuclei (Kaul et al., 2012). Consequently, it has been postulated that telomeres exist in three 
states (Cesare et al., 2013). The first state is a ‘closed-state’ where telomeres form structures that 
prevent a DDR at the end of the chromosome. If the structure fails to form, the cells have an 
‘intermediate-state’ telomere which induces a DDR but is still able to prevent repair by end-joining; if a 
sufficient number of intermediate-state telomeres is present, then senescence is induced, associated 
with changes in the level of histones and consequently the chromatin architecture (O'Sullivan et al., 
2010). The ‘uncapped-state’ allows chromosome end fusions to occur when cells continue to proliferate 
beyond the normal induction of senescence. 
Dysfunctional telomeres are only one of the stimuli that can induce senescence. Indeed, chronic 
activation of a DDR regardless of the genomic site will induce senescence (Nakamura et al., 2008). 
Double-stranded DNA breaks, potent activators of senescence, can be the result of ionising radiation, 
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topoisomerase inhibitors, and other types of cytotoxic chemotherapies (Chang et al., 2002; Novakova 
et al., 2010; Robles and Adami, 1998; Schmitt et al., 2002; Sedelnikova et al., 2004). Oxidative stress 
results in DNA damage to a nucleotide or a ssDNA break which gets converted to a dsDNA break during 
base excision repair or DNA replication (Kuzminov, 2001; Wilstermann and Osheroff, 2001). The 
resulting dsDNA break can ultimately initiate senescence. Oxidative stress has also been implicated in 
telomere shortening by inducing damage at the G-rich sites of the telomere sequence (Kawanishi and 
Oikawa, 2004). Therefore, senescence is frequently induced as a result of directly or indirectly generated 
dsDNA damage. 
Senescence can also be induced by upregulated or unbalanced mitogenic and proliferation-
associated signals. Chronic activation of the mitogen-activated protein kinase (MAPK) signalling 
pathway will induce senescence in normal cells (Lin et al., 1998). Mutations to the Ras pathway including 
the H-RASV12 mutant (Serrano et al., 1997) and oncogenic mutations to BRAF (Michaloglou et al., 2005) 
also result in senescence when the p53 and p16INK4A pathways are intact. Subsequent studies 
determined that senescence is mediated by activation of the DNA damage signalling pathway in 
response to oncogenic mutations (Bartkova et al., 2006; Di Micco et al., 2006; Mallette et al., 2007). 
There is emerging evidence that genes frequently altered in cancer, including c-Myc (Wu et al., 2007), 
CDKN1B (Lin et al., 2010), SKP-2 (Lin et al., 2010) and PTEN (Chen et al., 2005), are involved in mediating 
senescence in normal cells.      
1.2.2. Immortalisation 
Senescence is primarily established or maintained by activation of the p53/p21 and p16INK4A/pRB 
pathways (Beausejour et al., 2003). Therefore, the p53, pRb and p16INK4A proteins are considered tumour 
suppressor proteins and inactivation of their normal function is associated with an increased 
proliferative capacity in cells (Beausejour et al., 2003; Gire and Wynford-Thomas, 1998). The normal 
function of p53 can be abrogated as the result of spontaneous loss of the wild type TP53 allele of Li-
Fraumeni cells (a syndrome where one TP53 allele contains a null-mutation) (Rogan et al., 1995), 
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transduction with mutated TP53 (Bond et al., 1994), or infection with human papillomavirus (HPV). 
Regardless of the mechanism, loss of p53 function results in proliferation beyond the PDs that generally 
induce senescence (Bond et al., 1999). Adenovirus, HPV and Simian virus 40 (SV40) are DNA viruses that 
express proteins capable of binding to and inactivating p53 and pRB tumour suppressor proteins. When 
the SV40 T-antigen (binds p53 and pRB), E1A/E1B (binds pRB/p53 respectively) adenovirus genes, or the 
E6/E7 (binds p53/pRB respectively) HPV genes are artificially expressed in human fibroblasts the cells 
have an increased proliferative capacity (Shay et al., 1991). Loss of up- or down-stream genes in the p53 
or pRB pathways also result in the bypass of senescence (Brown et al., 1997; Dimri et al., 2000; 
Huschtscha et al., 1998; O'Loghlen et al., 2015; Okamoto et al., 1994; Vogt et al., 1998). Therefore, a 
critical step in the development of cells with indefinite replicative potential, or cellular immortality, is 
inactivation of the p53 or pRB pathways (Duncan et al., 1993; Lehman et al., 1993; Rogan et al., 1995; 
Shay et al., 1995). 
 With bypass of senescence by inactivation of the p53 or pRB pathways the telomere sequence 
continues to be eroded during each round of cell division. The short, unprotected telomere ends are 
able to undergo classic NHEJ or alternative end joining (alt-NHEJ) (Rai et al., 2010; Sfeir and de Lange, 
2012) when there are <13 pure TTAGGG repeats distal to the final telomere variant repeat (Capper et 
al., 2007). The resultant di-centric chromosomes lead to chromatin bridges between the daughter cells 
during cell division and the resolution of these bridges causes genomic instability (Artandi et al., 2000; 
Soler et al., 2005). The telomeres will eventually become critically short and induce the cells to enter a 
period of crisis where most cells will undergo apoptosis (Girardi et al., 1965). In the case of human 
fibroblasts, approximately 1 in 107 cells escape crisis (Huschtscha and Holliday, 1983) by activation of a 
telomere lengthening mechanism (TLM) which stabilises the telomere lengths and allows unlimited 
proliferation of the cells hence the immortal nature of post-crisis cells (Counter et al., 1992; Meyerson 
et al., 1997; Rogan et al., 1995) (Figure 1.2). Cellular immortalisation is a hallmark of cancer (Hanahan 
and Weinberg, 2000; Hanahan and Weinberg, 2011) and to date two TLMs have been described:  
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Figure 1.2. Telomere length during cell division. 
Cells that have constitutively active telomerase activity such as embryonic stem cells may 
completely maintain telomere length (blue line). Stem cells that express tightly regulated levels of 
telomerase partially maintain telomere length (green line). In normal somatic cells telomere 
erosion occurs as a result of normal cell division (grey line) until cells reach senescence. A 
proportion of cells may acquire an abrogation to the p53 or pRb pathway that allows the cells to 
overcome senescence. Cell division continues until cells enter crisis. A small proportion of cells may 
escape crisis through activation of a telomere lengthening mechanism which allows continued cell 
division without telomere length erosion (red line).   
 
telomerase (Greider and Blackburn, 1989) and alternative lengthening of telomeres (ALT) (detailed in 
section 1.4.). 
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1.3. Telomere length regulation 
The telomere length of normal human cells is determined by a balance of lengthening and shortening 
events (Gilson and Londono-Vallejo, 2007). Overlengthening of telomeres by activation of a TLM results 
in telomere trimming and the generation of t-circles (Pickett et al., 2009). A t-circle refers to double-
stranded circular telomeric DNA that has a nick in both the C- and G-rich strands preventing the structure 
from becoming supercoiled (Cesare and Griffith, 2004; Wang et al., 2004). They are generated when 
telomere lengths are extended past a threshold length, likely due to resolution of the HJ formed by the 
T-loop (Pickett et al., 2009). A number of genes are involved in the regulation of t-circles (XRCC3 
(Compton et al., 2007; Wang et al., 2004), NBS1 (Compton et al., 2007; Wang et al., 2004), SLX4 (Sarkar 
et al., 2015), ZBTB48 (encodes TZAP) (Li et al., 2017) and RTEL1 (Deng et al., 2013)) and their involvement 
in homologous recombination and DNA replication supports this hypothesis. Recently, TZAP has been 
implicated in the initiation of telomere trimming as long telomeres have a reduced concentration of 
shelterin proteins which allows TZAP to bind to the telomere, and it is this switch from shelterin to TZAP 
that is proposed to initiate telomere trimming (Li et al., 2017). T-circles are conserved in mammals 
(Pickett et al., 2011; Rivera et al., 2017), yeast (Lustig, 2003), and plants (Watson and Shippen, 2007) 
and observed in normal human and mouse cells (Pickett et al., 2011) indicating that telomere trimming 
is a conserved process with a role in normal telomere biology. This process is tightly controlled and does 
not result in activation of a DNA damage response or telomere fusions (Pickett et al., 2009). 
1.4. Telomere lengthening mechanisms 
1.4.1. Telomerase 
1.4.1.1. Structure and function 
In 1985 Greider and Blackburn discovered an enzyme in Tetrahymena capable of synthesising telomeric 
sequence (Greider and Blackburn, 1985) by reverse transcribing the template region of its RNA subunit 
(Greider and Blackburn, 1989) and in 1989 Morin described the human equivalent, telomerase (Morin, 
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1989). Telomerase, a ribonucleoprotein, is comprised of the catalytic reverse transcriptase domain 
hTERT (human telomerase reverse transcriptase) (Nakamura et al., 1997), the human telomerase RNA 
hTR (Feng et al., 1995), and the associated protein dyskerin (Cohen et al., 2007). In vitro studies indicate 
that telomerase is a dimer comprised of two molecules each of hTERT, hTR and dyskerin (Cohen et al., 
2007; Sauerwald et al., 2013; Wenz et al., 2001) although there is debate about whether a higher order 
structure is strictly necessary for telomerase function as several studies indicate that telomerase is 
functional as a monomer (Alves et al., 2008; Errington et al., 2008). Experiments to isolate subunits of 
the enzyme responsible for telomere elongation in yeast Saccharomyces cerevisiae utilised mutants 
defective for telomere addition (Lundblad and Szostak, 1989). This led to a continual loss of telomere 
length and ultimately senescence, a phenotype known as ever shorter telomeres (EST) with the gene 
subsequently termed EST1. Further studies identified other EST genes including EST2 which was 
subsequently identified as the catalytic component of telomerase in S.cerevisiae (Counter et al., 1997; 
Lendvay et al., 1996).   
The RNA subunit of telomerase permits de novo addition of six nucleotide repeats of telomere 
sequence, 5’-GGTTAG-3’, to the 3’ single-stranded overhang of telomeres. The hTR transcript is 
comprised of 451 nucleotides with an eleven nucleotide (5’-CUAACCCUAAC-3’) template region (Feng 
et al., 1995), encoded from the TERC gene. The hTR RNA is composed of four domains; a pseudoknot 
domain (CR2/CR3), a H/ACA box domain (CR6/CR8), CR4/CR5 domain, and C7 domain (Chen et al., 2000). 
The H/ACA box domain is a characteristic of small nucleolar RNA and the region also contains a Cajal 
body targeting sequence (CAB box) which facilitates localisation and retention of telomerase to Cajal 
bodies (Ganot et al., 1997). Cajal bodies are subnuclear structures that contain several proteins such as 
coilin and TCAB1. They provide a site for RNA processing and ribonucleoprotein assembly (Bauer and 
Gall, 1997; Jady et al., 2003) and facilitate the recruitment of telomerase to telomeres. 
The reverse transcriptase hTERT features: a reverse transcriptase motif located in the C-terminal 
end of the protein, a telomerase specific region (T motif), dissociates activities of telomerase (DAT) 
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domain, the telomerase essential N-terminal (TEN) domain and the N-terminal end of the protein 
(Armbruster et al., 2001; Moriarty et al., 2002; Nakamura et al., 1997; Xia et al., 2000). hTERT N-terminal 
regions are essential for hTR binding (Moriarty et al., 2002; Xia et al., 2000), whilst the C-terminus of 
hTERT and the TEN domain are responsible for the processivity of the telomerase enzyme (Akiyama et 
al., 2015; Bryan et al., 2000; Hossain et al., 2002; Peng et al., 2001), and the DAT domain is essential for 
correct telomerase localisation to the telomere (Armbruster et al., 2004).  
Telomerase requires accessory proteins for in vivo synthesis, subcellular localisation and 
function. The proteins dyskerin, NHP2, NOP10, GAR1, Nopp140, NAF1, pontin/reptin and TCAB1 
associate with the hTR/hTERT complex (Venteicher et al., 2009; Venteicher et al., 2008). The H/ACA 
ribonucleoproteins dyskerin, GAR1, NOP10 and NHP2 form a complex that can bind to H/ACA RNAs such 
as hTR (Ganot et al., 1997; Henras et al., 1998; Watkins et al., 1998). This complex is required to stabilise 
hTR and facilitate the synthesis of telomerase. Pontin and reptin act as a complex that mediates 
telomerase synthesis through an interaction with hTERT and dyskerin (Venteicher et al., 2008). These 
proteins are hypothesised to accumulate and stabilise hTR, potentially by pontin’s ATPase activity, and 
are present at a pre-telomerase intermediate complex with hTERT. TCAB1 binds the CAB box region of 
hTR, accumulates telomerase at Cajal bodies, and traffics it to the telomere (Chen et al., 2015; Stern et 
al., 2012). Recently, additional proteins including ATR and ATM were identified as contributing to 
telomerase recruitment to the telomere (Lee et al., 2015; Tong et al., 2015). Therefore, accurate 
telomerase function in vivo requires an array of telomerase-associated proteins in addition to the 
enzyme components hTR, hTERT and dyskerin. 
1.4.1.2. Role in cancer and normal cells 
Telomerase activity in normal human and cancer cells has been extensively characterised by telomerase 
activity assays, most commonly the telomerase repeat amplification assay (TRAP) (Kim et al., 1994). 
Telomerase activity is tightly controlled in normal human tissue, with activity detected during 
embryogenesis in tissues such as the liver, skin, lung and muscle which is subsequently downregulated 
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prior to birth (Ulaner and Giudice, 1997; Ulaner et al., 2001; Wright et al., 1996). However, highly 
proliferative tissues such as male germ cells, haematopoietic stem cells, epithelial cells including the 
gastrointestinal tract and hair follicle, and activated lymphocytes require tightly regulated telomerase 
activity to maintain their cell population (Bachor et al., 1999; Broccoli et al., 1995; Counter et al., 1995; 
Harle-Bachor and Boukamp, 1996; Hiyama et al., 1996; Hiyama et al., 1995b; Ramirez et al., 1997; 
Tanaka et al., 1998; Yashima et al., 1998; Yui et al., 1998).  
Telomere dysfunction can result in short telomere syndromes. Dyskeratosis congenita was the 
first short telomere syndrome identified and is generally caused by mutations in the genes for hTR 
(Mitchell et al., 1999; Vulliamy et al., 2001a), hTERT (Armanios et al., 2005) or dyskerin (Heiss et al., 
1998) that lead to defective telomerase, excessively short telomeres and reduced proliferation of highly 
regenerative cells such as the bone marrow and skin (Drachtman and Alter, 1992; Tummala et al., 2015). 
Mutations in telomerase genes, RTEL1, TCAB1, TIN2, TPP1 and PARN (Calado et al., 2011; Guo et al., 
2014; Kocak et al., 2014; Stuart et al., 2015; Tummala et al., 2015) have been identified in aplastic 
anaemia (Vulliamy et al., 2002), Hoyeraal-Hreidarsson syndrome (Knight et al., 1999; Marrone et al., 
2007), Coats plus syndrome (Anderson et al., 2012; Polvi et al., 2012), Revesz syndrome (Savage et al., 
2008), and idiopathic pulmonary fibrosis (Armanios et al., 2007; Tsang et al., 2012). Patients who have 
germ-line mutations in a telomerase gene also have significantly shorter telomeres than healthy age 
matched individuals (Alder et al., 2008; Marrone et al., 2007; Vulliamy et al., 2002; Vulliamy et al., 
2001b).  
To ensure that telomerase activity only occurs in specific normal cell types there is tight 
regulation over the expression of hTERT and hTR. hTERT is a limiting factor for telomerase expression as 
it has either low expression or is absent in telomerase-negative cells and ectopic expression of hTERT in 
these cells is sufficient to reactivate telomerase (Bodnar et al., 1998; Counter et al., 1998b; Hahn et al., 
1999; Meyerson et al., 1997; Wen et al., 1998). Expression of hTERT can be regulated at several levels; 
including transcription, alternative splicing, and post-translational modifications (Cong et al., 1999; Cong 
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et al., 2002; Horikawa et al., 1999; Liu et al., 1999; Takakura et al., 1999). hTR expression is present at 
limiting levels in all cell types and can become upregulated once hTERT is expressed (Avilion et al., 1996; 
Cao et al., 2008a; Cao et al., 2008b; Feng et al., 1995). Immortalisation is considered a critical step to 
oncogenesis, achieved when cells in crisis activate a TLM. Telomerase is responsible for the 
immortalisation of up to 90% of human cancers (Kim et al., 1994; Shay and Bacchetti, 1997) by 
preferentially extending the shortest telomeres in the cell (Britt-Compton et al., 2009; Hemann et al., 
2001; Teixeira et al., 2004). Initially two models were proposed to explain the presence of telomerase 
activity in cancer cells; the expansion of a stem cell population that failed to undergo differentiation and 
subsequently formed cancers (Greaves, 1996), or the dysregulation of endogenously expressed 
telomerase to overcome crisis (Shay and Wright, 1996). Subsequent studies identified upregulation of 
endogenously expressed hTERT or hTR as frequent events in cancer cells suggesting telomerase activity 
is upregulated during tumourigenesis to bypass crisis (Bell et al., 2015; Cao et al., 2008b; Fredriksson et 
al., 2014; Horn et al., 2013; Huang et al., 2013; Horikawa et al., 1999; Peifer et al., 2015; Wang et al., 
1998; Wu et al., 1999; Zhang et al., 2000). Endogenous expression of hTERT can be upregulated in cancer 
cells through a number of mechanisms including abnormally high levels of Myc activity (Horikawa et al., 
1999; Wang et al., 1998; Wu et al., 1999), gene amplification (Cao et al., 2008b; Zhang et al., 2000), 
C228T and C250T mutations in the promoter region leading to the introduction of transcription factor 
binding sites (Bell et al., 2015; Fredriksson et al., 2014; Horn et al., 2013; Huang et al., 2013), and 
structural rearrangements upstream of the promoter region that result in super-enhancer elements 
(Peifer et al., 2015).   
1.4.1.3. Telomerase inhibitors as anti-cancer therapeutics 
Telomerase is an attractive target for anti-cancer therapies because its expression is crucial for the 
majority of cancers and a minority of normal cells. There are a number of strategies for telomerase anti-
cancer therapeutics: the direct inhibition of telomerase, stabilisation of the telomere structure to 
prevent telomerase binding, or inducing cell death specifically in telomerase expressing cells (Shay and 
Keith, 2008). A number of potential anti-cancer therapies have progressed to clinical trials including the 
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antisense oligonucleotide GRN163L (targeting hTR) (Chanan-Khan et al., 2008; Roth et al., 2010; Ruden 
and Puri, 2013), immunotherapy GV1001 (hTERT peptide based vaccine) (Bernhardt et al., 2006; 
Brunsvig et al., 2011; Buanes et al., 2009; Kyte, 2009; Ruden and Puri, 2013; Shaw et al., 2010a; Shaw et 
al., 2010b), and immunotherapy GRNVAC1 (dendritic cell vaccine to stimulate TERT-specific CD4+ & 
CD8+ cells) (DiPersio et al., 2009; Khoury et al., 2010; Ruden and Puri, 2013). However, the results of 
these trials are still pending and there is currently no data available suggesting that these drugs improve 
patient outcome by inhibiting telomerase activity (Jafri et al., 2016). There are also concerns about the 
length of time required for telomerase inhibitors to induce telomere shortening and hence cell death or 
senescence. This has led to the development of novel drugs such as 6-thio-2'-deoxyguanosine (6-thio-
dG), a nucleoside analogue which can be incorporated into telomerase mediated de novo synthesised 
telomeric DNA, resulting in telomere dysfunction which leads to rapid cell death (Mender et al., 2015). 
There is also evidence that treating cells with a combination of PARP and telomerase inhibitors reduces 
the time required to observe telomere shortening (Lu et al., 2014; Seimiya et al., 2005). So, whilst there 
are currently no telomerase targeted therapies as a standard cancer treatment, telomerase remains a 
potential target for the development of novel therapies.  
1.4.2. Alternative Lengthening of Telomeres (ALT) 
The most common TLM used by human cancers is telomerase, however, a subset of cancer cells and 
immortalised cell lines utilise the alternative lengthening of telomeres (ALT) to confer immortalisation. 
ALT is defined as any telomerase-independent method of telomere length maintenance, which generally 
utilises a DNA template to synthesise de novo telomeric sequence (Dilley et al., 2016; Dunham et al., 
2000). The existence of ALT in human cells was first demonstrated by the observation that some 
immortalised cell lines maintain their telomere length without any detectable telomerase activity (Bryan 
et al., 1997; Bryan et al., 1995) and it has subsequently been estimated 10-15% of human cancers utilise 
the ALT mechanism to achieve unlimited proliferation (Henson et al., 2002). The molecular details of 
the ALT mechanism are not yet fully understood but studies have ascertained a number of 
characteristics that are hallmarks of the ALT mechanism. 
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1.4.2.1. Phenotypic characteristics of ALT 
For over a decade since the discovery of ALT there was no biochemical assay to determine ALT activity 
and the only definitive way to confirm cells utilise the ALT mechanism is to examine telomere length in 
telomerase-negative cells over time. However, this requires serial untreated samples from the same 
patient which are generally impossible to procure. Hence, a combination of ALT markers have 
historically been used to determine ALT activity in human cells.  
 One of the most notable phenotypes of ALT is the presence of long and heterogeneous telomere 
lengths within cells. Telomere lengths, in a mass population of cells, are observable by Southern blot 
analysis of pulse field gel electrophoresed terminal restriction fragment (TRF) lengths, considered the 
gold-standard technique to measure telomere lengths from a population of cells. From this technique, 
the range of telomere lengths in ALT cells varies from <3 kb to >50 kb with an average length of 20 kb 
(Bryan, 1997; Bryan et al., 1995; Grobelny et al., 2000; Murnane et al., 1994; Yeager et al., 1999) 
compared to telomerase-positive cells which have relatively homogeneous telomere lengths with an 
average length usually less than 10 kb (Bryan et al., 1995; Park et al., 1998). However, a large amount 
of high quality genomic DNA (at least 2 g) is required to perform the analysis, often a limitation when 
examining tumour samples. Telomere lengths within a single cell can be observed by telomere 
fluorescent in situ hybridisation (FISH) on metaphase spreads. The telomere probe is visible at a range 
of intensities within an individual ALT cell, with some chromosomes lacking a detectable signal 
altogether, so called signal-free ends. Comparisons of FISH and TRF analysis confirm that TRFs reflect 
the heterogeneous nature of telomere lengths within a single ALT cell (Lansdorp et al., 1998; Perrem et 
al., 2001). Alternatively, telomere FISH can be performed on interphase cells allowing the examination 
of telomere lengths in a range of sample types including formalin-fixed paraffin-embedded (FFPE) 
tissues. Although long and heterogeneous telomere lengths are a marker of ALT in most situations, 
ectopic overexpression of hTR and/or hTERT can result in extreme telomere lengthening and an average 
length comparable to ALT cells (Cao et al., 2008b; Pickett et al., 2009). Therefore, telomere length alone 
is not sufficient to indicate ALT activity. The ability to examine individual telomeres has also shown that 
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telomeres in ALT are very dynamic with rapid unsynchronised elongation and deletion events (Murnane 
and Sabatier, 2004). 
Promyelocytic leukaemia nuclear bodies (PML-NBs) are present in the nuclei of the majority of 
mammalian cells (Bernardi and Pandolfi, 2007) and have been implicated in a number of cellular 
processes including cell cycle regulation and DDR (Bernardi and Pandolfi, 2003; Dellaire and Bazett-
Jones, 2004; Dellaire et al., 2006), tumour suppression (He et al., 1997), induction of senescence and 
apoptosis (Bernardi and Pandolfi, 2003; Ferbeyre et al., 2000; Jiang and Ringertz, 1997), transcriptional 
regulation (Luciani et al., 2006; Zhong et al., 2000), protein refolding and degradation (Mattsson et al., 
2001), the immune system (Zheng et al., 1998), and viral replication (Chung and Tsai, 2009). PML-NBs 
contain a number of proteins, including Sp100 and isoforms of PML, and in ALT cells a subset also contain 
telomeric DNA and shelterin proteins, in addition to DNA repair, recombination and replication factors 
(Henson et al., 2002; Jiang et al., 2005; Jiang et al., 2007; Yeager et al., 1999; Zhong et al., 2007). Hence, 
such foci are termed ALT-associated promyelocytic leukemia nuclear bodies (APBs) (Yeager et al., 1999). 
APBs associate with the termini of chromosomal telomeric DNA implying that this is a transient structure 
and the PML-NBs can dissociate from the telomere to allow normal cellular processes to occur 
(Molenaar et al., 2003). Methionine restriction in cells leads to an increase in the number of discernible 
APBs and has shown that TRF1, TRF2, TIN2, RAP1, PML, HP1 and the MRN (comprised of MRE11, RAD50 
and NBS1) complex are necessary for APB formation (Henson et al., 2002; Jiang et al., 2005; Jiang et al., 
2007; Zhong et al., 2007). APB formation also requires proteins of the SMC5/6 complex (Potts and Yu, 
2007). It has been hypothesised that APBs are the site of ALT activity, however, to date there is no 
conclusive proof that this is the case. Evidence in support of this hypothesis includes a reduction in the 
number of APBs following inhibition of ALT (Jiang et al., 2005; Perrem et al., 2001) by sequestration of 
the MRN complex (a complex involved in homologous recombination), and the increased frequency of 
APBs when cells approach senescence (Fasching et al., 2007; Jiang et al., 2007; Jiang et al., 2009). There 
is also evidence that the intensity of telomeric FISH signals increase in a subset of APBs compared to 
other telomeres (Yeager et al., 1999). Additionally, APB levels increase during the G2 phase of the cell 
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cycle which is when homologous recombination occurs most frequently and is likely when the ALT 
mechanism is active (Grobelny et al., 2000; Wu et al., 2000). The APB assay requires interphase cells and 
can be performed on a range of fixed cells including FFPA tissues and has often been used, in conjunction 
with telomere length, to determine the frequency of ALT in tumour cohorts. 
ALT cells have a high abundance of extrachromosomal telomeric repeats which can be either 
linear or circular in form (Cesare and Griffith, 2004; Nabetani and Ishikawa, 2009; Ogino et al., 1998; 
Pickett et al., 2009; Tokutake et al., 1998; Wang et al., 2004). Extrachromosomal telomeric DNA likely 
results from rapid deletion events, and is a feature of ALT cells. T-circles are the product of telomere 
trimming (see section 1.3.) and are more abundant in ALT cells than normal cells or endogenously 
expressing telomerase cells (Cesare and Griffith, 2004; Fasching et al., 2005; Henson et al., 2009; Wang 
et al., 2004). This greater proportion of t-circles is likely due to resolution of the T-loop during telomere 
trimming of over-lengthened telomeres as a result of the rapid elongation events caused by the ALT 
mechanism (Pickett and Reddel, 2012). When telomeres are over-lengthened by telomerase, generally 
via overexpression of hTERT and/or hTR, abundant t-circles are also generated at levels comparable to 
ALT-positive cell lines indicating it is telomere length and not a specific aspect of the ALT mechanism 
that results in t-circle formation (Pickett et al., 2009).  
C-circles are a type of circular telomeric DNA that appear to be closely related to the ALT 
mechanism. C-circles are a C-rich circular telomeric sequence that is only partially double-stranded and 
therefore able to self-prime a rolling circle amplification assay (Henson et al., 2009). G-circles are also 
specific to ALT cells however, they occur in far lower frequency than C-circles (Henson et al., 2009). C-
circles are a specific and quantitative marker of ALT activity, not found in mortal or telomerase-positive 
cells but detectable in all ALT cell lines assayed to date (Henson et al., 2009). Most importantly, 
treatment of ALT cells with high levels of YFP-Sp100 fusion protein to sequester the MRN complex and 
inhibit ALT, produced a rapid decrease in C-circle levels (Henson et al., 2009). Patients with ALT-positive 
osteosarcomas had detectable C-circles in their blood samples (Henson et al., 2009), signifying the 
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potential the C-circle assay has as a routine clinical test to diagnose ALT tumours. The discovery of C-
circles and a simple, rapid detection method for ALT is an important development for identifying TLMs 
in cancer patients and facilitates the development of anti-cancer therapeutics to target TLMs.    
Telomere variant repeats have also been examined in the context of ALT. Minisatellites are 
tandem variant repeat sequences 6-100 bp in length (Vergnaud and Denoeud, 2000). Notably, there is 
increased instability at the MS32 minisatellite locus in ALT cells although the frequency of mutation 
varies between cell lines (Jeyapalan et al., 2005). Further structural differences have been noted 
between the telomeres of ALT cells and non-ALT cells. In mortal or telomerase-positive cells, variant 
repeats are confined to the 2 kb region proximal to the end of the telomere (Baird et al., 1995; Coleman 
et al., 1999). However, homologous recombination in ALT cells has led to the dispersal of variant repeats 
throughout their telomeres, most frequently the TCAGGG variant but TTCGGG and GTAGGG have also 
been observed (Conomos et al., 2012; Varley et al., 2002). Orphan nuclear receptors have been 
identified at ALT telomeres through binding to the variant telomeric sequence TCAGGG, which in turn 
recruits the zinc finger protein ZNF827 to the telomere (Conomos et al., 2014; Conomos et al., 2012; 
Dejardin and Kingston, 2009). Subsequently, the histone deacetylation and nucleosome remodelling 
complex NuRD is recruited to the telomere through its binding with ZNF827 which leads to telomeric 
chromatin remodelling and facilitates the telomere-telomere interaction required for homologous 
recombination and ALT activity (Conomos et al., 2014). 
The telomeric transcript TERRA can form DNA-RNA hybrids with telomeres and has been found 
to localise to APBs (Arora et al., 2014). TERRA levels are higher in ALT-positive cells than telomerase-
positive cells and these levels are associated with telomere length (Arora et al., 2014; Episkopou et al., 
2014; Kreilmeier et al., 2016; Ng et al., 2009). The association between ALT activity and TERRA level may 
be the result of reduced sub-telomeric methylation in ALT cells (Ng et al., 2009) or the reduced 
chromatin compaction at telomeres which promotes not only the ALT mechanism but telomere 
transcription (Episkopou et al., 2014). Similarly, depletion of the chromatin remodeller α-thalassemia 
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mental retardation X-linked (ATRX) protein, an event observed in a subset of ALT cells and tumours 
(discussed in section 1.4.2.3) (Heaphy et al., 2011a; Lovejoy et al., 2012), results in decreased TERRA 
expression in telomerase-positive cells due to increased telomeric chromatin compaction, reduced RNA 
polymerase II recruitment, and decreased cohesion abundance at telomeres (Eid et al., 2015; Episkopou 
et al., 2014). A study in S. cerevisiae suggests that TERRA expression is sufficient to induce recombination 
(Yu et al., 2014). The evidence thus suggests that TERRA may be involved in telomere maintenance, 
although we do not currently understand the role of TERRA in the human ALT mechanism. 
Telomere-sister chromatid exchange (T-SCE) is a reflection of recombination at the telomere 
and has been used as a marker for ALT (Bechter et al., 2004; Londono-Vallejo et al., 2004). Whilst some 
studies reported that post-replicative telomere exchange events were detected at a greater frequency 
in ALT-positive cells compared to telomerase-positive cells (Bechter et al., 2004; Londono-Vallejo et al., 
2004), there is also evidence that some telomerase-positive cell lines have comparable T-SCE levels to 
ALT cells (Vera et al., 2008). T-SCEs may be more frequent in ALT cells because of the increased number 
of short, more recombinogenic telomeres resulting from the ALT mechanism. However, T-SCEs can also 
result from dsDNA break repair in the telomere and hence are not universally indicative of ALT activity 
(Doksani and de Lange, 2016).  
As identification of the ALT mechanism relies on the presence of phenotypic characteristics, 
some more specific for ALT than others, it is important to confirm the classification via as many 
techniques as possible. Given the specificity, and comparative ease of detection, the C-circle assay in 
conjunction with telomere length testing can be rapidly used to identify ALT in tumour samples, even 
with limited quantities of DNA (Lau et al., 2013).     
1.4.2.2. Mechanistic details of ALT 
The exact details of the ALT mechanism are currently unknown. The present model proposes that the 3’ 
single-stranded overhang of a telomere invades double-stranded telomeric DNA and anneals to the 
complementary telomere strand which can act as a primer to synthesise new telomeric DNA, which is 
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then converted to dsDNA. As outlined below, there are a number of potential sources of template 
telomeric DNA, including: sister chromatid exchange, replication within the t-loop structure, 
homologous recombination from linear extrachromosomal DNA, and DNA rolling circle replication 
(summarised in Figure 1.3.A, B, C, D).  
 Homologous recombination was first hypothesised to be involved in ALT telomere length 
maintenance because of the dynamic nature of the telomeres observed in ALT cells. Homologous 
recombination at the telomere can be detected in vivo in mammalian cells by inserting a DNA tag into 
one telomere and demonstrating that it is copied to other non-homologous telomeres (Dunham et al., 
2000; Neumann et al., 2013; O'Sullivan et al., 2014) or duplicated in the original location (Muntoni et 
al., 2009). This was observed in ALT but not telomerase-positive cells. These observations indicate that 
ALT cells can use a telomere on a sister chromatid, another telomere, or even itself as a template to 
copy telomeric sequence (Figure 1.3.A, B, C). This process appears to rely on break-induced replication 
(Dilley et al., 2016; Roumelioti et al., 2016).  
Break-induced replication is a process to repair DNA damage at the termini of the chromosome 
(McEachern and Haber, 2006). A recent study indicates replication factor C (RFC) loads proliferating cell 
nuclear antigen (PCNA) onto the exposed end of the chromosome, which is recognised as a site of DNA 
damage, leading to polymerase δ recruitment to the telomere (Dilley et al., 2016). This leads to one end 
of the break invading a template which is used for homology-directed telomere synthesis. In addition to 
linear chromosomes, circular extrachromosomal telomeric DNA can act as a template for telomere 
elongation via rolling circle amplification machinery (Henson et al., 2009; Natarajan and McEachern, 
2002)(Figure 1.3.D). Introduction of exogenous t-circles to the telomerase negative Kluyveromyces lactis 
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Figure 1.3. Potential templates of homologous recombination mediated telomere lengthening. 
Homologous recombination can use a number of templates to mediate telomere lengthening as 
proposed in the ALT mechanism. These include (A) another telomere, (B) the T-loop of the same 
telomere, and possibly (C) linear extrachromosomal DNA or (D) circular extrachromosomal DNA. 
 
resulted in incorporation of the exogenous sequence into the chromosomal telomere and subsequent 
spreading of the sequence by homologous recombination (Natarajan et al., 2003; Natarajan and 
McEachern, 2002; Topcu et al., 2005).  
 The telomere templates used for homology-directed synthesis may be spatially close to the 
termini of the telomere for example a sister chromatid, or spatially separated, such as a distant 
telomere. To allow telomeres to find templates over long distances the cells require a mechanism to 
move telomeres within the nuclei. Loss of the shelterin protein TRF2 results in a DDR at the telomere 
and an increased mobility within the nuclei (Dimitrova et al., 2008). A spontaneous DDR is commonly 
detected at the telomere of ALT cells (Cesare et al., 2009) and a subset of ALT telomeres have directional 
movement which allows transient binding with each other and APBs (Molenaar et al., 2003). Of late, 
evidence has emerged of a HOP2-MND1- and RAD51 dependent homology search mechanism that 
drives rapid, directional, long-range movement of telomeres leading to telomere clustering, ultimately 
initiating homology based telomere synthesis (Cho et al., 2014; Zhao and Sung, 2015). It is currently 
unknown what proportion of the telomere ends utilise long-range movement to find template DNA for 
the ALT mechanism.  
1.4.2.3. Genetic changes and telomeric chromatin in ALT 
It has been presumed that for the ALT mechanism to occur in cells, p53 would need to be inhibited to 
allow recombination events to occur. There is some indirect evidence to suggest this is the case: in 
glioblastoma, 78% of ALT tumours were p53 deficient but only 21% of telomerase-positive tumours 
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lacked p53 (Chen et al., 2006). However, this finding may be specific to glioblastoma, as ALT has also 
been detected in other tumour types, such as primary neuroblastoma (NB) tumours which have a very 
low incidence of p53 deficiency (Vogan et al., 1993; Kurihara et al., 2014; Lundberg et al., 2011; Onitake 
et al., 2009; Valentijn et al., 2015). Of the ALT cell lines characterised to date only four have a wild type 
TP53 allele and only one of these is known to have normal p53 protein levels (Henson and Reddel, 2010). 
These data suggest that inhibition of p53 may be required in the majority of circumstances to permit 
the ALT mechanism to activate, however, it is clearly not an absolute requirement for ALT to occur. 
 Genes that are involved in chromatin remodelling have recently been implicated in activation 
of the ALT mechanism. An association between ALT-positive tumours and mutations to ATRX or Death-
Associated protein 6 (DAXX) was established in pancreatic neuroendocrine tumours (PanNETs) (Heaphy 
et al., 2011a; Jiao et al., 2011; Scarpa et al., 2017). Studies in other tumour types including glioblastoma 
(Schwartzentruber et al., 2012), liposarcoma (Lee et al., 2015) and NB (Kurihara et al., 2014) have 
confirmed there is a correlation between ALT-positive tumours and ATRX mutations, although DAXX 
mutations are rarely observed. Mutations in the histone variant H3.3, encoded by the gene H3F3A, have 
also been associated with ALT (Schwartzentruber et al., 2012). ALT-positive cell lines frequently lack 
ATRX expression (Bower et al., 2012; Lovejoy et al., 2012) although this is not necessarily due to loss-of-
function mutations in the gene (Lovejoy et al., 2012). A study of 22 ALT cell lines indicated that loss of 
ATRX expression is not necessarily the result of somatic mutations, 19/22 cell lines had loss of ATRX 
and/or DAXX protein but only 7/19 cell lines contained a loss-of-function mutation in ATRX and 0/19 
had mutations in DAXX or H3F3A (Lovejoy et al., 2012). It is clear that loss of ATRX, DAXX and/or H3.3 
expression is not solely responsible for initiation of the ALT mechanism as 14% of ALT cell lines exist 
with normal levels of ATRX and DAXX and knockdown of either protein did not result in ALT 
immortalisation of mortal cells (Lovejoy et al., 2012; Napier et al., 2015).  
ATRX is a member of the ATP dependent SWI2/SNF2 family (Picketts et al., 1996) and mutations 
to the ATRX gene cause alpha thalassemia in patients with a normal alpha globin gene which led to the 
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hypothesis that ATRX is involved in the regulation of gene expression (Gibbons et al., 1995). ATRX is 
localised to PML bodies, pericentric heterochromatin, and sub-telomeric and telomeric DNA where the 
protein is involved in regulating DNA methylation and the chromatin structure (De La Fuente et al., 2004; 
Gibbons et al., 2000; Ritchie et al., 2008). To perform its chromatin remodelling function, ATRX forms a 
complex with DAXX (Xue et al., 2003). DAXX can bind to H3.3 and the ATRX/DAXX complex can then 
deposit H3.3 into ribosomal, telomeric, and pericentric repeat sequences (Drane et al., 2010; Goldberg 
et al., 2010; Lewis et al., 2010). H3.3 is a histone variant associated with nucleosomes undergoing rapid 
turnover at transcriptionally active sites (Ahmad and Henikoff, 2002). Therefore, H3.3 may be stabilising 
the telomere chromatin structure as it does at other sites of rapid nucleosome turnover.  Loss of either 
ATRX or H3.3 in mouse embryonic stem cells resulted in an increased number of cells with five or more 
TIFs (Wong et al., 2010) demonstrating that both proteins are important to maintaining telomere 
function. ATRX and H3.3 are involved in maintaining the heterochromatin state across the genome and 
mediate silencing of genetic regions including endogenous retroviral elements (Elsasser et al., 2015; 
Sadic et al., 2015) and imprinted loci (Voon et al., 2015). Defective function of ATRX or H3.3 results in 
hypo-methylation (Voon et al., 2015) and ALT cells have reduced compaction of telomeric chromatin 
compared to telomerase-positive cells (Episkopou et al., 2014). However, knockdown of ATRX in isogenic 
telomerase and ALT-positive cells led to increased telomeric chromatin compaction suggesting other 
factors mediate the reduced telomeric chromatin compaction observed in ALT cells (Episkopou et al., 
2014). Furthermore, depletion of ASF1, a histone chaperone that interacts with histone regulator A 
(HIRA) and the chromatin assembly factor 1 (CAF1) complex, led to the activation of ALT phenotypes in 
a mortal and telomerase-positive cell line providing further evidence that normal chromatin structure 
is critical in repressing ALT in normal cells (O'Sullivan et al., 2014). 
1.4.2.4. ALT proteins 
The hypothesis that ALT exploits normal homologous recombination pathways is supported by the 
involvement of proteins utilised in DDR, homologous recombination, and DNA replication in the ALT 
mechanism. Notably, a large proportion of these proteins are present in APBs lending support to the 
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hypothesis that they are the active site of the ALT mechanism (Henson and Reddel, 2010). Proteins 
required for homologous recombination including RAD51, RAD52, RPA, NBS1, SLX4, BLM, MRN, BRCA1 
and BRIT1, have been identified in the APBs of ALT-positive cells (Bhattacharyya et al., 2009; Cesare and 
Reddel, 2010; Conomos et al., 2014; Wan et al., 2013; Wilson et al., 2013; Yeager et al., 1999). The 
members of the MRN complex, involved in the early steps of homologous recombination (van den Bosch 
et al., 2003), were some of the first proteins identified as critical for telomere lengthening by ALT. The 
MRN complex recruits ATM to dsDNA breaks and facilitates resection of the chromosome end to create 
the 3’ overhang for strand invasion and subsequent homologous recombination (Lee and Paull, 2007). 
Therefore, the MRN complex may be involved in the initiation of ALT activity by recruiting ATM to the 
telomere and creating a larger 3’ overhang at the telomere end to be used for strand invasion of 
template telomeric DNA. Sp100 binds to and sequesters the MRN complex via its interaction with NBS1, 
and overexpression of Sp100 led to the repression of ALT, where normal cell division based telomere 
length attrition and a reduction in APBs was observed (Jiang et al., 2005). In support of the hypothesis 
that the MRN complex is critical for the ALT mechanism, depletion of any individual component of the 
complex resulted in loss of ALT mediated telomere maintenance (Zhong et al., 2007). The SMC5/6 
recombination complex is comprised of 8 subunits, three of which (methy methanesulphonate-
sensitivity 21 (MMS21), SMC5, and SMC6) are required for ALT-mediated telomere maintenance (Potts 
and Yu, 2007). The MMS21 SUMO ligase is required to sumoylate the telomere binding proteins TRF1, 
TRF2, TIN2, and RAP1 (Potts and Yu, 2007; Wu et al., 2012a). Whilst the exact role of the SMC5/6 
complex in ALT remains to be elucidated, the complex may recruit the telomere to APBs via sumoylation 
of shelterin proteins. 
 Other components of dsDNA break repair machinery and DNA replication including Fanconi 
anaemia group A (FANCA) (Fan et al., 2009), Fanconi anaemia group D2 (FANCD2) (Fan et al., 2009), flap 
enonuclease 1 (FEN1) (Saharia and Stewart, 2009), and MUS81 endonuclease (Zeng et al., 2009), have 
been implicated in the ALT mechanism although depletion of these proteins does not result in overall 
loss of telomere length due to ALT inhibition. RecQ family DNA helicases are important for the resolution 
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of atypical DNA structures and mutations to the proteins result in chromosomal abnormalities and 
disease in patients (Croteau et al., 2014). RecQ like proteins in humans include WRN, RECQL4, and BLM 
(Ellis et al., 1995; Killoran and Keck, 2006; Yu et al., 1996), mutations in which are responsible for 
Werner, Rothmund-Thomson, and Bloom syndrome, respectively. The binding partners of the BLM 
protein, as identified by mass spectrometry, include heat shock protein 90 (HPSP90), telomerase-
associated protein 1 (TEP1), topoisomerase III alpha (TOPO IIIα), and the shelterin proteins TRF1 and 
TRF2 (Bhattacharyya et al., 2009). Depletion of TOPO IIIα in ALT but not telomerase-positive cells 
resulted in increased cell death and DNA damage at the telomere but a concurrent reduction in the level 
of TRF2 protein could also account for these observations (Bhattacharyya et al., 2009; Temime-Smaali 
et al., 2008). Interestingly, the WRN protein is not essential to the ALT mechanism (Laud et al., 2005) 
despite its role in the separation of dsDNA, likely due to redundancy in the function of other RecQ 
helicases. Indeed, recent studies have suggested that many DDR and homologous recombination 
proteins maintain normal telomere function rather than, or perhaps in addition to, being required for 
the ALT mechanism (Fan et al., 2009; Saharia and Stewart, 2009; Saharia et al., 2010; Verdun and 
Karlseder, 2006; Zeng and Yang, 2009). 
1.4.2.5. ALT in cancer and normal cells 
The role of ALT has not been established in normal human cells and currently the best evidence for ALT 
function in embryogenesis and normal somatic cells comes from murine models. Telomere length 
analysis of oocytes and early embryos revealed that telomeres were short in oocytes but then 
lengthened until blastocysts were formed (Liu et al., 2007). Telomerase activity remained consistently 
low until blastocyst formation, demonstrating that telomerase activity alone was not responsible for the 
increase in telomere length and indeed, the early cleavage embryos contained evidence of telomere 
sister chromatid exchange and recombination suggestive of the ALT mechanism (Liu et al., 2007). 
However, there is not complete concordance with these results, as a subsequent study incorporating a 
tag into a single telomere only observed copying of the telomere via recombination in somatic cells and 
not germ-line cells (Neumann et al., 2013). This discrepancy may be due to the different detection 
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methods used by each group and the inability of the telomere tag to detect intra-telomeric 
recombination arising from the ALT mechanism (Neumann et al., 2013). The ALT mechanism has also 
been detected in a range of eukaryotes including mosquitoes (Mason and Biessmann, 1995), the plant 
Arabidopsis thaliana (Riha et al., 2001), the worm Caenorhabditis elegans (Cheng et al., 2012; Lackner 
et al., 2012) and the yeasts C. cerevisiae (Lundblad and Blackburn, 1993) and K. lactis (McEachern and 
Blackburn, 1996).  These studies provide evidence that ALT activity is present in a range of cells and the 
ALT mechanism observed in human cancers may be the result of a dysregulated normal TLM.  
The prevalence of ALT in human cancers has not been as widely studied as telomerase due to 
the difficulty in obtaining enough tumour material for assays and the need to perform multiple assays 
for the identification of the ALT mechanism. However, this has changed with the recent development 
of a telomere quantitative polymerase chain reaction (qPCR) based assay to detect C-circles which 
allows ALT to be detected from as little as 30 ng of DNA (Lau et al., 2013). Lau et al. (2013) described a 
cut-off for C-circle levels indicative of an active ALT mechanism, detected by qPCR, which gives 100% 
concordance with APB assay results and the conventional C-circle assay detected by a P32-radiolabelled 
telomere probe, validated in a cohort of 23 cell lines and 43 tumours including glioblastoma, melanoma, 
and soft tissue sarcoma samples. The prevalence of ALT has been studied in cancers including 
osteosarcoma, gastric carcinoma, soft tissue sarcoma, astrocytoma, mesothelioma, adrenocortical 
carcinoma, ovarian carcinoma, melanoma, NB, medulloblastoma, breast carcinoma, colon carcinoma, 
Ewings sarcoma, PanNETs and lung carcinoma (Figure 1.4. indicates prevalence of ALT according to 
tumour tissue type) (Bryan et al., 1997; Costa et al., 2006; Else et al., 2008; Guilleret et al., 2002; Hakin-
Smith et al., 2003; Heaphy et al., 2011b; Henson et al., 2005; Jiao et al., 2011; Johnson et al., 2005; 
Matsuo et al., 2009; Montgomery et al., 2004; Omori et al., 2009; Onitake et al., 2009; Sanders et al., 
2004; Scarpa et al., 2017; Subhawong et al., 2009; Ulaner et al., 2004; Ulaner et al., 2003; Villa et al., 
2008; Yan et al., 2002).  
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Figure 1.4. Prevalence of ALT in human cancer based on tumour tissue type.  
The prevalence of ALT varies depending on the tumour tissue type with ALT yet to be identified in 
any hematopoietic, pancreas or prostate tumours. Adapted from Dilley and Greenberg 2015. 
 
 
 The association between upregulation of ALT and prognosis is dependent on the tumour type. 
ALT is utilised for immortalisation by approximately 50% of osteosarcomas but there is no difference in 
survival between ALT-positive and ALT-negative patients (Henson et al., 2005). Interestingly, 29% of 
liposarcomas are ALT-positive and these patients have a worse survival than telomerase-positive 
patients (Pricolo et al., 1996). In contrast, glioblastoma patients with ALT tumours have a longer median 
survival compared to non-ALT tumours (Hakin-Smith et al., 2003). The prevalence of ALT is also highly 
variable in different tumour types, up to 60% of astrocytomas and sarcomas (neuroepithelial and 
mesenchymal origin respectively) are ALT-positive compared to carcinomas (epithelial in origin) where 
5-15% of tumours utilise ALT. This difference may be due to the regulation of ALT in specific cell types 
(Henson and Reddel, 2010).  
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Normal cells appear to contain repressors of the ALT mechanism since the fusion of the ALT cell 
line GM847 and normal fibroblasts resulted in a rapid loss of telomere sequence and onset of 
senescence (Perrem et al., 1999). Hybridisation of ALT and telomerase-positive immortalised cell lines 
created cells that utilised only one telomere maintenance mechanism (Bower et al., 2012; Ishii et al., 
1999; Perrem et al., 2001). This implies that telomerase-positive cells contain a repressor of ALT and 
ALT-positive cells contain repressors of telomerase (Bower et al., 2012). Hence, the tumour types with 
low or no ALT activity may contain repressors of ALT and tumour types with higher ALT prevalence may 
more tightly regulate telomerase expression.       
1.4.2.6. Anti-cancer therapeutics and ALT 
To date, there are no ALT targeted anti-cancer therapeutics available, although there is some debate 
regarding the potential to use ATR inhibitors as an anti-ALT therapy (Deeg et al., 2016; Flynn et al., 2015). 
A better understanding of the mechanism and the prevalence of ALT is necessary to develop treatments 
and determine patient groups eligible for targeted therapies. There is also evidence that cells within a 
single tumour can utilise both telomerase and ALT (Bryan et al., 1997), although it is unclear if both exist 
in a single cell or it is the result of heterogeneity within the tumour. It is possible to artificially generate 
telomerase expression in ALT immortalised cell lines, and this has been used to demonstrate that both 
mechanisms can co-exist in a single cell (Cerone et al., 2001; Grobelny et al., 2001; Perrem et al., 2001). 
Consequently, anti-cancer therapies targeted to a TLM must take into consideration whether one or 
both TLMs are present in the tumour. 
Another concern with telomere maintenance mechanism targeted therapies is the possibility 
that cells can change their active mechanism if one becomes non-functional. Inhibition of hTERT in a 
telomerase positive cell line resulted in cells that could maintain telomere length and grow for over 200 
PDs once telomerase became inactive, although the cells possessed no typical features of ALT such as 
APBs or long and heterogeneous telomere lengths (Kumakura et al., 2005). This indicates, in principle, 
that cells have the ability to activate alternative pathways for telomere length maintenance if their TLM 
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becomes compromised. Whilst, there is no evidence to suggest that human cancers treated with a 
telomerase targeted anti-cancer therapeutic activate the ALT mechanism to continue telomere length 
maintenance, telomerase inhibition has resulted in the emergence of ALT cells in mouse cells (Hu et al., 
2012). Therefore, targeting telomerase as an anti-cancer therapeutic has the potential to select for ALT-
positive cells which would be resistant to such therapies supporting the need to develop anti-cancer 
therapeutics against both TLMs.  
1.4.3. Telomere lengthening maintenance negative samples 
Immortalisation via activation of a TLM is currently regarded as a hallmark of cancer (Hanahan and 
Weinberg, 2000; Hanahan and Weinberg, 2011) although, it has been postulated that immortalisation 
may not be required in cancers with a low level of tumour cell death or genetically simple cancers that 
do not require extensive clonal evolution (Kipling, 1995; Parkinson, 1996; Reddel, 2000). A human 
fibroblast isolated from a middle-aged person is capable of an additional 20-40 PDs (Hayflick, 1965). If 
every cell survives, 40 PDs can generate 240 cells which would form a tumour mass of 1 kg. However, cell 
death occurs in most tumours due to factors like an inadequate blood supply resulting in hypoxia and 
necrosis, or due to non-viable cells created during the clonal evolution of the tumour. Consequently, 
the majority of tumours activate a TLM to obtain the proliferative capacity to form a tumour mass. This 
may not be required for tumours that have long telomere lengths in their progenitor cells, in cancers 
such as leukaemias which do not undergo cell death due to limited blood supply, and in genetically 
simple cancers. In keeping with the hypothesis that immortalisation is not an absolute requirement of 
carcinogenesis, a substantial proportion of liposarcomas (Costa et al., 2006; Jeyapalan et al., 2008), 
glioblastoma (Hakin-Smith et al., 2003), retinoblastomas (Gupta et al., 1996), and osteosarcomas 
(Ulaner et al., 2003) have been reported as TLM-negative. While these tumours may be truly TLM-
negative, this could also be the result of false negative assays or an as-yet unidentified ALT mechanism 
lacking the usual phenotypic characteristics. To date, it has been impossible to test which of these 
scenarios is true, as the definitive test for telomere length maintenance is to examine telomere length 
over time which would require serial samples of untreated human tumours, samples impossible to 
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obtain. It is increasingly important to define what is happening in this group of tumours as TLM-
inhibitors are moving toward clinical use and TLM-negative tumours would be resistant to such 
treatment. Large-scale studies are also moving towards genetic markers such as telomere length and 
hTERT and ATRX/DAXX mutations to define TLMs (Barthel et al., 2017; Pekmezci et al., 2017; Scarpa et 
al., 2017; Valentijn et al., 2015) and the molecular details of TLM-negative tumours would ensure that 
tumours are not misclassified.  
1.5. Neuroblastoma 
Neuroblastoma (NB) is an embryonal cancer that arises in the sympathetic nervous system. The disease 
predominantly affects infants or young children, with an annual incidence of 29 patients/million infants 
<1-year-old, which is reduced to one patient/million in children 10-14 years old (Lau and Irwin, 2017). 
NB is the most common extracranial solid tumour in children, responsible for 7-10% of cancers in 
children under 15 years, yet it accounts for 15% of deaths in paediatric oncology patients (Maris et al., 
2007).  
1.5.1. Disease stages 
The majority of NB patients (65%) present with a primary tumour in the abdomen, most commonly 
adjacent to the adrenal gland. Other sites of primary disease include the pelvis, chest and neck (Maris 
et al., 2007). Metastatic disease is present in nearly half of patients at diagnosis, either in lymph nodes 
adjacent to the primary tumour, or at distant sites such as the bone marrow, cortical bones, the liver 
and non-adjacent lymph nodes (Maris et al., 2007). Diagnosis can be made by the histology of the 
tumour or the presence of tumour cells in the bone marrow combined with elevated catecholamine 
levels in the urine. The tumour size and invasiveness and metastatic sites can be determined with CT or 
MRI scan in conjunction with radiolabelled meta-iodobenzylguanidine (123I-MIBG).  
 Established in 1993, The International Neuroblastoma Staging System (INSS) (Brodeur et al., 
1993) is a classification system based on clinical and biological prognostic markers. However, a more 
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recent system of classification, the International Neuroblastoma Risk Group Staging System (INRGSS) 
(Cohn et al., 2009), has been developed to ensure uniform risk stratification and comparison of clinical 
trials across large international bodies such as the Children’s Oncology Group (COG) and the 
International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN). The INRGSS classifies NB 
into stages L1, L2, M, and MS. Stage L1 and L2 represent locoregional disease in the absence and 
presence of image-defined risk factors, respectively. Stage M (equivalent to INSS stage 4) includes all 
metastatic disease unless classified stage MS. Stage MS is similar to INSS Stage 4S with metastases 
limited to the liver, skin and bone marrow, except that it includes patients up to age 18 months and 
large primary tumours (L1 or L2) (Monclair et al., 2009). Stage MS, which will be referred to as stage 4S 
in remainder of this thesis, is a unique group of NB that has the propensity to spontaneously regress in 
the absence of treatment (D'Angio et al., 1971). The staging of NB reflects the heterogeneity of the 
disease, ranging from tumours that can spontaneously regress, to metastatic disease that conveys a 2-
year event free survival of only 66% (Yu et al., 2010). 
1.5.2. Risk stratification 
There are a number of biological and clinical factors that need to be considered when stratifying NB 
patients into risk groups, including: stage, age at diagnosis, histology of the tumour, differentiation 
within the tumour, MYCN amplification, 11q aberration, and ploidy of the tumour. Based on these 
features the INRGSS classifies NB patients into 16 pre-treatment risk categories (A to R) which are 
further classified into risk subsets based on the 5-year event-free survival (EFS) of each category (Table 
1.2); very low risk (5-year EFS >85%), low-risk (5-year EFS >75 to ≤85%), intermediate-risk (5-year EFS 
≥50% to ≤75%) and high-risk (5-year EFS <50%) (Cohn et al., 2009; Monclair et al., 2009). 
1.5.2.1. Histology and degree of differentiation 
NB tumours are comprised of small, round blue cells with reduced cytoplasm and darkly staining nuclei. 
A panel of antibodies is used to distinguish NB from other solid tumour types and the International 
Neuroblastoma Pathology Classification System (INPC) uses a modified Shimada system to determine 
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the degree of Schwannian stroma (NB, stroma-poor; ganglioblastoma intermixed, stroma-rich; 
ganglioneuroma, stroma-dominant; or ganglioneuroblastoma, composite rich/dominant and stroma-
poor), neuroblast differentiation (differentiating, poorly differentiated, or undifferentiated) and mitosis-
karyorrhexis index (high, intermediate or low) of the tumour (Shimada et al., 1999). The tumours are 
classified into favourable or unfavourable histology groups based on the combination of these features 
and age at diagnosis (Shimada et al., 2001).      
1.5.2.2. Age at diagnosis 
The median age at diagnosis of NB is 19 months, and 90% of patients are younger than 5 years of age at 
diagnosis (London et al., 2005). Age at diagnosis correlates to the EFS of patients with Stage 4 MYCN 
non-amplified NB, with children >24 months at diagnosis (6-year EFS of 31%) having a significantly 
poorer prognosis than patients 12 to 18 months old at diagnosis (6-year EFS of 74%) (Schmidt et al., 
2005).  
1.5.2.3. MYCN amplification 
The proto-oncogene MYCN is located at chromosome 2p24 and amplification of the gene occurs in 
approximately 22% of primary tumours and is associated with high-risk NB across all stages of disease 
(Ambros et al., 2009; Bagatell et al., 2009; Brodeur et al., 1984; Cohn et al., 2009; Seeger et al., 1985). 
Amplified MYCN DNA can be found in double-minute chromatin bodies (DMs) or homogeneously 
staining regions (HSRs) which can be detected by MYCN FISH in the nuclei of NB cells (Corvi et al., 1994; 
Schwab et al., 1984). MYCN amplification is defined as ≥10 copies of MYCN in a diploid cell or a >4-fold 
increase in signal compared to chromosome 2. MYCN oncoprotein is a transcription factor that binds to 
the promoter region of target genes involved in differentiation, cellular proliferation, and apoptosis, 
through binding to E-box recognition sites (Murphy et al., 2009). Transgenic mouse models of MYCN 
overexpression result in spontaneous NB, indicating MYCN expression has a role in NB oncogenesis 
(Weiss et al., 1997), however, it remains to be elucidated by which mechanisms MYCN amplification 
results in aggressive NB tumours. Currently, there is no successful therapeutic to target MYCN but as  
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Table 1.2. Neuroblastoma risk group classification for stages L1/L2, L1 and MS. 
Stage L1/L2 L1 MS 
Age (months)     <18 
Histology  
Ganglioneuroma 
maturing; 
ganglineuroblastoma 
intermixed 
Any except 
ganglioneuroma 
maturing or 
ganglineuroblastoma 
intermixed 
      
Differentiation             
MYCN   
Non-
amplified 
Amplified Non-amplified Amplified 
11q loss of 
heterozygosity 
      No Yes   
Ploidy             
INRG category A B K C Q R 
Risk group Very low Very low High Very low High High 
 
 
Table 1.3. Neuroblastoma risk group classification of stage L2.  
Stage L2 
Age (months) <18 ≥18 
Histology  
Any except 
ganglioneuroma maturing 
or ganglineuroblastoma 
intermixed 
Ganglineuroblastoma nodular or neuroblastoma 
Differentiation   Differentiating 
Poorly or un-
differentiated 
  
MYCN Non-amplified Non-amplified Non-amplified Amplified 
11q loss of 
heterozygosity 
No Yes No Yes     
Ploidy             
INRG category D G E H H N 
Risk group Low Intermediate Low Intermediate Intermediate High 
 
 
Table 1.4. Neuroblastoma risk group classification of stage M. 
Stage M 
Age (months) <18 <12 Dec-18 <18 ≥18 
Histology            
Differentiation           
MYCN Non-amplified Non-amplified Non-amplified Amplified   
11q loss of 
heterozygosity 
          
Ploidy Hyperdiploid Diploid Diploid     
INRG category F I J O P 
Risk group Low Intermediate Intermediate High High 
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Aurora kinase A is required to stabilise MYCN protein, the inhibitor MLN8237 is currently in clinical trial 
in combination with chemotherapy (Mosse et al., 2012) (clinical trial: NCT01601535). Inhibition of the 
MYCN downstream target ornithine decarboxylase by difluoromethylorthinine is also in clinical trial 
(clinical trial: NCT02030964).           
1.5.2.4. Tumour ploidy and chromosome aberrations 
Tumour ploidy is an independent prognostic factor, predominantly in patients less than 18 months of 
age (George et al., 2005; Schleiermacher et al., 2010). The ploidy of a NB tumour refers to the DNA 
content of the cells and is indicative of the type of genetic rearrangement that the tumour has 
undergone. Hyperdiploid tumours have whole chromosome gains and therefore, little structural 
rearrangement of chromosomes, which confers a more favourable outcome for patients (Kaneko et al., 
1987; Look et al., 1991). In contrast, diploid tumours are associated with advanced-stage disease and 
poor prognostic markers including MYCN amplification and loss of 1p or 11q (Attiyeh et al., 2005; Cohn 
et al., 2009; Kaneko et al., 1987; Look et al., 1991). 
 Loss of heterozygosity (LOH) of 11q has been identified in 34-45% of primary NBs (Attiyeh et al., 
2005; Guo et al., 1999; Plantaz et al., 1997; Spitz et al., 2003). 11q LOH does not correlate with MYCN 
amplification but is associated with high-risk features such as unfavourable histology and poor survival.  
Consequently, LOH of 11q has been identified as a prognostic factor in MYCN non-amplified tumours 
and is used in the INRGSS to predict outcome in the stage L2 MYCN non-amplified tumours. The short 
arm of chromosome 1 (1p) is deleted in 25-35% of NBs and correlates with MYCN amplification (Attiyeh 
et al., 2005; Brodeur et al., 1981; Christiansen et al., 2000; Kaneko et al., 1987; Plantaz et al., 1997). 
Allelic loss at 1p36 is associated with an increased risk of relapse, although it is only an independent 
prognostic factor in low or intermediate risk tumours. Gain of additional copies of 17q, often occurs 
through unbalanced translocation with chromosome 1 or 11, and is associated with aggressive disease 
(Bown et al., 1999; Van Roy et al., 1997). It has been suggested that changes to ploidy are required for 
the gain of tumour driver genes on 17q and a loss of tumour suppressor genes on 1p or 11q, however, 
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a recent study identified loss of 1p and 11q in relapse but not matched primary tumours (Eleveld et al., 
2015), suggesting these events are not tumour initiating but rather a step in aggressive tumour 
evolution.    
1.5.3. Treatment 
NB treatment may vary depending on clinical trials group. The following therapies reflect COG protocols 
for NB treatment. Low-risk NB has a good prognosis and a 5-year EFS of 75-85% (Monclair et al., 2009). 
As such, minimal treatment is offered to patients who have tumours with favourable biology. If surgery 
is performed, partial resection with residual disease is not a risk for relapse in these patients (Strother 
et al., 2012). Chemotherapy (with or without surgery) consisting of low doses of carboplatin, 
cyclophosphamide, doxorubicin and etoposide is given to patients who have life-threatening symptoms, 
progressive disease after surgery, or unfavourable tumour biology in the resected tumour. In contrast, 
stage 4S NB with no high-risk markers can be observed and given supportive care. Treatment with 
chemotherapy is only given if the patient becomes symptomatic or the tumour has unfavourable biology 
as most tumours spontaneously regress without any intervention (Nickerson et al., 2000).       
 Intermediate risk NB have a poorer survival (5-year EFS 50-75%) than low risk patients, and are 
treated with chemotherapy and surgery (Baker et al., 2010). Chemotherapy can consist of 4 or 8 cycles 
of carboplatin, cyclophosphamide, doxorubicin and etoposide. Four cycles are given for tumours with 
favourable biology whilst 8 cycles are used when the biology is unfavourable. 
 The standard regimen for high-risk NB treatment consists of three phases: induction, 
consolidation, and post-consolidation (Matthay  et al., 1999; Park et al., 2011). The current COG trial 
protocol for induction therapy involves 6 cycles of dose-intensive chemotherapy. The first two cycles 
include a combination of topotecan and cyclophosphamide, then a combination of etoposide and 
cisplatin for cycles 3 and 5, and for cycles 4 and 6 a combination of doxorubicin, cyclophosphamide and 
vincristine (Park et al., 2011). The response to induction therapy is a prognostic indicator for high-risk 
patients, and correlates with patient survival after the completion of therapy (Cheung et al., 1991). 
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Consequently, tumours are monitored with MIBG scoring systems at diagnosis and at the end of 
induction therapy (Yanik et al., 2013). Local resection of the tumour is recommended after 4-6 cycles of 
chemotherapy, although it is debatable that complete resection improves the outcome of patients 
(Alonso et al., 2006; Castel et al., 2002; Du et al., 2014; Simon et al., 2013). Patients then receive 
consolidation therapy consisting of myeloablative chemotherapy and autologous stem cell 
transplantation. Myeloablative chemotherapy comprises of treatment with melphalan, followed by 
carboplatin and etoposide. After completion of consolidation therapy, patients may also receive 
radiation treatment. Though patients receive multi-modal therapy, relapse remains common in high-
risk NB, suggesting that minimal residual disease is an important factor in recurrence. To treat minimal 
residual disease, it is standard to use non-cytotoxic differentiation therapy (treatment with 13-cis 
retinoic acid), as post-consolidation therapy for high-risk NB (Matthay et al., 2009b) in addition to 
immunotherapy with anti-ganglioside 2 (GD2) chimeric antibody (Simon et al., 2011) and cytokines 
(interleukin-2 [IL-2] and granulocyte macrophage colony-stimulating factor [GMCSF]) (Yu et al., 2010). 
 Despite intensive treatment many high-risk patients have refractory disease or experience 
recurrence, and there is no curative therapy for the majority of these patients (London et al., 2011). 
Indeed, stage 4 patients with relapsed disease only have a 5-year overall survival of 8% (London et al., 
2011).  Relapsed patients generally present with metastatic disease, that has acquired mutations as a 
result of primary therapy and are consequently drug resistant (Carr-Wilkinson et al., 2010; Keshelava et 
al., 2001; Tweddle et al., 2001). Therefore, patients that are treated with further chemotherapy, receive 
agents with a mode of action distinct from therapies used in the initial treatment. Examples of relapse 
therapy include temozolomide with irinotecan, topotecan in combination with etoposide or 
cyclophosphamide, high dose 131I-MIBG therapy and a second autologous stem cell transplantation 
(Kushner et al., 2006; Matthay et al., 2009a; Simon et al., 2007). Patients can also be enrolled in early 
phase clinical trials.  
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1.5.4. Predisposition genes  
Familial NB is rare, accounting for only 1-2% of NB cases, and is generally autosomal dominant with 
incomplete penetrance (Kushner et al., 1986; Maris et al., 2002). Correlation between mutations and 
cases of familial NB led to candidate predisposition regions being located at 16p, 12p and 2p23-26 (Maris 
et al., 1997), ultimately resulting in the identification of the anaplastic lymphoma kinase (ALK) gene. A 
proportion of the ALK mutations identified in patients are the result of germline missense mutations 
(Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008). Patients with 
NB associated with Hirschsprung disease or congenital central hypoventilation have germline PHOX2B 
mutations (Mosse et al., 2004; Trochet et al., 2004). Consequently, the two most common 
predisposition genes associated with NB tumour formation are ALK and PHOX2B. Single nucleotide 
polymorphisms (SNPs) that have been reported to increase the risk of NB include HACE1 (Diskin et al., 
2012), LIN28B (Diskin et al., 2012), BARD1 (Capasso et al., 2009; Pugh et al., 2013), FGFR4 (Whittle et 
al., 2016), CHEK2 (Pugh et al., 2013), PINK1 (Pugh et al., 2013), TP53 (Pugh et al., 2013) and LM01 (Wang 
et al., 2011).  
1.5.5. Genetic features of sporadic neuroblastoma 
Despite the ability to stratify patients there is very little understood about how these factors drive the 
NB tumour. Recently, studies utilising next generation sequencing techniques have been undertaken to 
determine the genetic mutations that are responsible for driving NB pathogenesis in an effort to design 
targeted therapies. Genome-wide association studies (GWAS) have identified several SNPs that are 
associated with sporadic NB. Low-risk NB is associated with SNPs in DUSP12, HSD17B12, and 
DDX4/IL31RA at chromosome 5q11.2 (Nguyen le et al., 2011), whereas high-risk tumours are associated 
with SNPs within or upstream of 6p22 (Maris et al., 2008), HACE1 (Diskin et al., 2012), LIN28B (Diskin et 
al., 2012), BARD1 (Capasso et al., 2009), FGFR4 (Whittle et al., 2016), and LM01 (Wang et al., 2011). A 
common copy number variation in chromosome 1q21 that effects NBPF23 expression was also 
identified in NB tumours (Diskin et al., 2009). In addition to familial NB, ALK mutations are present in 
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sporadic cases: 6-12% carry somatic mutations, 15-22% have gained copies of ALK and 3-4% have ALK 
amplification (Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008; 
Pugh et al., 2013). Recent evidence suggests that there is epigenetic regulation of ALK expression in 
samples with wild type ALK sequence (Gomez et al., 2015). Due to the prevalence of upregulated ALK 
expression in unfavourable NB, ALK has become a target of novel NB therapies. Currently the ALK 
inhibitor, crizotinib, is in clinical trial (Mosse et al., 2013) (clinical trial NCT01606878) and newer 
inhibitors are under development.      
 With the increased ability to perform whole exome and whole genome sequencing several 
genome wide studies (Cheung et al., 2012; Molenaar et al., 2012; Peifer et al., 2015; Pugh et al., 2013; 
Sausen et al., 2013) have been conducted to determine the somatic alterations present in NB tumours. 
As expected, genetic events previously linked to NB prognosis were identified including MYCN 
amplification, 1p and 11q deletion and 17q gains. A very low level of recurrent gene mutations was 
detected, only 12-14 amino acid affecting mutations were present per tumour (Molenaar et al., 2012; 
Peifer et al., 2015; Pugh et al., 2013; Sausen et al., 2013). This is consistent with evidence that cancers 
in paediatric patients carry fewer genetic alterations than adult cancers (Alexandrov et al., 2013; Jones 
et al., 2008; Parsons et al., 2011; Vogelstein et al., 2013). The most frequently mutated genes in high-
risk NB are ALK (9.2%), ATRX (9.6%), PTPN11 (2.9%), MYCN (1.7%), and NRAS (0.83%) (Pugh et al., 2013). 
Of interest, alterations to the ATRX gene were seen at rates comparable to ALK (Molenaar et al., 2012; 
Peifer et al., 2015; Pugh et al., 2013) and predominantly in older patients without MYCN amplification 
(Cheung et al., 2012; Peifer et al., 2015; Pugh et al., 2013). This suggests that ALT may be a significant 
factor in NB pathogenesis, particularly for older patients. One study also identified the chromatin 
remodelling genes ARID1A and ARID1B as altered in 11% of tumours and associated with poor survival 
(Sausen et al., 2013). The Rac/Rho and neuritogenesis pathways were identified as frequently defective 
in NB tumours in one study (Molenaar et al., 2012) however, this was not evident in the high-risk tumour 
cohort of Pugh and colleagues (Pugh et al., 2013). Whilst mutations to TP53 are one of the most common 
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events in cancer overall, the gene is rarely mutated at diagnosis in NB (Vogan et al., 1993), although 15% 
of recurrent tumours have acquired a TP53 mutation (Carr-Wilkinson et al., 2010).  
 Chromothripsis is a form of chromosomal rearrangement caused by the shattering of a 
chromosomal region which results in the random reassembly of most of the fragments by DNA repair 
mechanisms (Stephens et al., 2011). Analysis of structural rearrangements in NB identified 
chromothripsis in 18% of high-stage tumours and absent in low-stage tumours (Molenaar et al., 2012). 
Consequently, chromothripsis correlated with poor outcome although, subsequent studies found 
chromothripsis in only 0-4% of NB (Peifer et al., 2015; Sausen et al., 2013). Another structural event that 
has been identified in 24-31% of high-risk NB is a structural rearrangement 30-50 kb upstream of the 
hTERT promoter on chromosome 5 (Peifer et al., 2015; Valentijn et al., 2015). This rearrangement results 
in an upregulation of hTERT mRNA expression due to super-enhancer elements now adjacent to the 
hTERT transcription start site (Peifer et al., 2015; Valentijn et al., 2015).  The implication of these studies 
is that NB is not a disease driven by a single mutation but rather by rare mutations, copy number 
variation, structural rearrangements, and possibly epigenetic changes.  
 Mutations to the p53 pathway have been identified as events that contribute to drug resistance 
and ultimately relapse in NB (Keshelava et al., 2001). Recently, next generation sequencing approaches 
have been used to identify novel mutations acquired by relapse tumours. Relapse tumours have a 1.5-
2-fold increase in single nucleotide variations (SNVs) compared to primary tumours (Eleveld et al., 2015; 
Schramm et al., 2015). Like primary tumours, relapse is not driven by one causative genetic aberration. 
Schramm and colleagues identified genes involved in the epithelial-mesenchymal transition, a process 
involved in cell migration, invasion and metastasis, as the most common pathway with aberrations in 
relapse tumours (Schramm et al., 2015) however, this has yet to be validated in another tumour cohort. 
The increased allelic frequency of CHD5, a putative tumour suppressor gene, from the primary to relapse 
tumour suggests that clonal selection of the primary tumour occurs, likely due to therapy (Schramm et 
al., 2015). A similar clonal evolution was observed in relapse tumours with activating ALK mutations in 
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which both increased allelic fraction of the ALK mutation, and an increase in the overall number of 
tumours effected by ALK mutations (7-9% of primary tumours to 20-26% of relapse tumours) was 
observed (Padovan-Merhar et al., 2016; Schleiermacher et al., 2014). Activating mutations to the 
RAS/MAPK pathway have been identified in primary tumours and several studies have found this is 
enriched in relapse tumours due to novel mutations and clonal selection (Eleveld et al., 2015; Padovan-
Merhar et al., 2016). Hence, the genome of NB tumours continually evolve under the selective pressure 
of treatment and biopsies of relapse tumours are required for the use of targeted therapy in these 
patients.  
1.5.6. Prognostic relevance of telomerase activity 
Telomerase expression in NB was first described over two decades ago. The initial studies utilised the 
TRAP assay to determine telomerase activity. In 1995 Hiyama and colleagues detected telomerase 
activity in 94% of tumours although, the level of activity ranged from high (20% of tumours) to low (76% 
of tumours) (Hiyama et al., 1995a). Low telomerase activity was detected in the majority of stage 1 and 
2 tumours whereas high telomerase activity was observed in stage 3 and 4 tumours. This correlated 
with a poor patient outcome in 75% of tumours with high telomerase activity but only 3.3% of tumours 
which exhibited low telomerase activity. Another study reported a similar number of tumours (96%) had 
detectable telomerase activity and that the level of activity correlated with patient outcome (Hiyama et 
al., 1997). It was therefore, concluded that telomerase activity could be a prognostic factor for NB.  
Further studies confirmed that telomerase activity correlated with NB prognostic risk group 
although, the total percentage of NB tumours reported as telomerase-positive decreased compared to 
the initial two studies. These studies described 20% (Poremba et al., 1999), 24% (Krams et al., 2001), 
29% (Poremba et al., 2000), 35% (Choi et al., 2000), and 37% (Onitake et al., 2009) of NBs as telomerase-
positive. The discrepancy between studies may be the result of false-positive TRAP results due to the 
sensitivity of the PCR. Approximately 10% of localised NB tumours maintain telomere length via 
telomerase compared to nearly 60% of metastatic disease (Poremba et al., 1999). Despite the varying 
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percentages of telomerase-positive NBs there is a correlation between high telomerase activity and 
poor prognosis (30-45% 5-year overall survival depending on tumour cohort) (Ohali et al., 2006; Onitake 
et al., 2009; Poremba et al., 2000).  
Telomerase activity has also been identified in some, but not all, stage 4S tumours that exhibit 
progressive disease (Brinkschmidt et al., 1998) and has been associated with fatal 4S tumours (Choi et 
al., 2000). It has been proposed that the spontaneous regression of stage 4S tumours is the result of 
telomere shortening and subsequent cellular senescence that occurs due to the low telomerase activity 
in these tumours (Brinkschmidt et al., 1998). Indeed, examination of the telomere length of progressive 
liver metastases biopsied from a single patient at different time points showed telomere shortening in 
spite of low levels of telomerase (Hiyama et al., 1995a).    
There are several ways that NB cells can upregulate telomerase activity. The amplification of 
MYCN has been associated with upregulated telomerase activity, in one study 65% of tumours with high 
telomerase activity were also MYCN amplified (Hiyama et al., 1997). This correlation is likely due to 
MYCN driven telomerase activity as the hTERT promoter contains binding sequences for the MYCN 
transcription factor (Cong et al., 1999; Mac et al., 2000; Wang et al., 1998). Expression of hTERT can also 
be upregulated as a result of two mutations upstream of the promoter. However, this appears to be a 
rare event in NB with 0/131 primary tumours harbouring either a C228T or a C250T mutation and only 
3/19 cell lines (all derived from the same tumour) having a C228T mutation (Lindner et al., 2015).  
Instead, up to 31% of NB tumours activate telomerase via chromosome 5 structural rearrangements 
(Peifer et al., 2015; Valentijn et al., 2015). A breakpoint 30-50 kb upstream or 6-40 kb downstream of 
the hTERT promoter results in the introduction of super-enhancer elements and the consequent 
upregulation of hTERT mRNA expression. This event is mutually exclusive with MYCN amplification and 
also with ATRX aberrations (Peifer et al., 2015; Valentijn et al., 2015). Telomerase activity has also been 
identified in all but four NB cell lines screened to date (4/40 cell lines; Farooqi et al., 2014).  
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Given the correlation between telomerase activity and poor prognosis in NB, the mechanism 
has become a target for the development of novel NB therapy. Long term treatment (4-6 weeks) with 
the telomerase inhibitor telomestatin, at non-toxic concentrations in four NB cell lines, results in a 
reduction in the growth rate of cells, a decrease in telomere length, and an increase in apoptosis (Binz 
et al., 2005). This suggests that therapies targeting TLMs may have therapeutic relevance in NB. 
1.5.7. ALT in neuroblastoma 
A subgroup of NB tumours upregulates telomerase activity to maintain their telomere length however, 
between 20 and 60% of high-risk tumours do not have detectable telomerase activity (Krams et al., 
2001; Onitake et al., 2009; Poremba et al., 2000; Poremba et al., 1999). The first evidence of ALT in NB 
relied on telomere length to identify the mechanism. Long and heterogeneous telomere lengths, a 
phenotypic characteristic of ALT, were observed in 5/9 telomerase-negative patients who had 
protracted but fatal disease (Onitake et al., 2009). Another study utilising telomere length as a marker 
of ALT indicated the mechanism may be used by up to 59% of NB tumours (Pezzolo et al., 2015). A 
subsequent study that utilised telomere length and APBs to determine ALT activity confirmed that ALT 
tumours have a poor outcome, approximately 45% 5-year overall survival, despite lacking poor 
prognostic markers such as MYCN amplification (Lundberg et al., 2011).  
 Aberrations of the ATRX gene have been reported in NB tumours (Kurihara et al., 2014; 
Lundberg et al., 2011; Onitake et al., 2009; Valentijn et al., 2015) and correlate with an upregulated ALT 
mechanism in other tumour types (Chen et al., 2014; Heaphy et al., 2011a; Jiao et al., 2012; Jiao et al., 
2011). In NB, alterations to the ATRX gene associate with long telomeres, suggestive of ALT, and patients 
with these tumours are older at diagnosis (ATRX mutations in 44% of patients aged ≥12 years, 17% of 
patients aged 18 months to <12 years and 0% patients aged <18 months) (Cheung et al., 2012). A 
retrospective examination of the tumours by Onitake and colleagues found all ALT tumours had an 
aberration to ATRX or DAXX and that ATRX alterations led to a 5-year overall survival of approximately 
40% (Kurihara et al., 2014). Mutations in ATRX or DAXX have been identified in 10-22% of high-risk NB 
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tumours (Cheung et al., 2012; Peifer et al., 2015; Valentijn et al., 2015). In most studies alterations to 
the ATRX, hTERT, and MYCN genes are mutually exclusive (Cheung et al., 2012; Peifer et al., 2015; 
Valentijn et al., 2015) and lead to a similarly poor overall survival rate of approximately 25% (Valentijn 
et al., 2015).  
 A caveat of using large genome studies to identify ALT is that ATRX and DAXX mutations are not 
a universal feature of the mechanism and relying on these genetic events would underestimate ALT in 
NB. To date four telomerase-negative NB cell lines derived from metastatic disease have been identified 
(Choi et al., 2000; Farooqi et al., 2014). Only one of these cell lines (CHLA-90) exhibited classical ALT 
phenotypes including abundant C-circles and APBs, was MYCN non-amplified and ATRX and TP53 
mutated, whilst a second cell line (SK-N-FI) retained wild type ATRX/DAXX expression but otherwise 
exhibited classical features of ALT (Farooqi et al., 2014). Therefore, it appears that ALT is present and 
clinically relevant in NB, although no study to date has utilised C-circles, the quantifiable ALT marker, to 
identify ALT in NB tumours. 
1.6. Aims of the project 
High-risk NB confers a very poor prognosis and the identification of novel biomarkers is required for the 
development of better therapy for these patients. Recent studies have identified mutations to genes 
involved in TLMs as relatively frequent events in NB (Cheung et al., 2012; Peifer et al., 2015; Valentijn 
et al., 2015). Telomerase activity is associated with poor outcome (Ohali et al., 2006; Onitake et al., 
2009; Poremba et al., 2000), whilst the identification of ALT has relied on genetic markers or telomere 
length to identify the presence of this mechanism rather than C-circles, the active marker of ALT (Cheung 
et al., 2012; Lundberg et al., 2011; Onitake et al., 2009; Peifer et al., 2015; Valentijn et al., 2015). 
Consequently, the initial aim of this study was to determine the prognostic relevance of ALT in high-risk 
NB utilising telomere length and abundant C-circles (Lau et al., 2013). Unexpectedly, we identified a 
subgroup of high-risk tumours that lacked C-circles but had a telomere content indistinguishable from 
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ALT tumours and no telomerase activity. Therefore, the aim of this study became to investigate the 
telomere biology of ALT-negative/long telomere NB. Specifically we sought to: 
1. Determine if a subgroup of fatal malignant NB tumours can develop in the absence of a TLM 
and the consequence of extensive proliferation on the telomere length of these cells. 
2. Examine the effect of activation of a TLM on ALT-negative/long telomere NB cells. 
3. Study the association between telomere biology and sensitivity to chemotherapeutics in NB.  
4. Investigate similar phenotype in other tumour types. 
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Chapter 2: Materials and Methods 
2.1. Buffers and solutions  
The buffers and solutions used throughout the methods are listed in Table 2.1. 
Table 2.1. Composition of common buffers and solutions. 
Solution Composition 
6X DNA loading buffer 0.0001% (v/v) SDS 
15% (w/v) Ficoll 400 
0.25% (w/v) Bromophenol blue 
6X TBE (Tris, borate and EDTA) 
10X phosphate buffered saline (PBS) 1.37 M NaCl 
0.1 M Na2HPO4 
0.018 M KH2PO4 
20X saline-sodium citrate (SSC) 3 M NaCl 
0.3 M Tri-sodium citrate 
Tris, borate and EDTA (TBE) 0.9 M Tris pH 8 
0.9 M Boric acid 
0.02 M ethylenediaminetetraacetic acid (EDTA) 
Tris-EDTA (TE) 10 mM Tris pH 7.6 
0.1 mM EDTA 
 
2.2. Patient samples 
The study cohort contained 149 high-risk NB samples: 19 frozen tumour specimens from The Children’s 
Hospital at Westmead Tumour Bank (Australia), 46 DNA samples from the Children’s Cancer Institute 
Tumour Bank (Australia), and 84 samples (35 frozen and 49 DNA) from the Children’s Oncology Group 
Neuroblastoma Biobank (USA). High-risk NB was defined as tumours with MYCN amplification or 
metastatic disease in patients aged ≥12 months. The samples were obtained at original diagnosis and 
data on sex, age at diagnosis, tumour stage, MYCN status (Figure 2.1), and survival were retrieved from 
the clinical database from the source of the sample. The Sydney Children’s Hospital Network and 
Northern Hospital Network Human Research Ethics Committees provided ethics approval for this study. 
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Figure 2.1. Schematic of neuroblastoma (NB) tumours used in this study based on MYCN 
amplification status. 
One hundred and forty-nine high-risk NB tumours were examined in this study, 55 were MYCN 
amplified and 94 were MYCN non-amplified tumours.  
 
2.3. Cell culture 
NB cell lines (characteristics of 6 cell lines predominantly used in the thesis in Table 2.2), and ALT and 
telomerase lines used as controls (Table 2.3), were cultured with medium supplemented with fetal 
bovine serum (FBS) and additional additives, as listed in Table 2.4. All cell lines were grown in a 
humidified incubator at 37°C with atmospheric oxygen and 5% CO2, except COG-N-328h which was 
grown under normoxic conditions (5% oxygen balanced with nitrogen). Cell lines were authenticated by 
16-locus short tandem repeat (STR) profiling and were found to be free of Mycoplasma species by 
CellBank Australia (Children’s Medical Research Institute, Westmead, NSW, Australia). 
2.4. Vectors and viral transfections 
Plasmid contructs pBABE-hTERT (Counter et al., 1998a), pBABE-hTR (Wong and Collins, 2006), pBABE 
hTR/hTERT (Wong and Collins, 2006), and pBABE empty vector (Morgenstern and Land, 1990) were 
obtained from Addgene (Plasmid #1771, 27666, 27665, 1764, respectively). Retrovirus was generated 
by Lipofectamine 2000 (Life Technologies) transfection of Phoenix-AMPHO cells (ATCC CRL-3213) with 
the plasmids, followed by harvest of the retrovirus 24 hours (hrs) later. LA-N-6 cells were retrovirally 
transduced by two rounds of viral infection with 4 µg/mL polybrene (Sigma) and retrovirus. Cells that 
stably expressed the plasmid were selected with culture medium containing 0.3 µg/mL puromycin (Life  
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Table 2.2. Characteristics of NB cell lines 
Cell Line Patient 
Characteristics 
Tissue sample 
of origin 
Tumour 
Formation in 
Mice 
References 
SH-SY5Y Stage 4,  
Female, 
48 months old at 
diagnosis 
Progressive 
disease, post 
chemotherapy, 
bone marrow 
Yes (Ross et al., 1983) 
(Nevo et al., 2008) 
SK-N-BE2c Stage 4, 
Male, 
24 months old at 
diagnosis  
Progressive 
disease, post 
chemotherapy, 
bone marrow 
Yes  (Biedler et al., 1978) 
(Ciccarone et al. 1989) 
(Reynolds et al., 1988) 
SK-N-FI 
Stage 4, 
Male, 
132 months old 
at diagnosis 
Progressive 
disease, post 
chemotherapy, 
bone marrow 
Yes (Reynolds et al., 1988) 
(Tsutsumimoto et al., 
2014) 
(Farooqi et al., 2014) 
CHLA-90 
Stage 4, 
Male, 
102 months old 
at diagnosis 
Progressive 
disease, bone 
marrow 
transplant 
 (Keshelava et al., 1998) 
LA-N-6 
Stage 4, 
Male, 
60 months old at 
diagnosis 
Progressive 
disease, post 
chemotherapy, 
bone marrow 
Yes (Reynolds et al., 1988) 
(Wada et al., 1993) 
COG-N-291 
 Progressive 
disease, post 
chemotherapy 
 (Farooqi et al., 2014) 
 
Table 2.3. Telomere lengthening mechanism of control cell lines 
Cell Line Telomere Lengthening 
Mechanism 
Reference 
A2182 Telomerase + (Ng et al., 2009) 
DOS16 ALT + (Henson et al., 2009) 
G292 ALT + (Bryan et al., 1997) 
GM639 Telomerase + (Bryan et al., 1995) 
GM847 ALT + (Bryan et al., 1995) 
HeLa 1.2.11 Telomerase + (Whitaker et al., 1995) 
HFF5 Mortal (Bryan et al., 1995) 
HT1080 Telomerase + (Whitaker et al., 1995) 
HT1080 hTR Telomerase + (Pickett et al., 2009) 
IIICF/c ALT + (Bryan et al., 1995) 
MeT-4A ALT + (Bryan et al., 1995) 
MG-63 Telomerase + (Bryan et al., 1997) 
MRC-5 Mortal (Huschtscha and Holliday, 1983) 
SAOS-2 ALT + (Bryan et al., 1997) 
U-2 OS ALT + (Bryan et al., 1997) 
 
 
55 
 
Technologies) for 7 days. Sub-clones were isolated by plating cells, post puromycin selection, at a density 
of 100 cells/mL with conditioning medium. 
2.5. Cell proliferation assay 
Cells were seeded in 96-well plates according to the density in Table 2.5 and treated with serial dilutions 
of drugs (6 wells were treated with every drug concentration; Table 2.6) at 37°C with 5% CO2 for 6 PDs. 
Drugs were replenished every 72 hrs and experiments were performed in triplicate. At the end of 
treatment 10 µL of AlamarBlue (Thermo Fischer Scientific) was added to each well containing 100 µL of 
medium/drug and incubated at 37°C with 5% CO2 for 4 hrs. AlamarBlue is a fluormetric indicator, where 
the change in fluorescence correlates with the number of metabolically active cells. The fluorescence 
was measured in a fluorescence plate reader (EnSpire, Perkin Elmer) with an excitation wavelength 570 
nm and an emission wavelength at 585 nm. The results were expressed as a percentage of the untreated 
control and GraphPad Prism6 was used to determine the IC50 dose (the dose that inhibited 50% of 
untreated control cells growth). 
2.6. Immunostaining and fluorescence in situ hybridisation (FISH) 
2.6.1. ATRX and DAXX immunofluorescence (IF) 
Cells grown in two-well chamber slides were washed once with 1X PBS and then fixed with 4% PFA for 
10 minutes (mins) at room temperature. The cells were rinsed with 2X PBS and permeabilised in 0.1% 
Triton-X for 10 mins, and then washed again with 2X PBS. Cells were blocked, at room temperature, with 
5% goat serum/bovine serum albumin (BSA) for 20 mins before the cells were incubated for 1 hr at 37°C 
with either anti-ATRX or DAXX rabbit polyclonal antibody (Sigma) diluted 1:500 in 3% BSA/4X SSC. To 
remove excess antibody, the cells were washed three times with 0.1% Tween-20/4X SSC and were then 
incubated with Alexa Fluor 594 goat anti-rabbit secondary antibody (Invitrogen) diluted 1:1000 in 3% 
BSA/4X SSC. After incubation at room temperature for 1 hr, the cells were washed three times with 0.1% 
Tween-20/4X SSC and the DNA was stained with 20 µg/mL 4, 6 diamidino-2-phenylindole (DAPI) in 1X  
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Table 2.4. Cell culture medium. 
 
Cell Line 
Cell Type Medium FBS (%) Additives 
A2182 Lung Carcinoma DMEM- with L-glutamine 10  
CHLA-42 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
CHLA-90 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
CHLA-95 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
CHLA-119 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
CHLA-122 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
CHLA-136 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
CHLA-140 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
CHLA-171 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
CHLA-172 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
CHLA-225 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
CHP-134 Neuroblastoma RPMI-1640 10 1% L-glutamine 
COG-N-291 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
COG-N-328h Neuroblastoma IMDM 20 
2% L-glutamine 
1X ITS 
COG-N-347 Neuroblastoma IMDM 20 
2% L-glutamine 
1X ITS 
DOS16 Leiomyosarcoma RPMI-1640 10  
FU-NB-2006 Neuroblastoma IMDM 15 
2% L-glutamine 
1X ITS 
G292 Osteosarcoma 
McCoy's 5a Medium 
Modified 
10  
GM639 Fibroblast, skin DMEM- with L-glutamine 10  
GM847 Fibroblast, skin DMEM- with L-glutamine 10  
HeLa 1.2.11 Cervical carcinoma RPMI-1640 10 1% L-glutamine 
HFF5 Fibroblast, foreskin DMEM- with L-glutamine 10  
HT1080 Fibrosarcoma DMEM- with L-glutamine 10  
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Abbreviations: DMEM, Dulbecco’s Modified Eagle’s Medium; IMDM, Iscove's Modified Dulbecco's 
Medium; LHC-MM, Laboratory of Human Carcinogenesis Mesothelial Medium; MEM, minimum 
essential medium; ITS, insulin-transferrin-selenium-sodium pyruvate; NEAA, non-essential amino acids; 
RPMI-1640, Roswell Park Memorial Institute 1640. 
 
HT1080 hTR Fibrosarcoma DMEM- with L-glutamine 10  
IIICF/c 
Fibroblast, breast, 
Li-Fraumeni 
syndrome 
DMEM- with L-glutamine 10  
IMR32 Neuroblastoma DMEM- with L-glutamine 10  
KELLY Neuroblastoma RPMI-1640 10 1% L-glutamine 
LA-N-1 Neuroblastoma MEM-F12 with L-glutamine 10 1% NEAA 
LA-N-2 Neuroblastoma MEM-F12 with L-glutamine 10 1% NEAA 
LA-N-5 Neuroblastoma RPMI-1640 10 1% L-glutamine 
LA-N-6 Neuroblastoma RPMI-1640 10 1% L-glutamine 
MeT-4A Mesothelial LHC-MM 3  
MG-63 Osteosarcoma DMEM- with L-glutamine 10  
MRC-5 Fibroblast, lung DMEM- with L-glutamine 10  
NB69 Neuroblastoma RPMI-1640 10 1% L-glutamine 
SAOS-2 Osteosarcoma DMEM- with L-glutamine 10  
SH-EP Neuroblastoma DMEM- with L-glutamine 10  
SH-SY5Y Neuroblastoma DMEM- with L-glutamine 10 1% NEAA 
SK-LU-1 Adenocarcinoma DMEM- with L-glutamine 10  
SK-N-AS Neuroblastoma DMEM- with L-glutamine 10  
SK-N-BE1 Neuroblastoma RPMI-1640 10 1% L-glutamine 
SK-N-BE2c Neuroblastoma DMEM- with L-glutamine 10  
SK-N-DZ Neuroblastoma DMEM- with L-glutamine 10  
SK-N-FI Neuroblastoma RPMI-1640 10 1% L-glutamine 
SK-N-SH Neuroblastoma DMEM- with L-glutamine 10  
SMS-KANR Neuroblastoma RPMI-1640 10 1% L-glutamine 
SMS-KCN Neuroblastoma RPMI-1640 10 1% L-glutamine 
SMS-KCNR Neuroblastoma RPMI-1640 10 1% L-glutamine 
SMS-LHN Neuroblastoma RPMI-1640 10 1% L-glutamine 
SMS-SAN Neuroblastoma RPMI-1640 10 1% L-glutamine 
U-2 OS Osteosarcoma DMEM- with L-glutamine 10  
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Table 2.5. Seeding density of cell lines in the cell proliferation assay. 
Cell Line Seeding Density (X104 cells/well) 
COG-N-291 1.6 
CHLA-90 0.25 
GM639 0.125 
GM847 0.1 
HeLa 1.2.11 0.38 
HT1080  0.1 
HT1080 hTR 0.2 
LA-N-6 2.5 
SK-N-BE2c 0.15 
SK-N-FI 1 
SH-SY5Y 0.375 
U-2 OS 0.125 
 
 
PBS for 1 min. The slides were rinsed with water and mounted in DABCO (2.33% antifade compound 
1,4-Diazabicyclo[2.2.2]octane [Sigma], 90% [v/v] glycerol, 20 mM Tris-HCl pH 8.0). Cells were 
considered ATRX or DAXX positive when foci were present in the nucleus. 
2.6.2. APB detection 
Cell cultures were harvested by trypsinisation and resuspended in buffered hypotonic solution (United 
Biosciences). The cells (110,000 cells/mL) were cytocentrifuged onto SuperFrost Plus glass slides 
(Menzel-Glaser) at 110 x g for 10 min in a Shandon Cytospin 4 with medium acceleration. Slides were 
permeabilised at room temperature for 10 mins with KCM buffer (120 mM KCl, 20 mM NaCl, 10 mM Tris 
pH 7.5, 0.1% Triton X-100), rinsed in 1X PBS, and fixed in 4% (v/v) formaldehyde in 1X PBS at room 
temperature for 10 mins. After several rinses with 1X PBS, the slides were treated with 100 µg/mL 
DNase-free RNase A (Sigma) in antibody dilution buffer (ABDIL; 20 mM Tris pH 7.5, 2% BSA, 0.2% fish 
gelatin, 150 mM NaCl, 0.1% Triton X-100, 0.1% sodium azide) at 37°C for 30 mins. The slides were then 
incubated at 37°C for 1 hr with mouse anti-PML antibody (PG-M3; Santa Cruz), diluted 1:250 in ABDIL. 
Slides were washed three times with 0.1% Tween-20/1X PBS and then incubated with Alexa Fluor 594 
goat anti-mouse secondary antibody (Invitrogen; 1:1000). Following the incubation at 37°C for 30 mins, 
the cells were washed three times with 0.1% Tween-20/1X PBS, and proteins were cross-linked with 4% 
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PFA for 10 mins at room temperature. The cells were dehydrated with an ethanol series (70%, 90%, and 
100%) and then telomeric DNA was detected using the 5’ labelled telomere-specific peptide nucleic acid 
(PNA) probe, Alexa 488-(CCCTAA)3 PNA probe (PNA Bio) (Chen et al., 1999; Perrem et al., 2001). After 
the probe was placed on the slide, the DNA was denatured at 80°C for 3 mins and the probe was 
hybridised for 3 hrs at room temperature. Unhybridised probe was removed by washing with Buffer A 
(70% formamide, 0.01 M Tris pH 7.5, 0.1% BSA) for 15 mins, and then the nuclei were stained with DAPI 
(20 µg/mL) in wash Buffer B (0.1 M Tris pH 7.5, 0.15 M NaCl, 0.08% Tween-20) for 3 mins. The slides 
were washed with 1X PBS and rinsed in water before mounting in DABCO antifade mounting medium. 
A Zeiss Axio Imager Z2 with ApoTome was used to capture Z-stacked images (ACRF Telomere Analysis 
Centre). Quantitation was completed on three independent experiments, on at least 100 
cells/experiment, using Zeiss ZEN software. An APB was defined as the colocalisation of telomeric DNA 
and PML protein of any size (Yeager et al., 1999). 
2.6.3. MetaTIF assay 
Cell cultures were treated with 50 µg/mL vinblastine for 1 hr at 37°C in 5% CO2 to obtain metaphase 
chromosomes. Cells were harvested by trypsinisation and resuspended in buffered hypotonic solution 
at 37°C. NB cultures were incubated for 20 mins whereas control cell lines were incubated for 5 mins. 
To obtain metaphase spreads 110,000 cells/mL were cytocentrifuged onto SuperFrost Plus glass slides 
at 450 x g (high acceleration) for 10 min in a Shandon Cytospin 4. Slides were then permeabilised with 
KCM buffer for 10 mins, rinsed in 1X PBS three times, and fixed in 4% (v/v) formaldehyde in 1X PBS for 
10 mins at room temperature. The slides were treated with 100 µg/mL RNase A in ABDIL at 37°C for 30 
mins, and then incubated for 1 hr at 37°C with mouse anti-γH2AX antibody (Ser139 Clone JBW301; 
Merck Millipore) diluted 1:300 with ABDIL. To remove excess antibody, the slides were washed three 
times and then incubated with Alexa Fluor 594 anti-mouse secondary antibody (1:1000 in ABDIL) at 37°C 
for 30 mins. Slides were washed three more times with 0.1% Tween-20/1X PBS, cross-linked with 4% 
PFA for 10 mins, and dehydrated with increasing concentrations of ethanol (70%, 90% and 100%). 
Telomeric DNA was detected using the Alexa 488-(CCCTAA)3 PNA probe, applied to the slide prior to   
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Table 2.6. List of drugs and stock concentrations. 
Drug Company Target Diluent 
Highest Drug 
Concentration 
Dilution 
Factor 
for Serial 
Dilution 
All trans 
retinoic acid  
AbCam Differentiation induction Ethanol 45 µM 3 
Aphidicolin AbCam DNA replication inhibitor DMSO 30 µM 6 
Arsenic Trioxide 
Sigma-
Aldrich 
Complex mode of action, 
causes apoptosis  
1 M 
NaOH 
10 µM 3 
Cisplatin 
Cayman 
Chemicals 
Cross-links DNA 
0.9% 
Saline 
(w/v) 
30 µM 4 
Doxorubicin 
Cayman 
Chemicals 
Interferes with enzymes 
involved in DNA 
replication 
DMSO 1.5 µM 5 
Etoposide 
Cayman 
Chemicals 
Topoisomerase II 
inhibitor 
DMSO 400 µM 10 
Hydroxyurea AbCam 
Ribonucleotide reductase 
inhibitor 
DMSO 1600 µM 2 
Irinotecan 
Cayman 
Chemicals 
Topoisomerase I inhibitor DMSO 600 µM 6 
KU-60019 Selleckchem ATM inhibitor DMSO 24 µM 2 
Mitomycin C Selleckchem 
Interferes with enzymes 
involved in DNA 
replication 
Water 3 µg/mL 4 
ML216 
Sigma-
Aldrich 
Bloom helicase inhibitor DMSO 225 µM 3 
Temozolomide 
Cayman 
Chemicals 
Alkylating agent, induce 
DNA damage 
DMSO 400 µM 6 
Topotecan 
Cayman 
Chemicals 
Topoisomerase I inhibitor DMSO 90 µM 12 
VE-822 Selleckchem ATR inhibitor DMSO 7 µM 5 
Vincristine AbCam Mitotic inhibitor DMSO 0.05 µM 6 
 
 
denature at 80°C for 3 mins. After hybridisation of the probe at room temperature for 3 hrs, the slides 
were washed with Buffer A for 15 mins. The DNA was stained with 20 µg/mL DAPI/Buffer B for 3 mins 
and rinsed with water several times before mounting in DABCO. Images were obtained on the Metafer 
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slide scanning system (ACRF Telomere Analysis Centre) and a meta-TIF was defined as the localisation 
of γ-H2AX protein to the end of the chromosome (with or without the presence of telomere signal) 
(Cesare et al., 2009). Quantitation was performed, in triplicate, on at least 1000 chromosome ends.  
2.6.4. Telomere FISH on metaphase spreads 
Metaphase chromosomes were obtained by treating cells with vinblastine (50 µg/mL) overnight for 16 
hrs. Cell cultures were harvested by trypsinisation, resuspended in buffered hypotonic solution at 37°C 
for 20 mins, fixed (3:1 methanol/glacial acetic mix) and dropped onto SuperFrost Plus glass slides. The 
slides were baked at room temperature overnight, then treated with 100 µg/mL RNase A at 37°C for 30 
mins, and then dehydrated with increasing concentrations of ethanol. FISH was performed with an Alexa 
Fluor 488 telomere specific PNA probe applied to the slide prior to denaturing the DNA for 3 mins at 
80°C. After a 3 hr hybridisation, the slides were washed for 15 mins with Buffer A to remove excess 
probe. A second wash (with Buffer B) was performed for 5 mins at room temperature, and then the 
slides were stained with DAPI (20 µg/mL in PBS) for 3 mins to visualise the DNA. The slides were washed 
with 1X PBS, rinsed with water and mounted in DABCO. Fluorescence microscopy images were obtained 
on the Metafer slide scanning system (ACRF Telomere Analysis Centre) and the intensity of the telomere 
signal was quantitated using TFL-Telo software (Zijlmans et al., 1997) in fifteen metaphase spreads for 
each sample. 
2.6.5. Telomere sister chromatid exchange (T-SCE) analysis 
T-SCE analysis was performed as previously described (Bailey et al., 2004). Briefly, cells were cultured in 
medium containing a 3:1 ratio of BrdU:BrdC (Sigma) with vinblastine (50 µg/mL) added for the final 16 
hrs. Metaphases were harvested and resuspended in buffered hypotonic solution at 37°C for 20 mins. 
Chromosomes were then fixed with 3:1 ice-cold methanol:acetic acid and dropped onto SuperFrost Plus 
glass slides. The slides were incubated at 37°C for 30 mins with 100 µg/mL DNase-free RNase A (Sigma) 
in 2X SSC. Slides were postfixed with 4% formaldehyde in PBS for 10 mins and then dehydrated in an 
ice-cold ethanol series (75, 85, 100%) for 2 mins each. Metaphase spreads were stained with 0.5 µg/mL 
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Hoechst 33258 at room temperature for 15 mins and exposed to long wave 365 nm UV light for 45 mins. 
An exonuclease III (NEB) digest was then performed for 30 mins at 37°C. The chromosomes were 
denatured for 5 mins at 80°C in 70% formamide/30% 2X SSC before the slides were dehydrated in an 
ice-cold ethanol series as previously described. The slides were incubated overnight with 0.3 µg/ml 
TAMRA–OO-(TTAGGG)3 PNA probe (PNA Bio) and washed with Buffer A for 15 mins followed by a wash 
with Buffer B for 5 mins at room temperature. Slides were incubated with 0.3 µg/ml Alexa 488–OO-
(CCCTAA)3 PNA probe overnight and washed with buffer A and B as previously described prior to staining 
with DAPI (20 µg/mL in PBS) for 3 mins to visualise the DNA. Lastly, the slides were washed with 1X PBS, 
rinsed with water and mounted in DABCO. Imaging was performed on the Metafer slide scanning system 
(ACRF Telomere Analysis Centre). 
2.7. DNA extraction and quantitation 
Genomic DNA was extracted by lysis at 37°C overnight with 2% sodium dodecyl sulphate (SDS) buffer 
containing 50 mM Tris, 20 mM EDTA, and 200 µg/mL Pronase protease (Sigma). Lysis was followed by 2 
hrs salt precipitation at 4°C with 1.4 M NaCl, followed by serial centrifugation (15 mins at 3900 x g) until 
the white precipitant was removed. The DNA was precipitated at 4°C overnight with 100% ethanol (2.5 
X volume of lysis buffer with NaCl), before centrifugation at 3900 x g for 30 mins. The DNA pellet was 
washed with 70% ethanol, centrifuged for 15 mins, and then allowed to air-dry. The DNA was 
resuspended in TE and quantitated with a Qubit Fluorometer (Invitrogen). 
2.8. C-circle assay 
2.8.1. Slot-blot detection 
Rolling circle amplification of C-circles was performed on 10 ng of genomic DNA. The assay was 
performed with and without Φ29 polymerase for each sample. The DNA (10 µL) was added to 10 µL of 
the amplification mix, for a 20 µL reaction containing 4 µM DL-Dithiothreitol (DTT), 200 µg/mL BSA, 0.1% 
Tween-20, 1X Φ29 buffer (New England BioLabs), 7.5 Units Φ29 polymerase (New England BioLabs), and 
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1 mM each of dATP, dGTP and dTTP (Roche), which was incubated at 30°C for 8 hrs and then at 65°C for 
20 mins to heat inactivate the enzyme (Henson et al., 2009). The C-circle assay product was diluted with 
100 µL of 2X SSC, and using slot-blot apparatus, blotted onto a Biodyne B 0.45 µM nylon membrane 
(Pall). The membrane was dried and then the DNA was UV-cross-linked onto the membrane in a 
Stratagene UV Stratalinker 1800. PerfectHyb Plus buffer (Sigma) was used to pre-hybridise the 
membrane for 1 hr at 37°C, and a 32P-ATP-labelled (CCCTAA)3 telomeric probe was hybridised to the 
DNA overnight, under native conditions. The membrane was washed four times at 37°C with 0.5X 
SSC/0.1% SDS for 15 mins and exposed to a storage phosphor screen, which was scanned on a Typhoon 
imager (GE Healthcare) the following day. Signals were quantitated using ImageQuant (GE Healthcare) 
and the level of C-circles was calculated by subtracting the 32P-probe signal of the C-circle assay without 
Φ29 from that of the C-circle assay with Φ29.  
2.8.2. Exonuclease treatment of DNA 
Genomic DNA was pretreated with 6 U/ug of the restriction enzymes HinfI and RsaI (New England 
BioLabs) and 25 ng/µg RNase (Roche) at 37°C for 12 hrs, followed by heat inactivation of the enzymes 
at 80°C for 20 mins. The digested DNA was ethanol precipitated (0.3 volume of 10 M ammonium acetate 
and 3.3 volumes of 100% ethanol with 1 µL glycogen) and resuspended in TE, prior to quantitation by 
the Qubit Fluorometer. To remove linear DNA from the C-circle reaction, 1 µg of pretreated DNA was 
digested with lambda exonuclease (12.5 U/µg; New England BioLabs), exonuclease I (100 U/µg; New 
England BioLabs), and 1X lambda buffer (New England BioLabs) at 37°C for 20 mins followed by 80°C for 
20 mins (Henson et al., 2009). The DNA was quantitated, and additional rounds of exonuclease digestion 
were performed, until there was <100 ng of DNA remaining. As a control, a mock reaction without 
exonucleases was also carried out for each sample. The exonuclease digested DNA, and control sample, 
were precipitated by ethanol precipitation as described above and resuspended in 20 µL Tris. To perform 
the C-circle amplification reaction, 5 µL of the DNA was diluted with 5 µL of Tris and added to the 
reaction. The rolling circle amplification product was quantitated by slot-blot analysis as described in 
section 2.8.1.  
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2.8.3. Telomere quantitative polymerase chain reaction (qPCR) detection 
Rolling circle amplification of C-circles was performed on 16 ng (in 5 µL) of genomic DNA, with and 
without Φ29 polymerase for each sample. The total reaction volume was 10 µL (including DNA), and the 
components and conditions were the same as section 2.8.1, with a modification to the amount of Φ29 
polymerase (Lau et al., 2013), which was halved. The 10 µL C-circle assay product was diluted with 30 
µL of TE, and 5 µL of the diluted product was used for each PCR. For every sample, the following PCRs 
were performed in triplicate: telomere PCR of C-circle assay/Φ29+, telomere PCR of C-circle assay/    
Φ29-, single copy gene (SCG) PCR of C-circle assay/Φ29+, and SCG PCR of C-circle assay/Φ29-. The SCG 
for NB cell lines and tumours was VAV2 (Lau et al., 2013), whilst the SCG for oesophageal and PanNETs 
was HBG, and the SCG for melanoma tumours and cell lines was 36B4 (Lau et al., 2013). Primer 
sequences are listed in Table 2.7. A standard curve of DNA was included for each PCR, to allow for 
subsequent analysis. Concentrations in the telomere PCR were 2.5, 1, 0.2, 0.04, 0.02, 0.01 ng/µL and 
concentrations of the SCG genes were 2.5, 1.25, 0.625, 0.3125, 0.156, 0.078 ng/µL. Each qPCR reaction 
consisted of 1X Rotor-Gene SYBR Green (Qiagen), 5 µL C-circle assay product or standard DNA, and the 
primer sets. The final primer concentrations were, telomere: forward 500 nM and reverse 500 nM, 
VAV2: forward 700 nM and reverse 400 nM, 36B4: forward 300 nM and 500 nM reverse, and HBG: 
forward 500 nM and reverse 500 nM. PCR conditions were, telomere: 95°C for 15 mins, 30 cycles of 95°C 
for 7 sec and 58°C for 10 sec, VAV2: 95°C for 5 mins, 43 cycles of 95°C for 15 sec, 61°C for 30 sec, and 
72°C for 20 sec, and 36B4/HBG: 95°C for 5 mins, 40 cycles of 95°C for 15 sec and 58°C for 30 sec. All PCR 
conditions concluded with a melt curve analysis. Analysis was conducted using the two standard curves 
method (Cawthon, 2002), and the telomere product was corrected for loading with the SCG product. All 
PCR results were expressed as the mean of triplicate reactions. The relative telomeric DNA content (TC) 
of a sample was obtained from the mean normalised C-circle assay/Φ29- reaction, relative to the TC of 
SK-N-FI or IIICF/c, ALT-positive cell lines with arbitrary TC values of 14.0 and 30.0, respectively. The 
relative C-circle level of a sample was the normalised C-circle assay/Φ 29+ subtracted by the normalised 
C-circle assay/Φ29-, relative to the C-circle level of SK-N-FI and IIICF/c, with arbitrary values of 196 and 
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100, respectively. Long telomeres were indicated by a relative TC≥15, and a sample was considered ALT+ 
when the relative C-circle level was ≥7.5 (Lau et al., 2013). 
2.9. Telomere length analysis 
2.9.1. Telomere restriction fragment (TRF) analysis 
Genomic DNA was digested at 37°C for 12 hrs with 6 U/µg of the restriction enzymes HinfI and RsaI (New 
England BioLabs) and 25 ng/µg RNase (Roche) (Perrem et al., 2001), followed by heat inactivation of the 
enzymes at 80°C for 20 mins. Prior to gel electrophoresis, the DNA was ethanol precipitated (0.3 volume 
of 10 M ammonium acetate and 3.3 volumes of 100% ethanol with 1 µL glycogen) and then resuspended 
in TE. The digested DNA was quantitated by the Qubit Fluorometer and 1.5 µg/well was loaded on a 1% 
(w/v) agarose gel in 0.5X TBE. To resolve bands in COG-N-291 and LA-N-6, the DNA was separated using 
pulsed-field gel electrophoresis (BioRad) in 14°C recirculating 0.5X TBE buffer at 6 V/sec for 16 hrs, with 
an initial switch time of 1 and final switch time of 6. Gels containing other samples were run for 14 hrs. 
The gels were dried for 2 hrs at 65°C, denatured in 0.82 M NaOH/2.5 M NaCl for 1 hr, and neutralised in 
0.7 M Tris pH 8/1.5 M NaCl for 1 hr at room temperature. Gels were pre-hybridised for 1 hr at 50°C in 
Church buffer (0.5 M Na2HPO4 pH 7.2, 1 mM EDTA, 7% SDS, and 1% BSA) and then hybridised with a 32P-
ATP-labelled (CCCTAA)4 telomeric probe overnight. The gels were washed for 30 mins in 4X SSC, three 
times at room temperature and once at 50°C, and then exposed to a storage phosphor screen. The 
screen was scanned the following day with a Typhoon imager and the signals were quantitated using 
Las4000-Multigauge software. The unweighted mean TRF length was calculated using Telorun software 
(Baur et al., 2004), which utilised linear regression analysis of molecular weight marker positions to 
calculate telomere length.  
2.9.2. Telomere qPCR 
The TC of cells, independent of C-circles, can be determined via the protocol described in section 2.8.3. 
with modification to the input sample. Rather than rolling circle amplification product, 5 µL of 1 ng/µL 
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Table 2.7. List of primers. 
Gene Primer sequence 
Methods 
section 
Telomere 
F: 5’-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT- 3’ 
R: 5’-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT- 3’ 
2.8.3. 
VAV2 
F: 5’ -TGGGCATGACTGAAG ATGAC- 3’ 
R: 5’ -ATCTGCCCTCACCTTCTCAA- 3’ 
2.8.3. 
36B4 
F: 5’ -CAGCAAGTGGGAAGGTGTAATCC- 3’ 
R: 5’ -CCCATTCTATCATCAACGGGTACAA- 3’ 
2.8.3. 
HBG 
F: 5’ -GCTTCTGACACAACTGTGTTCACTAGC- 3’ 
R: 5’ - CACCAACTTCATCCACGTTCACC- 3’ 
2.8.3. 
TP53 exon 
2-3 
F: 5’ -CCAGGTGACCCAGGGTTGGA- 3’ 
R: 5’ -AGCATCAAATCATCCATTGC- 3’ 
2.14. 
TP53 exon 
4 
F: 5’ -TGCTCTTTTCACCCATCTAC- 3’ 
R: 5’ -ATACGGCCAGGCATTGAAGT- 3’ 
2.14. 
TP53 exon 
5-6 
F: 5’ -TGTTCACTTGTGCCCTGACT- 3’ 
R: 5’ -TTAACCCCTCCTCCCAGAGA- 3’ 
2.14. 
TP53 exon 
7 
F: 5’ -CTTGCCACAGGTCTCCCCAA- 3’ 
R: 5’ -AGGGGTCAGCGGCAAGCAGA- 3’ 
2.14. 
TP53 exon 
8-9 
F: 5’ -TTGGGAGTAGATGGAGCCT- 3’ 
R: 5’ -AGTGTTAGACTGGAAACTTT- 3’ 
2.14. 
TP53 exon 
10 
F: 5’ -CAATTGTAACTTGAACCATC- 3’ 
R: 5’ -GGATGAGAATGGAATCCTAT- 3’ 
2.14. 
TP53 exon 
11 
F: 5’ -AGACCCTCTCACTCATGTGA- 3’ 
R: 5’ -TGACGCACACCTATTGCAAG- 3’ 
2.14. 
H3F3A 
exon 1 
F: 5’ -GATTTTGGGTAGACGTAATCTTCA- 3’ 
R: 5’ -AACAAAAAGATGGATAACAGGAAA- 3’ 
2.14. 
H3F3A 
exon 2 
F: 5’ -TTTCTTTGAAGCTGCCCACT- 3’ 
R: 5’ -TCCAAATTGTTGCATGTGCT- 3’ 
2.14. 
H3F3A 
exon 3 
F: 5’ -AGCATCTTGCCCAGTCATTTT- 3’ 
R: 5’ -CAGGTATTGGCAGTTTTTCCA- 3’ 
2.14. 
TERT 
F: 5’-CGGAAGAGTGTCTGGAGCAA- 3’ 
R: 5’-TCGTAGTTGAGCACGCTGAACAG- 3’ 
2.16.1. 
TERC 
F: 5’-CTAACCCTAACTGAGAAGGGCGT- 3’ 
R: 5’-GGCGAACGGGCCAGCAGCTGAC- 3’ 
2.16.1. 
Dyskerin 
F: 5’-GCCGAAATACAACACGCTGAAG- 3’ 
R: 5’-CAGAGGATTTGAACCACATGCA- 3’ 
2.16.1. 
GAPDH 
F: 5‘-ACCCACTCCTCCACCTTTG- 3’ 
R: 5’-CTCTTGTGCTCTTGCTGGG- 3’ 
2.16.1. 
SLX4 
F: 5’-CTGTGCCATCAAAGCAGAAA-3’ 
R: 5’-CGGAGATTTTTCTGGGAACA- 3’ 
2.16.1. 
XRCC3 
F: 5’-CCATTCCGCTGTGAATTTG-3’ 
R: 5’-GCCTCTGTCACCTGGTTGAT- 3’ 
2.16.1. 
RTEL1 
F: 5’-CACTCGCAACTCACACAGGT-3’ 
R: 5’-TTACGGCACAAGTGGATCTG- 3’ 
2.16.1. 
ZBTB48 
F: 5‘-GGGTGAGGAAGTTTGAGTGC- 3’ 
R: 5’-ACCACCACCATCTTCTCGTC- 3’ 
2.16.1. 
NBS1 
F: 5‘-CCCACCTCTTGATGAACCAT- 3’ 
R: 5’-CCCACCTCCAAAGACAACTG- 3’ 
2.16.1. 
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MYCN 
F: 5’-GCCGGAAGAGACAGATAAGC-3’ 
R: 5’-TTCTCCACAGTGACCACGTC-3’ 
2.16.2. 
M2 5’-AAT CCG TCG AGC AGA GTT-3’ 2.18.3. 
ACX 5’-GCGC GGC TTA CCC TTA CCC TTA CCC TAA CC-3’ 2.18.3. 
Abbreviations: F, forward; R, reverse. Primer sequences for section 2.8.3. were described in Henson et al., 2017 
& Lau et al., 2013. TP53 primer sequences were obtained from the International Agency for Research on Cancer 
(IARC) website (http://p53.iarc.fr/Download/TP53_DirectSequencing_IARC.pdf). H3F3A primers were obtained 
from (Bower et al., 2012) and RT-qPCR primers from section 1.15.1 were obtained from (Cao et al., 2008b). The 
M2 and ACX primers were described in (Kim and Wu, 1997; Piatyszek et al., 1995). 
 
genomic DNA was added to the PCR. The relative TC of a sample was obtained from the mean of 
triplicate telomere reactions normalised to the SCG reactions.  
2.10. T-circle detection 
T-circles were detected using two-dimensional TRF analysis. Genomic DNA was restriction digested with 
HinfI and RsaI, using the TRF protocol. Digested DNA was separated in a 0.6% agarose gel at 1 V/cm for 
13.5 hr, in the first dimension. Lanes were excised and run in a 1.1% agarose gel containing 300 ng/mL 
ethidium bromide at 6 V/cm for 4 hrs, in the second dimension. Following the TRF protocol in section 
2.9.1, gels were dried, denatured and hybridised overnight to a 32P-ATP-labelled (CCCTAA)4 telomeric 
probe in Church buffer. Gels were washed, exposed to a storage phosphor screen and scanned on a 
Typhoon imager. 
2.11. Telomere chromatin immunoprecipitation (ChIP) 
2.11.1. Cell lysis and chromatin isolation 
Cells were harvested by trypsinisation, washed in 1X PBS and collected as 1X107 cell pellets. Pellets were 
resuspended in 1 mL of cell lysis buffer (5 mM HEPES-KOH pH 8, 85 mM KCl, 0.4% [v/v] NP-40, and, 
added fresh each time, 1X complete protease inhibitor (Roche), and 1 mM phenylmethylsulphonyl 
fluoride [PMSF]) and incubated on ice for 10 mins. To pellet the nuclei, samples were centrifuged at 
6000 x g for 15 sec at 4°C, and the supernatant discarded. The chromatin bound proteins were cross-
linked at room temperature with 1% (v/v) formaldehyde in cell lysis buffer, lacking NP-40, for 10 mins. 
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To end the fixation, 75 µL of 1.5 M glycine was incubated with the nuclei for 5 mins at room temperature. 
The nuclei were centrifuged at 4°C for 15 sec at 6000 x g, and the supernatant was discarded. Nuclei 
were lysed with 50 µL nuclei lysis buffer (50 mM Tris-HCl pH 8.1, 1 mM EDTA, 1% [v/v] SDS, added fresh 
each time: 1X complete protease inhibitor, and 1 mM PMSF) on ice for 10 mins, and then diluted with 
750 µL buffer A, containing 20 mM HEPES-KOH pH 8, 2 mM MgCl2, 300 mM KCl, 1 mM EDTA, 10% (v/v) 
glycerol, and 0.1% (v/v) Triton X-100. The DNA was fragmented by sonication on a Branson sonifier in 
an ice/ethanol bath. Sonication was performed with a duty cycle of 10, and 60 second pulse/pause cycles 
at outputs 3, 4, and 5. Solubilised chromatin was isolated by retaining the supernatant after 
centrifugation at 17,000 x g for 10 mins at 4°C.  
2.11.2. Immunoprecipitation (IP) 
IP was conducted in a buffer of 20 mM HEPES-KOH pH 7.9, 150 mM KCl, 1.5 mM EDTA, 1% (v/v) Triton 
X-100, and, added fresh each time, 1X complete protease inhibitor, and 1 mM PMSF. The chromatin 
(112 µL) was rotated at 4°C for 1 hr with 225 µL of the IP buffer, and the antibody as indicated in Table 
2.8. A pre-blocked suspension of Protein G agarose beads (Roche), were bound to the antibody by 
rotating 60 µL/sample at 4°C overnight. The next day, the chromatin/antibody/bead complexes were 
collected by centrifugation at room temperature for 30 sec at 17,000 x g. Unbound chromatin and 
antibodies were removed by washes: two washes with buffer A and once with TE, with the centrifuge 
step repeated between each wash.   
2.11.3. DNA isolation 
Immunoprecipitated DNA was eluted from the beads by digestion of the antibody with 200 µg of 
proteinase K (Sigma) in elution buffer (50 mM NaHCO3, 1% [v/v] SDS) at 45°C for 2 hrs. The DNA was 
purified with the Qiagen PCR purification kit and eluted in 140 µL of TE. 
2.11.4. Quantitation 
The amount of telomeric chromatin immunopurified by each antibody was quantitated using slot-blot 
analysis. The purified DNA was denatured with 980 µL of 0.46 M NaOH and heated at 95°C for 5 mins. 
69 
 
The cooled samples were then halved, and 560 µL loaded into a slot-blot well and blotted onto 
Biodyne B 0.45 µM nylon membrane (Pall). The remainder of the sample was used to make a duplicate 
membrane. For the purpose of quantitation, a standard was included for every sample; 1%, 5%, 10% 
and 25% purified input (lacking IP) was also blotted. The membranes were air-dried, cross-linked in a 
Stratagene UV Stratalinker 1800, and pre-hybridised with Church buffer at 50°C for 1 hr. One membrane 
was hybridised overnight with a 32P-ATP-labelled (CCCTAA)3 telomere probe, and the other was 
hybridised with 32P-dATP-labelled ALU sequence. The following day, both membranes were washed four 
times: telomere membranes with 2X SSC at room temperature for 15 mins, and ALU membranes with 
0.1% SDS/0.2X SSC at 37°C for 15 mins, and then exposed to a phosphor screen overnight. The phosphor 
screen was imaged with a Typhoon imager and then signals were quantitated using ImageQuant 
software. Standard curves were generated for each sample and used to normalise the telomeric DNA 
immunoprecipitated. All experiments were performed on two biological replicates. 
2.12. Labelling probes with 32P 
Experiments used two types of C-rich telomere probes, [CCCTAA]3 or [CCCTAA]4. Both probes were end 
labelled with ATP-γ32-P radiation (Perkin Elmer) by a T4 polynucleotide kinase (New England BioLabs) at 
37°C for 30 mins. Unlabelled probe was removed using a Quick Spin Mini Oligo Column (Roche). The 
same method was used to end-label the GAPDH probe in section 2.17. The ALU probe in section 2.11.4, 
was labelled with α-32P-dATP (Perkin Elmer) using the DECAprime II Random Primed DNA Labeling Kit 
(Ambion). Unlabelled DNA was removed using a Quick Spin Mini DNA Column (Roche). 
2.13. Whole genome sequencing (WGS) and bioinformatics 
2.13.1. WGS and read alignment 
Whole genome sequencing was performed on the Illumina HiSeq X Ten platform, by Macrogen Inc. 
(Korea) and the Kinghorn Centre for Clinical Genomics/Garvan Medical Research Institute, to generate 
paired-end (2 × 150 bp) sequence reads. Subsequent analysis was performed by Dr Erdahl Teber. The 
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reads were trimmed, and poor quality reads were removed using Trimmomatic (v0.32; parameters: 
ILLUMINACLIP:TruSeq3-PE.fa:2:30:10 LEADING:3 TRAILING:3 SLIDINGWINDOW:4:20 MINLEN:75). The 
remaining paired-end reads were aligned to NCBI hg19 reference genome using BWA (v0.7.10; main 
parameters: mem -M). Using Picard (v1.119), the generated BAM file was sorted; duplicates were 
removed, and the reads placed into read groups and indexed. Picard (v1.1.19) modules, 
CollectAlignmentSummaryMetrics and CollectMultipleMetrics, determined the mapping quality 
metrics. Insertion or deletion (indel) realignment was carried out with RealignerTargetCreator and 
IndelRealigner, and known indel sites were based on Mills_and_1000G_gold_standard.indels.hg19.vcf 
and 1000G_phase1.indels.hg19.vcf (GATK v3.2.2 resource bundle). This was followed by 
BaseRecalibrator (parameters for KnownSites are: Mills_ and_1000G_gold_standard.indels.hg19.vcf, 
1000G_phase1.indels.hg19.vcf,dbsnp_138.hg19.vcf) and PrintReads (GATK v3.2.2). MuTect v1.1.4 
(Cibulskis et al., 2013) (parameters: --dbsnp dbsnp_138.hg19.vcf --cosmic cosmic_v71.vcf) was used to 
generate single nucleotide variants (SNVs), only a ‘PASS’ entry in the FILTER column was accepted. Indels 
were generated using GATK v3.2.2 HaplotypeCaller (paremeters: --genotyping_mode DISCOVERY -
stand_call_conf 30 -stand_emit_conf 10), filtered by GATK VariantFiltration (parameters: --
filterExpression "QD < 2.0 || FS > 200.0 || ReadPosRankSum < -20.0"), and were decomposed and left 
Antibody Company Isolated from Dilution 
TERF21P/ RAP1 
Novus Biologicals 
(NB100-292) 
Rabbit 1:40 
TRF2 
Novus Biologicals 
(NB110-57130) 
Rabbit 1:70 
Normal Mouse IgG 
Merck Millipore 
(12-371) 
Mouse 1:30 
Normal Rabbit IgG 
Cell Signaling Technology 
(2729) 
Rabbit 1:30 
Histone H3 
Cell Signaling Technology 
(4620) 
Rabbit 1:40 
H3K9me3 
Abcam 
(ab8898) 
Rabbit 1:30 
H3K4me2 
Cell Signaling Technology 
(9725) 
Rabbit 1:50 
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normalised (Vt normalisation reference, http://genome.sph.umich.edu/wiki/Vt) (Tan et al., 2015). Short 
indel calls were generated by PINDEL v0.2.4w (Ye et al., 2009a) and were left normalised. For each cell 
line, a final vcf file was generated, and used in all downstream analysis. This file contained the 
intersecting variant calls between normalised Haplotypecaller and PINDEL, all unique HaplotypeCaller 
indels sized 1 to 9 bp, unique PINDEL calls ≥100 bp, and all SNV ‘PASS’ Mutect calls.   
 Delly v0.6.7 (Rausch et al., 2012) identified structural variant (SV) calls to detect the four SV 
types (deletion, DEL; duplication, DUP; inversion, INV; translocation, TRA). The results were 
concatenated and sorted using vcftools (v0.1.13) and annotated into Class A and Class B categories, 
whilst TxDb.Hsapiens.UCSC.hg19.knownGene (v3.2.2) R package was used to map the transcript and 
gene structures. A Class A annotation indicated the gene(s) overlapping at a breakpoint, and the Class B 
annotation, indicated the gene(s) between two breakpoints or within the SV.  
2.13.2. Variant annotations 
To determine potentially pathogenic genetic alterations Ingenuity Variant Analysis (IVA, v4.2.20160927) 
was used to filter and annotate SNV and indel results. To remove variants present in a healthy 
population, the analysis parameters included: a read depth of at least 10, variants had to be outside of 
the top 1% most exonically variable genes in healthy genomes (1000 genomes), and variants observed 
in at least 0.001% of the 1000 genomes project, ExAc and NHLBI ESP exomes were excluded. The next 
step was to determine potentially deleterious events using the predicted deleterious filter. From the 
settings used we obtained a gene list including mutations: pathogenic or likely pathogenic, established 
in literature, gene fusion, inferred activating mutation by Ingenuity, predicted gain of function by BSIFT, 
frameshift/in-frame indel or start/stop codon change, missense unless predicted tolerated by SIFT or 
PolyPhen-2, splice site loss up to 2 bases into intron or as predicted by MaxEntScan, or a loss of function 
structural variant.    
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2.14. Sanger sequencing 
All ATRX and DAXX exons were amplified using the primers, PCR buffer and PCR conditions previously 
reported (Jiao et al., 2011), and summarised in Appendix I. The protocol for TP53 sequencing was 
described on the International Agency for Research on Cancer (IARC) website 
(http://p53.iarc.fr/Download/TP53_DirectSequencing_IARC.pdf) and the primers are listed in Table 2.7. 
Briefly, the Qiagen HotStar Taq (0.8 Units) was used to amplify the TP53 exons 2-3 and 7 in a reaction 
mix containing 1X PCR buffer, 1X Q-solution, 0.2 mM each dNTP, 0.4 µM forward primer and 0.4 µM 
reverse primer. The PCR conditions for exon 2-3 were: 94°C for 2 mins, followed by 50 cycles of 94°C for 
30 sec, 61°C for 45 sec and 72°C for 45 sec, and the final cycle of 72°C for 10 mins, and for exon 7 were: 
95°C for 15 mins, followed by 50 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec, and the 
final cycle of 72°C for 10 mins. Whereas, 0.8 Units of Taq Platinum (Invitrogen) were used to amplify 
TP53 exons 4, 5-6, 8-9 and 11 in a reaction containing 1X PCR buffer, 1.5 mM MgCl2, 0.2 mM each dNTP, 
0.4 µM forward primer and 0.4 µM reverse primer. Exons 4, 5-6, 8-9, and 11 were amplified with the 
conditions: 94°C for 2 mins, followed by 20 cycles of 94°C for 30 sec, 63°C for 45 sec (-0.5°C every 3 
cycles) and 72°C for 60 sec, then 30 cycles of 94°C for 30 sec, 60°C for 45 sec and 72°C for 60 sec, and 
the final cycle of 72°C for 10 mins. Finally, TP53 exon 10 was amplified with the PCR conditions: 94°C for 
2 mins, followed by 20 cycles of 94°C for 30 sec, 58.5°C for 45 sec (-0.5°C every 3 cycles) and 72°C for 60 
sec, then 30 cycles of 94°C for 30 sec, 55°C for 45 sec and 72°C for 60 sec, and the final cycle of 72°C for 
10 mins. The gene H3F3A was sequenced using primers previously reported to amplify exons 1, 2 and 3 
of the gene (Bower et al., 2012). Invitrogen’s Taq Platinum was used to amplify the exons, using the 
primer sequences listed in Table 2.7, with the PCR conditions: 95°C for 5 mins, followed by 30 cycles of 
94°C for 30 sec, 60°C for 1 min and 72°C for 2 mins, and the final cycle of 72°C for 10 mins. Prior to 
sequencing, all PCR products were purified with the QIAquick PCR Purification Kit (Qiagen), and 
subsequent Sanger sequencing was conducted at the Australian Genome Research Facility. 
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2.15. RNA extraction  
RNA was extracted from cell pellets using the RNeasy Mini Kit (Qiagen) with on column DNA digestion 
(Qiagen DNase). The RNA was resuspended in RNase-free water and quantitated using a NanoDrop 
spectrophotometer. 
2.16. qPCR analysis  
2.16.1. Reverse transcriptase qPCR (RT-qPCR) 
Complementary DNA (cDNA) was synthesised from 1 µg of RNA using the Superscript III First Strand 
Synthesis Kit (Invitrogen) with random primers. Transcripts of TERT, TERC, DKC1, and GAPDH were 
detected as previously described (Cao et al., 2008b), using the primers in Table 2.7. Expression of NBS1, 
XRCC3, RTEL1, ZBTB48, and SLX4 mRNA was detected using the primers described in Table 2.7. PCR 
reactions contained 1X QuantiFAST SYBR Green PCR buffer (Qiagen), and 0.4 µM forward and reverse 
primers for TERC, DKC1, NBS1, XRCC3, RTEL1, ZBTB48, SLX4 and GAPDH transcripts or 0.5 µM forward 
and reverse primers for TERT transcripts. The cDNA reaction was diluted 1:2.5 with TE, and 2 µL was 
loaded into each PCR reaction. The PCR was performed in triplicate with the following conditions: 1 cycle 
at 95°C for 15 mins, followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec for TERT, TERC, DKC1, 
and GAPDH or 40 cycles of 95°C for 15 sec, 60°C for 20 sec and 72°C for 30 sec for NBS1, XRCC3, RTEL1, 
and SLX4 or 40 cycles of 95°C for 15 sec and 60°C for 60 sec for ZBTB48 and then melt curve analysis. 
The level of expression was calculated using a delta delta cycle threshold (Ct) method, with GAPDH as a 
reference gene, and expressed as RNA level relative to the appropriate control sample.  
2.16.2. Genomic qPCR 
MYCN copy number was determined by qPCR of 5 ng of genomic DNA. PCR reactions were performed 
in triplicate using 1X QuantiFAST SYBR Green PCR buffer (Qiagen) containing 0.5 µM of forward and 
reverse primers (Table 2.7) with the PCR conditions: 95°C for 5 mins then 43 cycles of 95°C for 15 sec, 
61°C for 30 sec and 72°C for 20 sec, and melt curve analysis. Samples were quantitated using a standard 
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curve method, MYCN was normalised to the VAV2 gene, and copy number was expressed relative to the 
normal DNA control (Applied Biosystems).    
2.17. Telomeric repeat-containing transcript (TERRA)   
The quantitation of TERRA was performed by slot-blot analysis of 1 µg of DNase treated RNA (Ng et al., 
2009). In addition to a DNase treated RNA sample for each cell line, 1 µg of RNA was also treated with 
25 ng/µg RNase A (Sigma) to confirm that there was no DNA contamination. All samples were denatured 
at 65°C for 15 mins in a solution of 66% (v/v) formamide, 2.6 M formaldehyde, and 13% (v/v) 3-(N-
morpholino)propanesulphonic acid (MOPS) solution (0.5 M sodium acetate, 0.01 M EDTA, 0.2 M MOPS). 
The denatured RNA was diluted with 100 µL of 2X SSC and slot-blotted onto a Biodyne B nylon 
membrane. Duplicates of all membranes were prepared. Membranes were dried and the RNA was 
crossed-linked to the membrane using the Stratagene UV Stratalinker 1800. After UV-cross-linking, both 
membranes were pre-hybridised with Church buffer at 55°C for 1 hr, then one membrane was 
hybridized with a 32P-ATP-labelled (CCCTAA)3 telomeric probe and the other a 32P-labelled GAPDH probe 
(ACCCACTCCTCCACCTTTG), overnight at 55°C. The following day, the membranes were washed three 
times for 15 mins at room temperature with 2X SSC/0.1% SDS and then at 50°C with 0.2X SSC/0.1% SDS 
for 15 mins. Membranes were exposed to a storage phosphor screen and scanned on a Typhoon imager. 
Images were quantitated with ImageQuant software and the amount of TERRA was corrected for loading 
by dividing by the intensity of the corresponding GAPDH transcript. Three biological replicates were 
analysed. 
2.18. Telomerase activity 
2.18.1. Protein Lysis 
Cells were trypsinised, washed with 1X PBS and pelleted. An equal number of cells were lysed at 4°C for 
30 mins with 3-([3-cholamidopropyl] dimethylammonio)-1-propanesulphonate (CHAPS) lysis buffer (10 
mM Tris-HCl pH 7.5, 1 mM MgCl2, 1 mM ethylene glycol-bis[2-aminoethylether]-N,N,N',N'-tetraacetic 
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acid [EGTA], 10% glycerol, 10% CHAPS), supplemented with 1mM PMSF and 5 mM 2-mercaptoethanol. 
Following lysis, the samples were centrifuged at 15,500 x g for 20 mins at 4°C, and then the supernatant 
was transferred to a new tube to remove cellular debris.  
2.18.2. Immunoprecipitation   
To purify the lysate and remove potential PCR inhibitors, anti-hTERT antibody (10 µg; obtained from Dr 
Scott Cohen) was bound to telomerase by rotating samples at 4°C for 30 mins (Cohen and Reddel, 2008). 
A 50% (v/v) suspension of Protein G beads (Roche), pre-blocked in BSA (New England BioLabs), was then 
bound to the antibody at 4°C for 1 hr. The telomerase/antibody/bead complex was collected in an 
Illustra micro-spin column (GE Healthcare) with vacuum suction, and the supernatant discarded. The 
beads were washed with ice cold lysis buffer to remove any unbound proteins. To release the 
telomerase enzyme from the bead/antibody complex, 1.5 mM antigenic peptide solution was combined 
with the complex in the column and incubated at room temperature for 1 hr before collection of the 
supernatant.  
2.18.3. Telomeric repeat amplification protocol (TRAP) 
Immunoprecipitated telomerase was added to 0.09 µg of the M2 primer (Table 2.7) and allowed to 
extend via telomerase mediated base addition in a buffer containing 45 mM Tris pH 8.8, 11 mM 
ammonium sulphate, 4.5 mM MgCl2, 10 mM EDTA pH 8, 76 mM 2-mercaptoethanol, 113 µg/mL BSA 
(Ambion), 1 mM each of dNTPs (Roche), 0.045 µg of the reverse primer ACX (Table 2.7), and 2 Units Taq 
polymerase (Roche). The TRAP reaction was performed under the conditions in Table 2.8. PCR products 
were separated on a 10% denaturing polyacrylamide gel in 0.5X TBE and detected with SYBR Green I 
(Molecular Probes), visualised on a Typhoon imager.  
2.19. Immunoblotting  
Cells were harvested, pelleted and resuspended in cold lysis buffer supplemented with complete 
protease inhibitor (Roche), 100 mM NaF, and 200 µM Na3VO4 immediately before use. For analysis of  
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Table 2.8. TRAP PCR conditions. 
Number of cycles Step Temperature Time 
1 cycle 
Telomerase extension of 
primer 
25°C 30 mins 
1 cycle Taq Hot start 95°C 2 mins 
35 cycles Denaturation 95°C 10 sec 
 Annealing 50°C 25 sec 
 Extension 72°C 30 sec 
1 cycle Denaturation 95°C 15 sec 
 Annealing 50°C 25 sec 
 Extension 72°C 60 sec 
 
Table 2.9. Antibodies and conditions used for Western blot analysis. 
Name Manufacturer Isolated 
from 
Blocking agent Diluent Dilution Incubation 
conditions 
anti-ATRX  
Abcam 
(ab72124) 
Rabbit 5% (w/v) skim milk 1X TBS 1:500 
Room 
temperature, 
2.5 hrs 
anti-DAXX  
Sigma 
(HPA008736-
100UL) 
Rabbit 5% (w/v) skim milk 1X TBS 1:250 
Room 
temperature, 
2 hrs 
anti-p53 (DO-
1) 
Merck 
Millipore 
(OP43L) 
Mouse 
5% (w/v) skim 
milk/1X TTBS 
Same as 
blocking 
agent 
1:1000 
Room 
temperature, 
1 hr 
anti-p21 
(Waf1/Cip1) 
Cell Signalling 
(2947) 
Rabbit 
5% (w/v) BSA/1X 
TTBS 
Same as 
blocking 
agent 
1:1000 
Room 
temperature, 
1 hr 
anti-GAPDH 
ThermoFisher 
Scientific  
(MA5-15738) 
Mouse 
5% (w/v) skim 
milk/1X TTBS 
Same as 
blocking 
agent 
1:5000 
Overnight, 
40C 
anti-β-actin 
Sigma 
(A2228-100UL) 
Mouse 5% (w/v) skim milk 1X TBS 1:3000 
Overnight, 
40C 
anti-HSP70 
Sigma 
(H5147-
100UL) 
Mouse 5% (w/v) skim milk 1X TBS 1:3000 
Overnight, 
40C 
 
 
ATRX and DAXX proteins the cells were lysed in EBC buffer (50 mM Tris pH 8, 120 mM NaCl, and 0.5% 
(v/v) NP-40), and for p53 and p21 immunoblots the cells were lysed in RIPA buffer (50 mM Tris pH 8, 
150 mM NaCl, 0.1% (v/v) SDS, 1% (v/v) NP-40, and 0.5% (v/v) sodium deoxycholate). Cells were lysed 
for 30 mins at 4°C and centrifuged at 15,500 x g for 20 mins to remove cell debris. The protein 
concentration of the whole cell extract was determined against known concentrations of BSA standards, 
using the bicinchoninic acid (BCA) protein assay kit. 
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 Equal concentrations of protein lysates were mixed with NuPAGE LDS Sample Buffer (Life 
Technologies) and denatured by boiling at 95°C for 10 mins. Proteins were resolved on a 3–8% NuPAGE 
Tris-acetate polyacrylamide SDS gel (Life Technologies) (running buffer: 2.5 mM tricine, 2.5 mM Tris, 
0.005% (v/v) SDS, pH 8.24) for ATRX, on a 10% Tris-glycine SDS polyacrylamide gel for DAXX, and on a 
12% Tris-glycine SDS polyacrylamide gel for p53 and p21 (running buffer: 0.02 M Tris, 0.2 M glycine, 
0.1% SDS (v/v), pH 8.3). Separated proteins were transferred to a methanol-activated 0.45 mm PVDF 
membrane (Millipore), in chilled transfer buffer (22 mM Tris, 171 mM glycine, 0.01% (v/v) SDS, 20% (v/v) 
methanol), and blocked for 1 hr at room temperature and then probed according to the conditions in 
Table 2.9. The membranes were washed with a solution of 0.1% Tween-20, 50 mM Tris, and 150 mM 
NaCl (TTBS) three times for 15 mins each, then probed at room temperature for 1 hr with HRP-
conjugated secondary antibodies (DakoCytomation) diluted 1:5000 in TTBS, and followed by another 
wash series with TTBS. Chemiluminescence detection was performed using SuperSignal West Pico 
chemiluminescent substrate (ThermoFisher Scientific) at room temperature for 5 mins, exposed to X-
ray film (Fujifilm), and developed on an X-ray developer (Konica). 
2.20. Statistical analyses  
GraphPad Prism 6 was used to generate graphs and perform statistical analysis. The Kaplan-Meier 
product-limit method was used to estimate survival, comparisons of survival curves were performed by 
the log-rank test, and medians and proportions were compared by the Mann-Whitney test and Chi- 
square test, respectively. Two data sets were compared with unpaired Student’s two-tailed t tests or 
two-tailed Mann-Whitney tests, and multiple data sets were compared using one-way ANOVA. 
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Chapter 3: A subgroup of high‐risk MYCN non‐amplified 
neuroblastomas lacks a telomere lengthening 
mechanism 
3.1. Introduction 
The acquisition of replicative immortality is a hallmark of human cancer, achieved by activation of a TLM 
to counter the normal telomere attrition that accompanies cellular proliferation (Hanahan and 
Weinberg, 2000; Hanahan and Weinberg, 2011). However, a substantial proportion of glioblastomas 
(Hakin-Smith et al., 2003), liposarcomas (Costa et al., 2006; Jeyapalan et al., 2008), osteosarcomas 
(Ulaner et al., 2003), and retinoblastomas (Gupta et al., 1996) have been reported as telomerase-
negative with no evidence of ALT activity. The consensus view in the telomere research field has been 
that these results are due to false-negative assays; however, there can be other plausible explanations. 
Firstly, telomerase-negative tumours may be able to maintain their telomere length by a different ALT 
mechanism which lacks the known phenotypic characteristics of ALT. A second potential explanation is 
that it is theoretically possible some tumours can achieve long term proliferation without an active TLM 
(Reddel, 2000). To date, it has been impossible to demonstrate the latter scenario as serial sampling of 
human tumours which are required to show continuous telomere shortening over extended periods of 
time cannot usually be obtained. Therefore, suitable cell line models are required to determine if an 
active TLM is a requirement for the long-term proliferation of malignant cells.     
 NB is an embryonal tumour of the sympathetic nervous system (Maris, 2010). Telomerase 
activity has been identified as a poor prognostic factor in NB (Ohali et al., 2006; Onitake et al., 2009; 
Poremba et al., 2000; Poremba et al., 1999) although it is absent in 20-60% of metastatic NB (Krams et 
al., 2001; Onitake et al., 2009; Poremba et al., 2000; Poremba et al., 1999), supporting the presence of 
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ALT in NB. Thus far, ALT has either been diagnosed in NB tumours by long telomeres (a feature of ALT) 
in the absence of telomerase (Onitake et al., 2009) or by the presence of mutation/deletion in ATRX 
(Cheung et al., 2012; Kurihara et al., 2014; Molenaar et al., 2012; Peifer et al., 2015; Valentijn et al., 
2015), a chromatin remodelling factor where loss of function is associated with ALT activity (Bower et 
al., 2012; Chen et al., 2014; Heaphy et al., 2011a; Lovejoy et al., 2012; Schwartzentruber et al., 2012). 
However, C-circles, a quantifiable marker of ALT activity (Henson et al., 2009), have not been used to 
detect ALT in any of these studies. Relying solely on long telomeres and the absence of telomerase can 
potentially misclassify tumours as ALT-positive, especially in embryonal tumours that tend to have 
longer telomeres, while using only ATRX mutations will likely underestimate the prevalence of ALT as 
ATRX mutations are not a universal feature of ALT (Lovejoy et al., 2012). 
 We hypothesised that (1) a proportion of high-risk NB with long telomeres were ALT-negative 
and (2) a subset of ALT-positive high-risk NB tumours were ATRX wild-type. Utilising quantitative PCR to 
measure telomere content (TC) and C-circle levels (Lau et al., 2013) in a cohort of high-risk NB, we 
detected ALT in a significantly higher frequency than previously reported on the basis of ATRX mutation 
frequency, supporting the hypothesis that some ALT-positive NB are ATRX wild-type. Furthermore, we 
found that a subset of MYCN non-amplified tumours with long telomeres lacked ALT activity. We also 
went on to screen a large panel of NB cell lines and identified two NB cultures with exceptionally long 
telomeres which were negative for both telomerase and C-circles. 
3.2. Results 
3.2.1. Unique subgroup of high-risk MYCN non-amplified neuroblastoma 
Here we describe a cohort of 149 high-risk NB screened for C-circles and TC using telomere quantitative 
PCR where ALT-positive tumours were defined as those with a relative C-circle level of ≥7.5 compared 
to the ALT+ IIICF/c cell line with an arbitrary value of 100 (Lau et al., 2013) (Appendix II Table A2.1-4). 
Twenty-four percent (36/149) of tumours were found to be C-circle/ALT-positive. None (0/36) of the 
ALT-positive tumours had MYCN amplification, consistent with other studies reporting MYCN  
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Figure 3.1. A subgroup of high-risk MYCN non-amplified neuroblastoma with long telomeres are 
ALT-negative.  
(A) Relative telomere content (TC) in arbitrary units (AU), measured by telomere qPCR for individual 
patient tumours (n=149), are plotted according to ALT status (ALT+ n=36, ALT- n=113). ALT+ was 
defined by a relative C-circle (CC) level ≥7.5 compared to the ALT+ IIICF/c cell line with an arbitrary 
value of 100. (B) Age at diagnosis for individual patient tumours is plotted according to ALT status 
(n=149). (C) Relative TC of MYCN non-amplified tumours (n=94) is plotted according to ALT status 
(ALT+ n=36, ALT- n=58). A subgroup of ALT- tumours (n=17) had long telomeres (TC≥15, indicated 
by the bracket). (D) Age at diagnosis for individual MYCN non-amplified ALT-negative patient 
tumours (n=58) is plotted according to TC. 
Data points represent the average of triplicate TC measurements by qPCR. Horizontal red bar 
indicates group median. * P<0.01 
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amplification and ATRX aberrations are mutually exclusive (Cheung et al., 2012; Kurihara et al., 2014; 
Peifer et al., 2015; Pugh et al., 2013; Valentijn et al., 2015). This is contrast with ALT-negative tumours 
where 49% (55/113) had MYCN amplification. The relative TC of ALT-positive tumours was significantly 
higher than that of ALT-negative tumours (median 19.7 vs. 6.2; P<0.0001; Figure 3.1.A); this was not due 
to younger patients in the ALT-positive group as patients with ALT NB were significantly older at 
diagnosis than patients with ALT-negative NB (median age 4.4 vs. 2.3 years; P<0.0001; Figure 3.1.B). Of 
note, within the MYCN non-amplified group, 29% (17/58) of tumours with long telomeres (TC≥15) were 
ALT-negative (Figure 3.1.C). In addition, patients with ALT-negative/TC≥15 tumours were older at 
diagnosis than patients with ALT-negative/TC<15 tumours (median age 4.67 vs. 2.72 years; P<0.01; 
Figure 3.1.D). There was sufficient DNA to assess telomere length by Southern blot terminal restriction 
fragment (TRF) analysis for 45 samples, including four of the 17 ALT-negative/TC≥15 tumours. The TRF 
telomere length profile of the four ALT-negative/TC≥15 tumours was long and heterogeneous (relative 
TC≥15 corresponds to mean TRF length 20 kb; Figure 3.2.A), with a mean length indistinguishable from 
ALT-positive tumours (P>0.05). Frozen tumour samples were available for the four ALT-negative/TC≥15 
tumours which allowed us to perform TRAP assays; all four tumours were telomerase-negative (Figure 
3.2.B). This suggests that a subgroup of metastatic NB with long telomeres may not require a TLM to 
allow long term proliferation as a result of their extensive telomere reserves.   
The molecular details of ALT upregulation are not well defined but there is a correlation 
between ALT activity and the loss of expression of ATRX or its binding partner DAXX (Bower et al., 2012; 
Heaphy et al., 2011a; Lovejoy et al., 2012). Inactivation of p53 is also strongly correlated with ALT in cell 
lines although this is less apparent in tumours (Henson and Reddel, 2010). Next-generation sequencing 
results were available for 32 tumour samples; 13 ALT-positive and 19 ALT-negative. This includes 
previously reported whole exome sequence data for 26 samples (Pugh et al., 2013) and whole genome 
sequence data for nine tumours obtained as part of this study (of which 3 had existing whole exome 
data from Pugh et al., 2013). Of the 13 ALT-positive tumours, eight had an ATRX mutation, one had a  
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Figure 3.2. A unique subgroup of high-risk ALT-negative/MYCN non-amplified/TC≥15 NBs have 
poor survival.   
(A) Terminal restriction fragment (TRF) analysis of 13 selected tumour samples. Telomere content 
(TC) and C-circle (CC) status measured by telomere qPCR is indicated at the bottom with mean TRF 
lengths. Black boxes represent the four ALT-negative/TC≥15 samples, green boxes represent the 
ALT-positive samples, and ALT-negative/TC<15 are indicated by white boxes. (B) Telomere repeat 
amplification protocol (TRAP) to detect telomerase activity in six selected tumour samples. Cell 
lysates were immunopurified with anti-hTERT antibody to remove potential inhibitors. The ALT 
sample U-2 OS was negative for telomerase and SH-SY5Y was included as a telomerase positive 
control. (C, D) Event-free and overall survival of ALT-negative/TC≥15 (ALT-/ TC≥15) (n=17), ALT-
positive (n=36), and MYCN amplified (amp) (n=55) tumours. 
TRF and IP-TRAP were performed by Dr Loretta Lau. 
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DAXX mutation, and one had a TP53 mutation. In contrast, abnormalities of ATRX, DAXX or TP53 were 
observed in 0/19 ALT-negative tumours. 
It is well established that MYCN amplification results in a worse outcome for patients than MYCN 
non-amplified NB tumours (Ambros et al., 2009; Seeger et al., 1985). In our cohort, the outcome for 
patients with ALT NB was as poor as the outcome for MYCN amplified patients (5-year event-free 
survival 28% vs. 24%; 5-year overall survival 36% vs 28%; Figure 3.2.C, D), despite all ALT-positive 
tumours being MYCN non-amplified. Like ALT NB, ALT-negative/TC≥15 NB also had later events or 
deaths and a poor survival that was not significantly different from the ALT tumours, although this may 
be due to the number of cases in each subgroup (5-year overall survival 49% vs. 36%; P=0.1908; Figure 
3.2.C, D), ultimately leading to death in 51% of patients with this subgroup of disease.   
3.2.2. ALT-negative and telomerase-negative cancer cell lines 
3.2.2.1. Neuroblastoma 
To determine whether ALT-negative/TC≥15 NB cells lack a TLM, or have an as-yet unidentified 
telomerase-independent mechanism, the telomere length of these cells must be examined over time. 
To perform this study, we screened 35 cell lines derived from metastatic NB for a phenotype 
corresponding to the ALT-negative/TC≥15 tumours (TC≥15 and C-circle negative via quantitative PCR 
and MYCN non-amplified). We identified three cell lines that have a TC≥15 (CHLA-90, COG-N-291, LA-N-
6) and one cell line with a TC of 14 (SK-N-FI); two cell lines (SK-N-FI and CHLA-90) were C-circle positive, 
as previously reported (Farooqi et al., 2014; Lau et al., 2013), and two were C-circle negative (COG-N-
291 and LA-N-6; Table 3.1) and also had the highest TC of the 35 cell lines (25 and 38, respectively). TRF 
analysis confirmed long and heterogeneous telomere lengths in COG-N-291 and LA-N-6 cells (mean 31.0 
and 37.8 kb, respectively), comparable to U-2 OS, an ALT cell line with very long telomeres (mean TRF 
38.8 kb; Figure 3.3.A). The TRF blots of LA-N-6 and COG-N-291 showed a banding pattern that has only 
been observed when ALT activity was suppressed in ALT-positive cells by overexpression of Sp100 a 
component of PML bodies (Jiang et al., 2005), and when telomerase-mediated telomere extension was  
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Table 3.1. Characteristics of 35 neuroblastoma cell lines.  
 
 Telomere 
content 
SD 
C-
circle 
SD hTERT SD hTR SD Dyskerin SD MYCN SD 
LA-N-6 38.0 0.047 -0.4 0.036 0.0 0.01 1.1 0.07 0.5 0.05 3.9 0.4 
COG-N-291 25.0 0.006 -3.3 0.022 0.0 0.00 0.0 0.00 0.9 0.13 2.7 0.2 
CHLA-90 15.6 0.005 139 0.285 0.1 0.06 2.8 0.44 0.8 0.04 18.9 0.8 
SK-N-FI 14.0 0.013 196 0.695 0.0 0.00 0.3 0.04 1.4 0.24 4.2 0.5 
CHLA-119 2.0 0.002 2.1 0.014 0.1 0.02 0.7 0.10 0.9 0.14 262 16.0 
CHLA-122 0.8 0.001 -0.1 0.000 3.0 0.40 4.2 0.29 1.2 0.08 154 14.5 
CHLA-136 0.8 0.003 -0.1 0.000 0.5 0.07 1.7 0.07 1.3 0.13 141 24.0 
CHLA-140 1.2 0.009 -0.2 0.001 4.6 0.56 2.2 0.34 0.3 0.01 6.9 0.7 
CHLA-171 1.3 0.001 0.3 0.001 3.3 0.28 1.1 0.07 0.6 0.11 2.7 0.1 
CHLA-225 2.5 0.001 0.0 0.006 2.2 0.29 2.6 0.29 1.5 0.18 127 14.2 
CHLA-42 0.4 0.001 0.3 0.001 0.6 0.09 2.5 0.08 1.0 0.13 4.8 0.6 
CHLA-95 1.0 0.001 0.1 0.002 0.6 0.04 0.7 0.07 0.8 0.10 495 41.9 
CHP-134 1.3 0.002 -0.1 0.001 2.1 0.07 1.0 0.14 1.6 0.07 485 60.5 
COG-N-328h 0.5 0.001 -0.1 0.000 0.9 0.13 1.9 0.15 2.0 0.22 252 26.7 
COG-N-347 0.4 0.002 -0.1 0.000 0.6 0.08 1.5 0.11 0.3 0.02 1066 77.0 
FU-NB-2006 0.6 0.000 0.3 0.004 1.0 0.25 5.5 0.53 1.2 0.18 5.7 0.7 
IMR32 0.5 0.002 0.0 0.002 1.0 0.10 1.0 0.11 1.0 0.10 120 25.4 
KELLY 0.6 0.001 0.0 0.002 2.5 0.26 0.8 0.08 0.7 0.07 676 56.5 
LA-N-1 1.3 0.001 0.0 0.002 0.3 0.05 0.8 0.13 1.0 0.09 392 85.5 
LA-N-5 0.5 0.000 0.0 0.001 2.7 0.25 1.2 0.14 1.4 0.17 256 10.7 
NB69 1.1 0.000 0.1 0.002 2.7 0.36 0.7 0.07 0.6 0.09 4.5 0.7 
SH-EP 2.5 0.002 0.0 0.004 8.1 0.50 1.1 0.12 1.3 0.11 1.0 0.1 
SH-SY5Y 1.2 0.003 -0.2 0.001 2.9 0.31 1.2 0.06 0.8 0.05 3.7 0.3 
SK-N-AS 1.8 0.004 0.2 0.001 2.3 0.29 0.3 0.02 1.0 0.14 2.8 0.7 
SK-N-BE1 1.8 0.005 0.3 0.005 1.0 0.14 1.6 0.14 0.4 0.05 475 41.6 
SK-N-BE2c 0.6 0.001 0.0 0.002 0.4 0.05 0.9 0.11 1.0 0.14 115 8.4 
SK-N-DZ 2.1 0.036 -0.3 0.001 0.8 0.11 0.9 0.08 1.0 0.08 220 36.3 
SK-N-SH 1.2 0.001 -0.1 0.002 1.8 0.19 0.9 0.15 0.6 0.07 3.1 0.3 
SMS-KANR 0.4 0.000 0.0 0.002 0.8 0.11 1.6 0.08 1.1 0.12 164 17.7 
SMS-KCN 0.7 0.001 0.1 0.000 0.4 0.06 0.7 0.07 0.5 0.04 909 55.7 
SMS-KCNR 0.4 0.000 0.0 0.002 0.5 0.07 1.2 0.09 0.6 0.02 537 32.5 
SMS-LHN 1.3 0.002 -0.3 0.001 0.2 0.02 2.3 0.33 1.3 0.17 6.2 0.7 
SMS-SAN 0.5 0.001 0.0 0.001 0.2 0.03 1.8 0.10 0.9 0.10 835 64.1 
 
Note: Relative hTERT, hTR, and dyskerin mRNA levels (samples normalised to IMR32 set to 1) and MYCN 
copy number were measured by qPCR and expressed as the mean of triplicates. 
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Figure 3.3. Two neuroblastoma cell lines (COG-N-291 and LA-N-6) have long and heterogeneous 
telomere lengths similar to the ALT-negative/TC≥15 tumour group. 
(A) TRF analysis of a panel of seven cell lines. ALT-positive (ALT+) and telomerase-positive (TEL+) cell 
lines are indicated. The HT1080 hTR line is a clone of HT1080 with telomeres over-lengthened due to 
overexpression of hTR and upregulation of telomerase. (B) Representative images of telomere 
fluorescent in situ hybridisation (FISH) including the ALT cell line U-2 OS and telomerase-positive cell 
line SH-SY5Y. Telomeres are represented by green signals at the end of the chromosomes. (C) 
Quantitation of telomere FISH in a panel of eleven cell lines. Dots in graph represent individual 
telomere signals with mean telomere fluorescence indicated by red horizontal bar. 15 metaphases 
were analysed per cell line. (D) Percentage of chromosome ends without telomere signal (images 
from Figure 3.3.B). 15 metaphase spreads were analysed per cell line.   
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inhibited by deletion of the essential DNA helicase RTEL1 (Uringa et al., 2012). Telomere fluorescence 
in situ hybridisation (FISH) analysis showed COG-N-291 and LA-N-6 have a greater range of fluorescent 
intensities and fewer short telomeres (signal-free ends) than ALT cell lines (Figure 3.3.B, C, D).  
Although COG-N-291 and LA-N-6 had very long telomeres, they did not have elevated markers 
of ALT or telomerase activity. Both cell lines were telomerase-negative by TRAP (Figure 3.4.A). To 
confirm this was not the result of PCR inhibitors present in the sample lysate resulting in a false-negative 
TRAP result, the samples were spiked with a telomerase-positive lysate (Figure 3.4.B). The presence of 
telomerase activity in the spiked samples confirmed these two cell lines were telomerase-negative. The 
cells also lacked detectable mRNA expression for hTERT, the catalytic subunit of telomerase (Table 3.1, 
Figure 3.4.C). Although a low level of APBs was identified in COG-N-291 and LA-N-6, the level was similar 
to telomerase-positive samples and significantly lower than ALT-positive cell lines (P<0.001; Figure 
3.4.D). C-circle levels were measured using a second method where a 32P-labelled telomeric probe was 
used to detect products of the C-circle rolling circle amplification catalysed by Φ29 polymerase (Henson 
et al., 2009). This detection method identified very low levels of signal above the no Φ29 polymerase 
control (Figure 3.4.E). To determine whether this low level of signal was due to extension of genomic 
linear telomeric DNA or amplification of C-circles, exonuclease digestion of linear telomeric DNA was 
performed prior to the C-circle assay. The presence of radioactive signals following exonuclease 
digestion confirmed that the cells contained very low levels of C-circles (Figure 3.4.F).   
 Both COG-N-291 and LA-N-6 lacked genetic variations associated with ALT activation, and like 
the ALT-negative/TC≥15 tumours were MYCN non-amplified (Table 3.1). Whole genome sequencing 
indicated both cell lines were wild-type for H3F3A, TP53, ATRX and DAXX genes (Appendix II Table A2.5, 
6) and was confirmed by Sanger sequencing, although it has been previously reported that LA-N-6 
possesses a homozygous deletion of CDKN2A (Garcia et al., 2010) and COG-N-291 possesses a TP53 
polymorphism (Farooqi et al., 2014). Consistent with wild type TP53, the downstream target p21 was 
induced when cells were treated with the DNA damaging agent doxorubicin (Figure 3.5.A). Full- length  
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Figure 3.4. The COG-N-291 and LA-N-6 cell lines are phenotypically similar to the ALT-
negative/TC≥15 tumour group.  
(A) TRAP assay to detect telomerase activity in a panel of NB cell lines. Cell lysates were 
immunopurified (IP) with anti-hTERT antibody to remove potential PCR inhibitors. (B) Telomerase 
activity measured by TRAP. All telomerase-negative samples were spiked with lysate from the 
telomerase-positive sample, SH-SY5Y, to confirm that no PCR inhibitors were present. (C) Melt curves 
from SYBR Green hTERT RT-qPCR. Arrows indicate that primer dimers formed when no template was 
present in CHLA-90 (ALT+) and LA-N-6. Second peak represents product formed by qPCR 
amplification of template in telomerase-positive samples (SK-N-BE2c and SH-SY5Y). (D) ALT-
associated promyelocytic leukaemia bodies (APBs) in a panel of cell lines (co-localisation of telomeric 
foci (green) and PML nuclear body (red), indicated by arrows). ALT-positive (ALT+) and telomerase-
positive (TEL+) cell lines are indicated. Data represent mean (+SD) of 3 independent experiments. 
Scale bar represents 3 µM. (E) Representative C-circle (CC) assay with and without Φ29 polymerase, 
followed by detection using a 32P labelled telomeric probe in slot-blot analysis. CC level was 
calculated relative to that of the ALT-positive U-2 OS cell line (designated to be 100 AU). ALT-positive 
(ALT+) and telomerase-positive (TEL+) cell lines are indicated. (F) Confirmation of C-circle assay 
products in COG-N-291 and LA-N-6 at three different population doublings (PD). To remove linear 
telomeric DNA prior to the C-circle assay, restriction enzyme-treated DNA was subjected to 
exonuclease digestion. MeT-4A and DOS16 are ALT-positive cell lines with low CC levels (Henson et 
al., 2009). SK-N-BE2c, a telomerase-positive cell line, was used as negative control. 
 
ATRX and DAXX proteins were also expressed in both cell lines (Figure 3.5.B) and localised to the nucleus 
(Figure 3.5.C). As expected for TP53 wild-type cultures (Cesare et al., 2009), the cells do not accumulate 
DNA damage at the telomere (Figure 3.6.A). The level of the telomeric transcript TERRA has been 
associated with telomere length and accordingly, levels are higher in ALT cells than telomerase-positive 
cells (Arora et al., 2014; Episkopou et al., 2014; Ng et al., 2009). However, TERRA levels in COG-N-291 
and LA-N-6 were well below those of any other sample with long telomeres (Figure 3.6.B). Taken 
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Figure 3.5. The cell lines COG-N-291 and LA-N-6 lack characteristic of ALT. 
(A) p53 and p21 immunoblot with GAPDH loading control. Cultures were treated for 72 hrs with a 
doxorubicin (DOX) dose equivalent to their IC50. p53 status is indicated for each cell line (W, wild 
type; M, mutant). (B) ATRX and DAXX immunoblot with HSP70 loading control. CHLA-90 and U-2 OS 
(ATRX-negative cell line with partial deletion of ATRX gene) were used as negative controls. (C) 
Representative images of ATRX and DAXX foci (red) in the nuclei (blue) of NB cell lines.  
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together these data suggest that COG-N-291 and LA-N-6 cells lack the genetic and/or epigenetic 
(Episkopou et al., 2014) changes that allow upregulation of ALT in some cancer cells. 
 To determine whether differences in the chromatin structure of COG-N-291 and LA-N-6 were 
responsible for preventing upregulation of ALT in these cells, we performed telomere chromatin 
immunoprecipitation (ChIP) for shelterin proteins and histone 3 (H3) marks. There was no difference in 
the level of TRF2 or RAP1 shelterin proteins bound to the telomeres of ALT or COG-N-291 and LA-N-6 
cells (Figure 3.7.A). Similarly, there was no increase in repressive histone marks at H3 compared to ALT 
NB cell lines (Figure 3.7.B).  
From the work described in this section, we conclude that the cell line screen has identified two 
cell lines (COG-N-291 and LA-N-6) that are phenotypically and genetically similar to the ALT-
negative/TC≥15 tumours. 
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Figure 3.6. COG-N-291 and LA-N-6 lack DNA damage at the telomere and characteristics of ALT. 
(A) Representative images of meta-TIF assay (telomere foci green and γ-H2AX red, arrows indicate 
damage at telomere). Bottom panel is percentage of chromosome ends with or without telomere 
signal that have DNA damage. p53 status is indicated below each cell line (WT wild type; M, mutant; 
LgT, SV40 large T antigen). Mean +SD from 3 independent experiments. (B) Telomeric repeat-
containing RNA (TERRA) was quantitated from DNase treated RNA, followed by detection using a 32P 
labelled telomeric or GAPDH (loading control) probe in slot-blot analysis. The TERRA levels of ALT 
samples (CHLA-90, SK-N-FI, U-2 OS, SK-LU-1, SAOS-2 and G292), telomerase-positive cells (SH-SY5Y, 
SK-N-BE2c, A2182 and MG63) and mortal cell lines (HFF5 and MRC-5) were compared to COG-N-291 
and LA-N-6. Bar graph shows mean (+SD) TERRA levels from 3 independent experiments.   
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Figure 3.7. The level of telomere bound proteins does not differ between ALT neuroblastoma cell 
lines and COG-N-291 and LA-N-6. 
(A) Telomere-ChIP against the shelterin complex components RAP1 and TRF2. The telomerase-
positive cell lines SK-N-BE2c and SH-SY5Y, and ALT-positive cell lines SK-N-FI and CHLA-90 are 
included for comparison. Quantitation of the percentage of telomeric pulled down is shown in the 
graph. Mean +SD from 2 independent experiments. (B) Telomere-ChIP against histone H3 and 
histone marks. The telomerase-positive cell line SH-SY5Y and ALT-positive cell lines SK-N-FI and 
CHLA-90 are included for comparison. Quantitation of the percentage of telomeric pulled down 
and normalised to H3 is shown in the panel below. Mean +SD from 2 independent experiments.   
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3.2.2.2. Other tumour types 
In addition to NB, we screened a cohort of 94 PanNET tumours, 48 oesophageal tumours, and 2 cohorts 
of melanoma tumours (n=82 and n=62) for the ALT-negative/TC≥15 phenotype. Four melanoma 
tumours met the criteria, C-circle negative and TC≥15, whilst one oesophageal tumour had a TC just 
below the cut-off for long telomeres (Figure 3.8.A, B, C, D). As with the NB tumours, to determine if 
these samples are utilising an as-yet unidentified ALT mechanism, or if they proliferate despite lack of a 
TLM, we require cell line models to examine telomere length over time. Subsequently, 146 melanoma 
cell lines were examined for C-circle level and TC. There were four melanoma cell lines with longer 
telomere lengths (TC>10; Figure 3.9.A) and no C-circles, however, they had detectable mRNA expression 
for hTERT and hTR RNA (Figure 3.9.B), components of telomerase, and had telomerase activity (Figure 
3.9.C). Therefore, the ALT-negative/TC≥15 phenotype is present in melanoma tumours but the current 
study did not identify any corresponding cell line model.       
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Figure 3.8. Some melanoma tumours are ALT-negative with TC≥15.   
(A) Relative TC in arbitrary units (AU) of pancreatic neuroendocrine tumours (PanNET), measured by 
telomere qPCR for individual patient tumours (n=94), plotted according to ALT status (ALT+ n=33, 
ALT- n=61). ALT+ was defined by a relative C-circle level ≥7.5 compared to the ALT+ IIICF/c cell line 
with an arbitrary value of 100. (B) Relative TC of oesophageal tumours (n=48) is plotted according to 
ALT status (ALT+ n=0, ALT- n=48). (C) Relative TC of melanoma tumours cohort 1 (n=82) is plotted 
according to ALT status (ALT+ n=12, ALT- n=70). ALT-negative samples with TC≥15 compared to ALT+ 
IIICF/c cell line with arbitrary value of 30 are indicated by the bracket. (D) Relative TC of melanoma 
tumours cohort 2 (n=62) is plotted according to ALT status (ALT+ n=1, ALT- n=61), ALT-negative 
samples with TC≥15 compared to ALT+ IIICF/c cell line with arbitrary value of 30 are indicated by the 
bracket. 
Data points represent the average of triplicate measurements by qPCR. Horizontal red bar indicates 
mean. 
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Figure 3.9. ALT-negative/long telomere melanoma cell lines are telomerase positive. 
(A) Relative telomere content, in arbitrary units (AU), of ALT-negative cell lines. Data points represent 
the average of triplicate TC measurements by qPCR. A cohort of 146 melanoma cell lines are 
represented. The box indicates 4 melanoma cell lines with long telomeres (TC>10). (B) mRNA 
expression of the telomerase components hTR and hTERT, measured by RT-qPCR, for the TC>10 
melanoma cell lines in Figure 3.8.A. (C) TRAP to detect telomerase activity in the long telomere TC>10 
melanoma cell lines from Figure 3.8.A, B. The cell lines LA-N-6 and U-2 OS (ALT) are included as 
negative controls whilst SH-SY5Y is a telomerase positive NB cell line.  
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3.3. Discussion 
In the past two decades, numerous reports have identified telomerase activity as a poor prognostic 
factor in NB (Ohali et al., 2006; Onitake et al., 2009; Poremba et al., 2000; Poremba et al., 1999). 
However, reports also identified a subgroup of metastatic disease that does not utilise telomerase for 
continued proliferation (Choi et al., 2000; Krams et al., 2001; Poremba et al., 2000; Poremba et al., 1999; 
Reynolds et al., 1997). Studies of ALT in NB tumours thus far have relied on telomere length (Onitake et 
al., 2009), or ATRX/DAXX mutations (Cheung et al., 2012; Kurihara et al., 2014; Molenaar et al., 2012; 
Peifer et al., 2015; Valentijn et al., 2015) to identify the mechanism. This is the first study of ALT in NB 
tumours to utilise telomere length and C-circles, a quantifiable marker of ALT activity, to determine the 
prevalence of ALT in metastatic NB. 
 We found 24% of high-risk NB were ALT-positive and that MYCN amplification and ALT were 
mutually exclusive, in agreement with previous studies (Cheung et al., 2012; Farooqi et al., 2014; 
Molenaar et al., 2012; Peifer et al., 2015; Pugh et al., 2013). Interestingly, ALT-positive patients had 
more late events than MYCN amplified patients. The presence of ALT correlated with poor outcome in 
high-risk NB as previously reported in ATRX mutated NB tumours (Kurihara et al., 2014; Lundberg et al., 
2011; Onitake et al., 2009; Valentijn et al., 2015), liposarcoma, and malignant fibrous histiocytoma 
tumours (Henson and Reddel, 2010). Thirteen ALT tumours had whole exome or whole genome 
sequence data available and four of these tumours were wild type for ATRX and DAXX. Mutations in 
ATRX/DAXX, and consequently the prevalence of the ALT mechanism, have been reported in 10-22% of 
high-risk NB tumours (Cheung et al., 2012; Peifer et al., 2015; Valentijn et al., 2015). The broad range of 
ALT prevalence reported via ATRX/DAXX sequencing indicates inter-study variables impact significantly 
on the final prevalence estimates obtained from sequencing. These studies under-report the prevalence 
of ALT by 2-12% compared to ALT in high-risk NB detected by the presence of C-circles. Therefore, 
relying on ATRX and DAXX mutations to identify ALT-positive NB tumours would underestimate the 
prevalence of this mechanism. 
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Of note, we identified a subgroup of high-risk NB that had telomere lengths similar to the length 
of ALT cells but with very low levels of C-circles and no telomerase activity. In addition, 51% of the 
patients in this subgroup died from the disease. This is distinct from Stage 4S NB, a group of unique 
tumours that generally spontaneously regress and has a survival of 70-90% (Nickerson et al., 2000; van 
Noesel et al., 1997). Like ALT-negative/telomerase-negative tumours reported in liposarcoma, 
glioblastoma, osteosarcoma, and retinoblastoma (Costa et al., 2006; Gupta et al., 1996; Hakin-Smith et 
al., 2003; Jeyapalan et al., 2008; Ulaner et al., 2003), serial tumour samples are required to determine if 
these tumours represent an unidentified ALT mechanism lacking phenotypic characteristics of ALT, or if 
these tumours do not require a TLM for long term proliferation. The only definitive way to determine 
which hypothesis is correct, is to determine what happens to telomere length over time. In the first 
scenario telomere lengths would be maintained, whilst in the second telomeres would shorten over 
time. To determine if telomere length shortened during tumour growth we had to identify 
corresponding cell line models, as it is not possible to obtain serial tumours samples from the same 
patient over an extended period of time when the high-risk NB is left untreated. Two NB cell lines, COG-
N-291 and LA-N-6, derived from patients who died of metastatic disease, were identified with 
characteristics that correspond to the ALT-negative/TC≥15 tumours. Interestingly, these cells have a 
very low level of C-circle activity (at least 2 times lower than MeT-4A which has one of the lowest C-
circle levels reported in ALT-positive cells (Henson et al., 2009)) which indicates a very low level of ALT 
activity in these cells. The only definitive way to determine if this is sufficient for telomere maintenance 
is to examine telomere length over time. Subsequent chapters of this thesis describe the consequences 
of continued proliferation on telomere length in these cells.  
 We were unable to identify potential TLM-negative cell lines in other tumour types. The criteria 
used to identify ALT-negative/TC≥15 NB may not reflect the phenotype of ALT-negative/telomerase-
negative cells in other tumour types. NB is a childhood cancer and consequently the tumour initiating 
cells have not undergone as many cycles of replication induced telomere shortening as in adult cancers. 
The NB ALT-negative/TC≥15 cells have extreme telomere lengths, hence cell lines derived from these 
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tumours still have very long telomeres despite the PDs, and consequent telomere shortening, 
undergone by the cells during the establishment of the cell line. Whilst adult tumour types, such as 
melanoma, have ALT-negative/TC≥15 tumours, they do not have the extreme telomere lengths seen in 
NB. Hence cell lines derived from these tumours may not have lengths above the normal range after the 
PDs required to derive a cell line from the tumour. Indeed, this hypothesis is supported by the 
observation, by the Decottignies laboratory, that melanoma cells with telomeres which are at the upper 
end of the normal length do not have a TLM (Viceconte et al., 2017). Consequently, when screening 
adult cancer types for ALT-negative/telomerase-negative cell lines the telomere length cut-off may need 
to be adjusted.   
 In conclusion, telomere biology plays an important role in NB pathogenesis as activation of 
either TLM confers poor outcome, although the disease course differs between ALT and telomerase-
positive tumours. Currently, TLM inhibitors are being developed as anti-cancer therapies and may be 
effective in improving the outcome in high-risk NB with TLM. However, we require a greater 
understanding of the ALT-negative/TC≥15 phenotype to determine whether such inhibitors would be 
effective in these tumours. Success of targeted therapies requires appropriate biomarkers to predict 
response. Establishing the TLM status of a tumour is therefore required prior to treatment with TLM 
inhibitors or other TLM-targeted therapies. Care must be taken to correctly define ALT tumours, because 
neither high telomere content nor ATRX/DAXX mutation is sufficient to classify ALT tumours, and are 
best complemented with C-circles as an ALT activity assay.    
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Chapter 4: Long-term proliferation 
occurs in cancer cells with ever-shorter 
telomeres  
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Chapter 4: Long‐term proliferation occurs in cancer cells 
with ever‐shorter telomeres 
4.1. Introduction  
A subgroup of high-risk NB tumours lack telomerase activity and upregulate the ALT mechanism to 
maintain telomere lengths; however, previous identification of ALT in NB has been limited to 
examination of telomere length (Onitake et al., 2009) or ATRX/DAXX mutations (Cheung et al., 2012; 
Kurihara et al., 2014; Molenaar et al., 2012; Peifer et al., 2015; Valentijn et al., 2015). In the previous 
chapter we examined ALT in high-risk NB by simultaneous detection of long telomeres and abundant C-
circles. This method identified ALT in 24% of high-risk NB, as well as a subgroup of TLM-negative tumours 
that had extremely long telomeres. In previous studies, TLM-negative tumours were assumed to result 
from false-negative assays. Yet, it is possible that the cells utilise a yet to be identified mechanism to 
lengthen telomeres. It has also been hypothesised that extreme telomere length in tumour progenitor 
cells would be sufficient for the tumour to achieve long term proliferation, without the need to activate 
a TLM (Reddel, 2000). The aim of this chapter was to determine the consequence of continued 
proliferation on the telomere length of two NB cell lines, COG-N-291 and LA-N-6. These cells are 
characteristic of ALT-negative/TC≥15 tumours when screened by qPCR. However, detection by 32P 
labelled telomere probe revealed the cells have a very low level of C-circles (compared to MeT-4A, an 
ALT cell line with low C-circle levels (Henson et al., 2009)) indicative of low levels of ALT activity. To 
determine if this was sufficient to maintain telomeres in these cells, telomere length was examined 
during four years of continuous cell culture. We found that the COG-N-291 and LA-N-6 telomeres 
undergo continuous shortening during continuous proliferation for 500 PDs, a phenotype we termed 
ever-shorter telomeres (EST) in accordance with terminology from S. cerevisiae mutants (Lundblad and 
Szostak, 1989).     
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4.2. Results 
4.2.1. Cells with ever-shorter telomeres are capable of long-term proliferation 
To determine whether the NB cell lines COG-N-291 and LA-N-6 utilise an alternative non-telomerase 
method to maintain telomeres, or if they are truly TLM-negative, we examined the telomere length of 
the cells during continual proliferation for 500 PDs. If the first scenario was true, telomere lengths would 
be maintained, whilst truly TLM-negative cells would have continuous telomere length shortening. 
Southern blot TRF analysis showed the telomeres of both cell lines shortened continuously during 
culture (Figure 4.1.A, B), at a rate of 80 and 55 bp/PD for COG-N-291 and LA-N-6, respectively (Figure 
4.2.A). Normal somatic cell division results in a 31-85 bp/PD loss of telomere sequence (Harley et al., 
1990). Hence, the shortening exhibited by COG-N-291 and LA-N-6 is the result of cell division related 
telomere erosion, indicating the cells lack a TLM. A reduction in telomere content by qPCR confirmed 
the telomere shortening demonstrated by TRF analysis (Figure 4.2.B). Despite shortening telomeres and 
a very slow proliferation rate (3.4 days/PD for COG-N-291 and 3 days/PD for LA-N-6), the cells have yet 
to reach senescence after 500 PDs and over four years in culture (Figure 4.2.C). Therefore, NB cells 
derived from lethal high-risk tumours continue to proliferate long-term in spite of their EST phenotype.           
4.2.2. Characteristics of EST cells 
Telomerase activity and levels of ALT characteristics were monitored during continuous proliferation of 
the EST cells. The cells remained telomerase negative throughout the culture period (Figure 4.3.A) and 
the APB levels did not change (Figure 4.3.B). The C-circle levels were compared to the ALT cell line MeT-
4A set at 10 arbitrary units. This ALT cell line has one of the lowest levels of C-circles previously detected 
(Henson et al., 2009). The C-circles in COG-N-291 and LA-N-6 persisted at very low levels with sporadic 
increases for the first 300 PDs in culture, but for the next 200 PDs of culture there was a stabilisation of 
C-circle levels, at an amount similar to MeT-4A (Figure 4.3.C). ATRX and DAXX were expressed across 
the period of culture (Figure 4.3.D).      
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Figure 4.1. Two neuroblastoma cell lines (COG-N-291 and LA-N-6) are capable of long term 
proliferation despite the ever-shorter telomere (EST) phenotype. 
(A, B) TRF analysis of COG-N-291 and LA-N-6 telomere lengths at progressive population doublings 
(PD). The white gaps between lanes and different well heights indicate individual TRF analysis 
performed at progressive time points throughout the culture period. Individual blots are aligned 
with each other by molecular weight marker.  
Initial half of TRFs were completed by Dr Loretta Lau. 
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Figure 4.2. EST cells are capable of proliferation for hundreds of population doublings. 
(A) The average rate of telomere shortening was calculated by plotting the average TRF length of 
four individual TRF bands (indicated by asterisks in Figure 4.1) against the number of population 
doublings (PD). (B) Telomere content measured by telomere qPCR. Data represent mean + SD, n=3. 
(C) Growth curves of COG-N-291 and LA-N-6 demonstrate long-term proliferation.  
Calculations in panel (A) completed by Dr Loretta Lau. 
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Figure 4.3. Characteristics of EST cells during continuous proliferation for 600 population 
doublings.  
(A) Telomerase activity was monitored by TRAP at the specified PDs in COG-N-291 and LA-N-6 cells. 
SH-SY5Y and SK-N-BE2c were used as positive controls, and SK-N-FI and CHLA-90 (ALT+) as negative 
controls. (B) Frequency of APBs in EST cells at early and late population doublings (PD). Data 
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represent mean +SD of 3 independent experiments. (C) C-circle levels detected using 32P labelled 
telomeric DNA probe on slot blot. Levels were calculated relative to those of the ALT+ MeT-4A cell 
line (designated to be 10 AU). SK-N-BE2c (telomerase-positive) was included as a negative control. 
(D) ATRX and DAXX immunoblot at specified population doublings (PD) with β-actin as loading 
control.  
IP-TRAP was, in part, performed by Dr Christine Napier. 
 
4.2.2.1. ALT and the EST phenotype 
C-circles were present at low levels in early populations of the EST cell lines. The cells undergo 
continuous telomere shortening during this time, indicating that a small amount of ALT activity may be 
present in these cells but at levels insufficient to confer telomere maintenance. This is consistent with 
the observation that telomere shortening can occur in telomerase-positive normal cells (Broccoli et al., 
1995; Marion et al., 2009), and that ALT activity has been detected in somatic cells of mice (Neumann 
et al., 2013). However, within the first 300 PDs of culture the cells had sporadic increases in C-circle 
levels despite continuous telomere shortening ultimately resulting in a level of C-circles similar to the 
ALT cell line MeT-4A after PD400 and telomere length stabilisation. To determine if a subpopulation of 
the EST mass culture was responsible for the sporadic increases in C-circle levels at early PDs, COG-N-
291 cells at PD247 (the first timepoint where COG-N-291 had increased C-circle levels, Figure 4.3.C) were 
sub-cloned by plating cells at very low density until colonies from a single cell arose. The TRF analysis of 
subclones indicated clone 4 has long and heterogeneous telomere lengths, typical of ALT cells, whilst 
the remaining cell lines have the banding pattern seen in the EST mass culture (Figure 4.4.A). The level 
of C-circles in clone 4 was at least five-fold higher than the other COG-N-291 subclones (Figure 4.4.B), 
which indicates that a subpopulation of cells is responsible for the increased C-circle level in the mass 
culture. 
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Figure 4.4. A subpopulation of COG-N-291 cells are responsible for sporadic increases in C-circles 
in the first 300 PDs of culture. 
(A) TRF of the telomere length of COG-N-291 clones isolated at PD247. (B) C-circle slot blot detected 
with 32P-labelled telomeric DNA probe. SK-N-FI was used as an ALT-positive, C-circle positive control 
and SK-N-BE2c a telomerase-positive, C-circle negative control. 
 
 
 The TRF pattern and C-circle level in COG-N-291 clone 4 suggests that these cells have 
upregulated the ALT mechanism whilst the other subclones isolated were EST cells. Examination of 
telomere length over time by both TRF and qPCR analysis showed telomere maintenance in clone 4, 
whereas clones 3 and 11 exhibited the EST phenotype (Figure 4.5.A, B). As expected, none of the 
subclones exhibited telomerase activity during 100 PDs of culture (Figure 4.5.C), confirming that, by 
definition, the clone 4 cells must be utilising some form of an ALT mechanism to maintain telomere  
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Figure 4.5. Periodically a population of COG-N-291 cells activate an ALT mechanism but a slower 
proliferation rate prevents them outgrowing the EST cells.    
(A) TRF analysis of the COG-N-291 subclones telomere lengths at progressive population doublings 
(PD). (B) Telomere content measured by telomere qPCR in arbitrary units (AU). Data represent 
mean + SD, n=3. (C) Telomerase activity was monitored by TRAP at the specified PDs. SH-SY5Y was 
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included as a positive control and U-2 OS as a negative control. (D) Growth curves of COG-N-291 
subclones over 50 population doublings (PD). 
  
lengths. The EST subclones had faster growth rates than clone 4; 3.3 days/PD for clone 3, 2 days/PD for 
clone 11 vs. 3.8 days/PD for clone 4 but this did not result in senescence in the cultures after 100 PDs of 
continuous proliferation (Figure 4.5.E). The slower growth rate of clone 4 implies that activation of the 
ALT mechanism has not provided a survival advantage for these cells, and consequently they do not 
become the predominant population in a mixed culture with the EST cells in the first 300 PDs of growth 
(Figure 4.3C). Presumably, further molecular changes, caused by long term culture, were required for 
these ALT-like cells to become the predominant population of cells observed after PD400 leading to the 
increased C-circle levels (Figure 4.3C). 
 Subclone 4 was able to upregulate the ALT mechanism to a sufficient level to confer telomere 
length maintenance; however, these cells do not possess any of the other characteristic features of ALT. 
As expected, clone 4 cells maintained a high level of C-circles during culture whilst the EST subclones 
had very low levels although, like the mass culture, clone 3 had a sporadic increase in C-circles (Figure 
4.6.A). There was no increase in the level of APBs observed in clone 4 compared to the EST controls 
(Figure 4.6.B). Gene mutations associated with ALT, such as alterations to ATRX, DAXX and TP53, were 
absent in the clone 4 culture and ATRX and DAXX full length proteins were expressed (Figure 4.6.C). 
There was also no increase in TERRA levels with activation of ALT (Figure 4.6.D) and as expected for TP53 
wild type cells meta-TIFs did not accumulate (Figure 4.6.E).  
4.2.3. Genetics of EST cells 
To determine whether EST cells had genetic events that prevented sufficient upregulation of a TLM to 
counteract telomere attrition, we used whole genome sequencing to examine 656 genes related to 
telomere biology, ALT, and processes relating to RNA or DNA replication, repair and damage response  
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Figure 4.6. Characteristics of COG-N-291 sublines during continuous long-term proliferation.  
(A) C-circle levels of three sub-clones of COG-N-291 (clone 4, 3, 11) detected using 32P-labelled 
telomeric DNA probe on slot blot. Levels were calculated (as arbitrary units [AU]) relative to those 
of the ALT cell line MeT-4A set to 10 AU. SK-N-BE2c (telomerase-positive) was included as a 
negative control. (B) Frequency of APBs in COG-N-291 sublines compared to the COG-N-291 mass 
culture. Graph shows the mean +SD of three independent experiments. (C) ATRX and DAXX 
immunoblot with GAPDH as loading control. (D) Graph of meta-TIF assay results, percentage of 
chromosome ends with or without telomere signal that have DNA damage. Mean +SD from 3 
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independent experiments. (E) TERRA detected by slot-blot analysis with GAPDH loading control. 
Quantitation in bottom panel from 3 independent experiments (mean +SD). 
 
(Appendix II Table A2.5). To represent each of the three telomere-biology groups (EST, ALT and 
telomerase-positive), a total of 6 cell lines and 9 tumours were analysed (two NB cell lines and three 
tumours per group). As matched normal DNA was not available for the samples, we filtered the data 
using Ingenuity Variant Analysis to exclude genetic events previously reported in publicly available data 
sets of normal genomes. Relevant alterations were those predicted to have unknown or deleterious 
consequences and were not present in the ALT or telomerase-positive samples. There were no specific 
genetic events identified for the EST phenotype (Appendix II Table A2.6). 
4.3. Discussion 
Cellular immortalisation, via activation of a TLM to counteract normal telomere attrition, is considered 
to be an essential step in malignant transformation and therefore a hallmark of cancer (Hanahan and 
Weinberg, 2000; Hanahan and Weinberg, 2011). To form a mass of approximately 1 kg, a single cell 
needs to go through 40 cell divisions (240 cells), which many types of normal cells are able to achieve 
(Parkinson, 1996; Reddel, 2000). However, this would require all cells to survive, which is not possible 
in a tumour environment where there is an inadequate supply of oxygen and nutrients. Oncogenesis 
also requires multistep oncogenic mutation and associated clonal evolution, resulting in an increase in 
the number of cell divisions required for a tumour mass to form, and consequently the cells may require 
immortalisation in order to form a clinically significant tumour (Parkinson, 1996; Reddel, 2000). 
However, it has been postulated that immortalisation is not required if the progenitor cells have long 
telomeres, the tumours are genetically simple such as paediatric cancers (Alexandrov et al., 2013; Jones 
et al., 2008; Parsons et al., 2011; Vogelstein et al., 2013) and don’t require multiple rounds of clonal 
evolution, or the tumour environment supports a high surviving fraction such as leukaemias (Reddel, 
2000). The presence of the EST phenotype in malignant NB cells provides direct evidence to support the 
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hypothesis that immortalisation is not an absolute requirement for oncogenic development. The NB EST 
cells have very long telomeres that can act as a substitute for an active TLM, permitting the cell divisions 
required for additional oncogenic changes which are essential to the formation of malignant tumours. 
 The discovery of malignant and lethal TLM-negative cancer cells has implications for the 
development of TLM inhibitors for clinical use as anti-cancer therapies. Tumours that rely on extreme 
telomere length, and not a TLM, for continual proliferation will be resistant to these inhibitors. The 
existence of EST cells illustrates the need to assay for TLMs prior to therapy with such drugs. The 
similarity of the telomere lengths in EST and ALT cells indicate that it is not appropriate to define ALT by 
telomere length alone: measurement by telomere qPCR, TRF or telomere FISH is not sufficient to 
differentiate the two phenotypes. Furthermore, care must be taken when utilising C-circles to define 
ALT; presence of low levels of C-circles does not indicate sufficient ALT activity to counter the EST 
phenotype. This is further complicated by the evidence that EST cultures have periodic increases in C-
circles. Although misclassification of such a phenotype as ALT could result in the use of an ALT inhibitor 
that targets a subpopulation of the tumour cells, the bulk of the tumour would be resistant to such 
treatment.    
 The majority of ALT cell lines report inactivation of p53 function, either by viral oncoproteins or 
TP53 mutations (Henson and Reddel, 2010). This implies that p53 has a role in supressing ALT, likely due 
to p53 mediated senescence or apoptosis which may be triggered by the high levels of chromosomal 
instability (Montgomery et al., 2004; Scheel et al., 2001; Ulaner et al., 2004) and telomeric DNA damage 
signals present in ALT cells (Cesare et al., 2009; Stagno d'Alcontres et al., 2007). COG-N-291 subclone 4 
is an example of a cell line that can maintain telomeres by a telomerase-independent mechanism while 
retaining functional p53. As expected, these cells do not accumulate DNA damage signals at the 
telomere, although they have reduced proliferation rates compared to the EST cells. In a mixed culture 
of ALT and EST COG-N-291 cells, clone 4 is unable to outgrow the EST cells due to this reduced rate of 
proliferation, resulting in their removal from the population and the fluctuating C-circle levels we 
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observed. Previous studies indicate ATRX can supress the ALT mechanism (Clynes et al., 2015; Napier et 
al., 2015). Clone 4 cells lack abundant APBs but have wild type ATRX and DAXX, which may act with p53 
to suppress some of the characteristics of ALT. However, a small proportion of ALT cell lines retain ATRX 
and DAXX protein, whilst exhibiting classic ALT phenotypes (Lovejoy et al., 2012), indicating that 
retention of p53, ATRX and DAXX protein is not soley responsible for the repressed ALT phenotype in 
COG-N-291 clone 4 cells.  
 In conclusion, this chapter has provided evidence that lethal, malignant human cancers may, in 
some cases, contain cells that can proliferate long term with continuously shortening telomeres. The 
extreme telomere length which was presumably present in the progenitor cells gave rise to EST cells 
that do not require immortalisation for proliferation in excess of 500 PDs. The overlap in some features 
of the EST and ALT phenotypes indicates that appropriate assaying for TLMs is required before the use 
of TLM inhibitors as anti-cancer therapeutics. 
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Chapter 5: Activation of a telomere lengthening 
mechanism rescues the ever‐shorter telomere 
phenotype 
5.1. Introduction 
The previous chapter describes two NB EST cell lines that were capable of extensive proliferation in spite 
of their continually shortening telomeres. Examination of C-circle levels in these cells identified a 
subpopulation of cells that were able to activate a telomerase-independent TLM, although these cells 
did not possess many of the characteristics of ALT. In principle, these cells show that activation of a TLM 
would rescue the EST phenotype. The aim of this chapter is to provide evidence that ectopic expression 
of hTERT in EST cells results in telomerase activity, and that TP53 mutated EST cells activate a typical 
ALT mechanism, and ultimately, that activation of either TLM rescues the EST phenotype. In addition to 
proving that activation of a TLM abolishes the EST phenotype, we determined that the EST lines were t-
circle deficient, suggesting that the EST phenotype may arise due to a failure of t-circle formation and 
telomere trimming.  
5.2. Results 
5.2.1. Activation of telomerase rescues the EST phenotype 
To confirm that activation of a TLM would abolish the EST phenotype we activated telomerase in LA-N-
6 cells at PD83. As established in Chapter 3, LA-N-6 cells lack expression of the telomerase catalytic 
subunit, hTERT. Retroviral transduction of hTERT, or of hTERT plus hTR (telomerase RNA subunit; Figure 
5.1.A), resulted in telomerase activity (Figure 5.1.B). To confirm that the telomerase activity detected 
116 
 
 
Figure 5.1. Retroviral transduction of hTERT results in telomerase activity in LA-N-6 cells. 
(A) mRNA expression of the three telomerase components (hTR, hTERT and dyskerin; measured by 
RT-qPCR) in LA-N-6 infected with plasmids for either hTR (clones, hTR C3 & C4), hTERT (clones, 
hTERT C4 & C23) or hTR/hTERT (clones, hTR/hTERT C19 & C23). (B) Telomerase activity detected 
by TRAP. U-2 OS and SH-SY5Y cells are negative and positive controls, respectively, for telomerase 
activity. (C) TRAP assay performed on heat-inactivated lysates (55°C for 20 mins) from Figure 5.1.B 
shows that there is no PCR product contamination. (D) Growth curves of LA-N-6 derivatives. 
*P<0.0003 
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Figure 5.2. Ectopic expression of telomerase rescues the EST phenotype. 
(A) TRF analysis of the telomere length of LA-N-6 clones at the indicated PDs. (B) Verification of TRF 
results by telomere qPCR at the indicated PDs. qPCR data represent mean of triplicates +SD. (C) 
Relative telomere fluorescent signals measured from telomere FISH (15 metaphases analysed per 
cell line). Dots represent individual telomere signals and red horizontal bar indicates mean. (D) Graph 
indicates the percentage of chromosome ends without telomere signal in telomere FISH from Figure 
5.2.C.   
 
was not due to PCR contamination a proportion of all samples had the telomerase enzyme heat 
inactivated prior to the TRAP assay. These samples were negative on a TRAP gel (Figure 5.1.C) confirming 
that the banding pattern in Figure 5.1.B was due to the presence of the telomerase enzyme in these 
cells. As expected, expression of hTR alone did not result in telomerase activity. Activation of telomerase 
led to a significant increase in the growth rate of these cells compared to LA-N-6 transduced with hTR 
alone (Figure 5.1.D). Telomere length was examined by both TRF and qPCR, which showed that the EST 
phenotype was abolished in all clones expressing telomerase (Figure 5.2.A, B). Two clones expressing 
hTERT (C4 and C23) and one clone expressing hTR/hTERT (C19) maintained telomere length, whereas 
one hTR/hTERT expressing clone (C23) underwent telomere lengthening over the 50 PDs of culture 
(Figure 5.2.A, B). In the telomerase-positive cells, the shortest telomeres were preferentially elongated 
(Figure 5.2.C, D). In contrast, two independent clones with overexpression of hTR did not abolish the 
EST phenotype (Figure 5.2.A, B). The activation of telomerase resulted in elongated telomere lengths in 
LA-N-6 but as expected this did not result in any changes to ALT characteristics. The level of APBs, C-
circles and TERRA did not differ between the hTR, hTERT, and hTR/hTERT clones (Figure 5.3.A, B, C, D). 
Consequently, we have demonstrated that activation of telomerase in an EST cell line rescued the EST 
phenotype. 
 
119 
 
 
Figure 5.3. No change to ALT characteristics following ectopic expression of hTERT.  
(A) APB (localisation of telomere FISH signal to PML body) analysis of LA-N-6 derived cell lines. Mean 
+SD from 3 independent experiments. (B) C-circle levels were detected by slot blot analysis. MeT-4A 
and SK-N-BE2c were included as the ALT-positive control and the telomerase-positive negative 
control, respectively. (C) Quantitation of C-circle results in Figure 5.3.B. (D) TERRA detected by slot-
blot analysis. Quantitation in bottom panel from 3 independent experiments (mean +SD).  
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Figure 5.4. A LA-N-6 subline spontaneously acquired a premature stop codon in TP53. 
(A) Chromatograph from Sanger sequencing of LA-N-6 TP53 wild-type cells (LA-N-6 WT p53) and 
the LA-N-6 subline that spontaneously acquired a stop codon (Y236*) (LA-N-6 MUT p53). (B) p53 
immunoblot of LA-N-6 cells with wild-type and mutant TP53. GAPDH was used as loading control.  
Western blot performed by Dr Loretta Lau. 
 
5.2.2. Activation of ALT rescues the EST phenotype 
Activation of telomerase in telomerase-negative cells only requires ectopic expression of the telomerase 
components hTR and hTERT (Weinrich et al., 1997). By comparison activating ALT is far more 
challenging. Currently, no one gene has been identified that is responsible for activating the ALT 
mechanism. In the previous chapter, we provided evidence that COG-N-291 cells can spontaneously 
activate ALT. In contrast to COG-N-291, LA-N-6 cells have a single copy of TP53 and consequently there 
is a high likelihood that these cells may develop a spontaneous TP53 mutation during long-term culture. 
Therefore, to determine if activation of ALT can rescue the EST phenotype, we developed a strategy to 
identify a spontaneously activated ALT mechanism in LA-N-6 TP53 mutated cells.     
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Figure 5.5. Activation of ALT results in rescue of the EST phenotype.  
(A) TRF analysis of the LA-N-6 culture from acquisition of the p53 mutation (PD90) to PD654. 
(B) Telomere content of LA-N-6 MUT p53 cells measured by telomere qPCR. Mean +SD, n=3. 
(C) Percentage of chromosome ends free of telomere signal (obtained from telomere FISH) in LA-
N-6 parental (wild-type TP53) and LA-N-6 MUT p53 cells. Quantitation from 15 metaphase spreads. 
(D) Growth curves of LA-N-6 parental (wild-type TP53) and LA-N-6 MUT p53 culture. (E) Telomerase 
activity was monitored by TRAP at the specified PDs in LA-N-6 MUT p53 cells. Lysates were 
immunopurified (IP) with anti-hTERT antibody to remove potential inhibitors which could lead to 
false negative results. SH-SY5Y and SK-N-BE2c were used as positive controls. 
 
We first identified a subculture of LA-N-6 that spontaneously acquired a TP53 mutation at PD90. The 
subclone had spontaneously acquired a base change in exon 7 of TP53 (Figure 5.4.A), resulting in a 
premature stop codon (Y236*) and loss of p53 protein expression (hereafter referred to as LA-N-6 MUT 
p53; Figure 5.4.B). As expected, the loss-of-function mutation was insufficient to activate ALT, and the 
telomeres of this LA-N-6 MUT p53 subculture continued to shorten until PD209, i.e., for another 119 PD 
(Figure 5.5.A). By PD222, the telomere length profile of the cells had changed to have the typical 
appearance of ALT (Figure 5.5.A). Over the next 99 PD, the mean telomere length fluctuated slightly, 
but after PD240 the continuous telomere shortening previously exhibited by these cells had ceased, 
demonstrating that a TLM had been activated (Figure 5.5.A). Telomere qPCR confirmed telomere length 
maintenance in LA-N-6 MUT p53 cells after PD209 (Figure 5.5.B). From PD222 onwards, the shortest 
telomeres in the TRF were elongated, an observation supported by a decrease in the percentage of 
chromosomes with telomere signal-free ends (Figure 5.5.C). The growth rate of the culture was 
unchanged by the loss of p53 at PD90 and by activation of a TLM at PD209 (Figure 5.5.D). The LA-N-6 
MUT p53 cells exhibited telomere maintenance in the absence of telomerase (Figure 5.5.E), therefore 
the TLM that was activated was, by definition, an ALT mechanism. Consistent with this conclusion, we 
observed a 2 to 4-fold increase in C-circle levels from PD222 until PD503, after which a further 2 to 
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Figure 5.6. Loss of p53 results in activation of ALT in an EST culture (LA-N-6).  
(A) C-circle assay product was detected using slot-blot analysis. Levels were calculated relative to 
the ALT-positive MeT-4A cell line with an arbitrary unit of 10 and graphed on the right. SK-N-BE2c 
was included as a negative control. (B) Percentage of APB positive cells in TP53 wild type LA-N-6 at 
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PD95 compared to LA-N-6 mutant cells at PD704 (mean +SD, n=3 independent experiments). (C) 
TERRA level in the ALT-positive LA-N-6 MUT p53 PD618 compared to TP53 wild-type LA-N-6 PD93 
cells. Quantitation shows mean +SD (n=3 independent experiments). (D) Telomere sister chromatid 
exchange (T-SCE) events indicated by colocalisation of red and green FISH labelled telomeres 
(shown by arrows) and quantitated in the graph (mean +SD, n=2 independent experiments).  
 
4-fold increase was observed (Figure 5.6.A), there was a 4-fold increase in APBs (Figure 5.6.B), a 2-fold 
increase in TERRA (Figure 5.6.C), and a 4-fold increase in T-SCE events (Figure 5.6.D). The mechanism of 
ALT activation in LA-N-6 MUT p53 cells is currently unknown; although down-regulated, ATRX and DAXX 
expression was not abolished, and the proteins continued to localise to the nucleus (Figure 5.7.A, B). 
Although loss of p53 removes a barrier to the accumulation of DNA damage responses at the telomere 
(Cesare et al., 2009), the number of meta-TIFs remained unchanged (Figure 5.7.C). Irrespective of the 
mechanism utilised to activate ALT, our results demonstrate that ALT is able to rescue the EST 
phenotype.  
5.2.3. EST neuroblastoma cell lines are unable to generate t-circles 
During the investigation of spontaneous ALT activation in COG-N-291 clone 4 and LA-N-6 MUT p53 cells, 
we examined the level of t-circles, a type of double-stranded circular telomeric DNA. T-circles are 
abundant in ALT cells (Cesare and Griffith, 2004), and it has been proposed that this is the result of 
telomere trimming following telomere over-lengthening by ALT (Pickett and Reddel, 2012). T-circles 
have also been shown to form as a result of telomere trimming in cells that have had telomeres over-
lengthened by telomerase (Pickett et al., 2009). The two EST cell lines lack t-circles, and as expected, t-
circles are present in the two ALT NB cell lines (Figure 5.8.A). Contrary to what was expected, no t-circles 
were generated in the LA-N-6 clones after activation of telomerase (Figure 5.8.B), even though all hTERT 
or hTERT/hTR expressing clones had extremely long telomeres after activation of telomerase. The 
LA-N-6 MUT p53 culture also failed to generate t-circles, even after hundreds of PDs utilising the ALT 
mechanism, and perhaps less surprisingly the COG-N-291 clone 4 cells also lacked t-circles (Figure 5.8.C). 
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Figure 5.7. LA-N-6 MUT p53 cells did not activate ALT due to aberrations to ATRX or DAXX.  
(A) ATRX and DAXX immunoblot with HSP70 loading control. (B) Immunofluorescence indicating 
the presence of ATRX or DAXX foci (red) in the nucleus (blue). CHLA-90 is included as the ATRX 
negative control and SH-SY5Y as the positive control for ATRX and DAXX expression. (C) Graph of 
meta-TIF assay results demonstrating percentage of chromosome ends which have both DNA 
damage and telomere signal (-H2AX/TTAGGG+) and chromosome ends which have DNA damage 
in the absence of telomere signal (-H2AX/TTAGGG-) in LA-N-6 TP53 wild type PD96 and LA-N-6 
MUT p53 PD707. Mean +SD from 3 independent experiments.  
 
These results suggest that both of the EST cell lines are unable to undergo telomere trimming and 
generate t-circles. A number of proteins are known to be involved in t-circle formation including: XRCC3 
(Compton et al., 2007; Wang et al., 2004), NBS1 (Wang et al., 2004), SLX4 (Sarkar et al., 2015), TZAP (Li 
et al., 2017), and RTEL1 (Deng et al., 2013), but whole genome sequencing of the EST cells did not reveal 
any mutations in these genes (Appendix II Table A2.6) and all NB cell lines have detectable transcript for 
the five genes involved in t-circle formation (Figure 5.9).    
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Figure 5.8. EST cells do not form t-circles after activation of ALT or extreme telomere lengthening 
by telomerase activity.  
(A) Two-dimensional gel electrophoresis of restriction-digested genomic DNA. Denatured gels were 
hybridised with a 32P-labelled C-rich telomeric DNA probe. T-circle arcs are indicated by the arrow. 
(B) hTR and hTERT expressing LA-N-6 clones do not have t-circles at early or later PDs. (C) T-circles 
(indicated by arrow) are present in the ALT control but not in LA-N-6 MUT p53 or COG-N-291 
clone 4. 
The investigation of t-circles was conducted by A/Prof Hilda Pickett. 
 
5.3. Discussion 
This chapter describes the features of EST cultures that have activated a TLM, and thereby abolished 
the EST phenotype. Spontaneous activation of a telomerase independent TLM, which is by definition 
ALT, in a p53-mutant LA-N-6 clone (presented in this chapter) resulted in a different phenotype than a 
COG-N-291 clone (described in Chapter 4). The COG-N-291 clone had a reduced proliferation rate with 
no increase in APBs and TERRA, compared to COG-N-291 EST cells. In contrast, the LA-N-6 clone had a 
similar proliferation rate, and increased APB and TERRA levels compared to LA-N-6 EST cells. 
Interestingly, both cultures have a typical ALT TRF profile, an increase in C-circles, and are wild type for 
ATRX and DAXX. The most notable difference between the ALT COG-N-291 and LA-N-6 cultures relates 
to TP53 status. The COG-N-291 clone (clone 4) is the first cell line reported to retain expression of wild 
type TP53 and full length ATRX protein whilst utilising a telomerase-independent mechanism to prevent 
telomere shortening (Henson and Reddel, 2010; Lovejoy et al., 2012). The presence of functional p53 
may account for the reduced proliferation rate in the COG-N-291 ALT clone that was not observed in 
LA-N-6. Currently, we do not understand the mechanism that these cells have used to activate telomere 
lengthening, but as we know that a proportion of ALT NB tumours are wild type for both TP53 and ATRX 
(Chapter 3), this cell line will provide a valuable model for understanding this disease.   
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Figure 5.9. EST cells express genes involved in t-circle formation. 
(A) Transcript levels of NBS1, TZAP, RTEL1, SLX4, and XRCC3, genes involved in t-circle formation. 
The cell lines GM847, SK-N-FI and CHLA-90 are ALT cell lines that form t-circles.  
 
 
 The EST cells that we have identified indicate that a TLM may not be required for the formation 
of metastatic and lethal tumours, presumably when the progenitor cells have telomeres long enough to 
sustain extensive proliferation, though we do not know how this initial lengthening occurred in EST NB 
cells. Telomerase is active during human embryogenesis, prior to downregulation during the late stages 
of gestation, leaving somatic cells telomerase-negative (Ulaner and Giudice, 1997; Wright et al., 1996). 
Telomere trimming, a process that generates t-circles, regulates telomere length in cells that have been 
over-lengthened by telomerase (Pickett et al., 2009). We propose that a failure of telomere trimming, 
and subsequently lack of t-circle formation, in EST NB cells resulted in in excessive telomere lengths 
during embryogenesis. The EST NB cells lacked detectable t-circles, even in circumstances where their 
long telomeres were lengthened further by telomerase. Abundant t-circles are also a feature of 
lengthening by ALT (Cesare and Griffith, 2004), but t-circles were not detected in either of the COG-N-
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291 or LA-N-6 clones that spontaneously activated an ALT mechanism. A lack of telomere trimming may 
cause inhibition to the full expression of the ALT phenotype as observed in the ALT COG-N-291 or LA-N-
6 clones. Presumably, the EST cells downregulated telomerase activity as normal during embryogenesis, 
leaving excessively lengthened telomeres, which have allowed very extensive proliferation to occur 
without requiring significant upregulation of a TLM. As with tumours that activate a TLM, additional 
oncogenic changes would need to have occurred to result in the development of malignant EST tumours, 
and the excessively long telomeres presumably provide sufficient reserves of telomere content to 
obviate the need for an activated TLM. 
 In summary, we have shown that activation of a TLM is sufficient to rescue the EST phenotype. 
EST cells lack t-circles implying a failure of telomere trimming, regardless of the mechanism (either 
activation of telomerase or ALT) used to overlengthen the telomeres. This is the first example of a 
disease that may result from a failure of telomere trimming. Despite treatment in these patients, EST 
tumours are lethal in approximately 50% of patients and the telomere trimming mechanism may 
provide a unique way to target therapies to these cells.  
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Chapter 6: Neuroblastoma EST cells are sensitive to 
topoisomerase inhibitors  
6.1. Introduction 
The aggressive behaviour of high-risk NB requires extensive cellular proliferation made possible via 
activation of a TLM, either telomerase or ALT, or by an EST phenotype which is characterised by 
extremely long telomeres that allow proliferation without significant upregulation of a TLM. In Chapter 
3 we show that the prognosis of each of these groups of tumours is poor: the 5-year overall survival is 
28% for patients with MYCN amplified tumours (which are generally telomerase positive (Hiyama et al., 
1997)), 36% for ALT-positive patients, and 49% for EST NB. In addition, telomere biology has an impact 
on disease course, with ALT and EST NB patients having late events compared to MYCN amplified 
tumours. Recently, several large scale genomic studies have been conducted to elucidate driver 
mutations in NB (Molenaar et al., 2012; Pugh et al., 2013). Whilst these studies were unable to identify 
a driver mutation, approximately 10% of tumours had mutations to the ATRX gene which is associated 
with ALT activity (Cheung et al., 2012; Kurihara et al., 2014; Molenaar et al., 2012; Pugh et al., 2013), or 
rearrangements upstream of hTERT which results in reactivation of telomerase (Peifer et al., 2015; 
Valentijn et al., 2015). Therefore, telomere biology has become an attractive target for the development 
of novel NB therapies.    
Over the last two decades telomerase inhibitors have gone through various stages of 
development, resulting in a number of clinical trials in diseases such as breast and lung cancer, 
glioblastoma, and lympho-proliferative disorders (Arndt and MacKenzie, 2016). In contrast, ALT 
inhibitors have yet to enter clinical trials and are still being developed in preclinical laboratory models 
(Deeg et al., 2016; Flynn et al., 2015).  
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The EST NB cell lines have very low levels of C-circles which likely represent a very low level of 
ALT activity that is insufficient to confer telomere maintenance in these cells. In yeast, ALT acts 
preferentially on the shortest telomeres (Fu et al., 2014) although, Murnane and colleagues suggest that 
this is not necessarily the case in human cells (Murnane et al., 1994). In the experiments described in 
this chapter, we tested the hypothesis that the low level of ALT in EST cells may preferentially lengthen 
the shortest telomeres as critically short telomeres will eventually trigger p53-mediated senescence or 
apoptosis. If this was the case, even though ALT activity is clearly insufficient to prevent telomere 
shortening, EST cells might rely on low levels of ALT to survive, and consequently inhibition of ALT would 
result in increased cell death. The ALT mechanism relies on homologous recombination. APBs potentially 
play a role in this process as proteins associated with homologous recombination are found at APBs 
(Pickett and Reddel, 2015). One such protein, RPA, is associated with replication stress via its interaction 
with ATR (Zou and Elledge, 2003). It has been suggested that ALT cells are acutely sensitive to ATR 
inhibitors (Flynn et al., 2015), implying that replication stress has a role in ALT activity that can be 
targeted by anti-cancer therapeutics. Therefore, the aim of this chapter was to determine the sensitivity 
of EST cells to common NB chemotherapeutics, and to determine if treatment with drugs that target 
the ALT mechanism led to an increased rate of cell death. 
6.2. Results 
6.2.1. EST cells are sensitive to topoisomerase inhibitors 
EST cells represent a novel prognostic group of NB, with an approximately 50% 5-year mortality in high-
risk patients. To develop better treatments for these patients we first need to understand the role 
telomere biology plays in the response of high-risk NB to chemotherapy. We asked whether cells of 
different telomere biology groups (ALT-positive, telomerase-positive, or EST) had different sensitivity to 
common NB chemotherapeutics. Using AlamarBlue, a redox indicator that provides a quantitative 
measure of cell viability, we determined the effect of chemotherapeutics on the proliferation of six 
telomerase-positive (SH-SY5Y and SK-N-BE2c NB cell lines; HT1080, GM639, HT1080 hTR and  
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Figure 6.1. EST cells are sensitive to topoisomerase inhibitors.  
Cell lines were treated with increasing concentrations of (A) doxorubicin, (B) etoposide, (C, D) 
irinotecan, and (E, F) topotecan for 6 PDs before proliferation was quantified using AlamarBlue. U-
2 OS and GM847 ALT cell lines, and HT1080, GM639, HT1080 hTR and HeLa 1.2.11 telomerase-
positive cell lines were included as non-NB controls. Results in panel (A), (B), (C), (E) are expressed 
as percentages of growth compared to untreated controls and as means of triplicate independent 
experiments +SD. Panel (D) displays the percentage of cell growth, compared to control cells, when 
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cells were treated with 2.8 µM irinotecan. COG-N-291 had significantly reduced growth compared 
to all cell lines except SH-SY5Y and HT1080 hTR whilst LA-N-6 had significantly reduced growth 
compared to U-2 OS, SK-N-BE2c and HeLa 1.2.11 cells (when significant P<0.05). Panel (F) displays 
the percentage of cell growth, compared to control cells, when cells were treated with 0.0004 µM 
topotecan. COG-N-291 and LA-N-6 cells had significantly reduced growth compared to all other cell 
lines (P<0.001). 
 
HeLa 1.2.11 non-NB cell line), four ALT-positive (SK-N-FI and CHLA-90 NB cell lines; U-2 OS and GM847 
non-NB cell lines), and the two EST (COG-N-291 and LA-N-6 NB cells) cell lines. As the cell lines in this 
panel had a range of growth rates, of which COG-N-291 and LA-N-6 were the slowest, it was not possible 
to treat for a fixed length of time, instead cells were treated for a duration of 6 PDs. The DNA damaging 
agent doxorubicin reduced proliferation of all cell lines, although there was no differential response to 
doxorubicin based on telomere biology (Figure 6.1.A; Table 6.1). Treatment with etoposide, a 
topoisomerase II inhibitor, resulted in the most significant growth inhibition of COG-N-291 cells (IC50 
0.08 µM; the dose to inhibit 50% of control growth) (Figure 6.1.B), although sensitivity to topoisomerase 
II inhibitors is not a general feature of EST cells as LA-N-6 had an IC50 of 0.23 µM, similar to telomerase-
positive cell lines (0.17 to 0.56 µM). In contrast, EST cells show a striking sensitivity to the topoisomerase 
I inhibitors, irinotecan and topotecan (Figure 6.1.C, D, E, F). At a dose of 2.8 µM irinotecan COG-N-291 
had significantly reduced cell growth compared to all cell lines except SH-SY5Y and HT1080 hTR whilst 
LA-N-6 cells had a similar trend of sensitivity with significantly reduced growth compared to U-2 OS, SK-
N-BE2c and HeLa.1.2.11 cells (where significant P<0.05, Figure 6.1D). The EST cells were particularly 
sensitive to topotecan treatment, 0.0004 µM topotecan led to significantly reduced EST cell growth 
compared to all other cell lines tested (P<0.001, Figure 6.1F). The IC50 of irinotecan and topotecan for 
non-EST cell lines with long telomeres (U-2 OS, HT1080 hTR, and HeLa 1.2.11), was generally higher than 
the EST cells (Figure 6.1.C, D; Table 6.1), indicating that the telomere length of EST cells is not entirely  
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Figure 6.2. Telomere biology does not influence sensitivity of NB cells to common NB therapies.  
Cell lines were treated with increasing concentrations of (A) vincristine, (B) cisplatin, (C) 
temozolomide, and (D) all-trans retinoic acid (ATRA) for 6 PDs before proliferation was quantified 
using AlamarBlue. U-2 OS and GM847 ALT cell lines, and HT1080, GM639, HT1080 hTR and HeLa 
1.2.11 telomerase-positive cell lines were included as controls. Results are expressed as 
percentages of growth compared to untreated controls and as means of triplicate independent 
experiments +SD. 
 
responsible for their sensitivity to topoisomerase I inhibitors. The response of cell lines to vincristine, 
cisplatin and temozolomide (Figure 6.2.A, B, C) varied depending on the cell line and was not associated 
with telomere length maintenance phenotype. All-trans retinoic acid (ATRA), a differentiating agent, did 
not reduce the proliferation of cells in a treatment period of 6 PDs (Figure 6.2.D).       
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Table 6.1. IC50 values for common NB chemotherapeutics. 
  
IC50 (µM) 
Doxorubicin Etoposide Cisplatin Irinotecan Topotecan Temozolomide Vincristineb 
All 
Trans 
Retinoic 
Acid 
LA-N-6  0.40 0.23 4.23 1.04 <0.0004 324.33 8.07 >45 
COG-N-291 0.01 0.08 0.77 0.31 <0.0004 58.87 12.64 >45 
SK-N-FI 0.69 3.65 2.62 5.64 0.07 >400 >25 >45 
CHLA-90 0.20 8.11 6.60 30.44 0.42 >400 2.21 >45 
GM847 0.01 0.41 1.57 6.14 0.02 191.54 0.59 >45 
U-2 OS 0.02 0.74 5.93 11.64 0.16 >400 6.02 >45 
SK-N-BE2c 0.03 0.29 16.19 8.59 0.09 >400 1.61 >45 
SH-SY5Y 0.03 0.56 2.20 2.50 0.01 98.96 19.35 >45 
HT1080 0.01 0.19 1.88 5.00 0.01 389.18 0.18 >45 
GM639 0.01 0.17 1.75 3.59 0.01 126.93 1.02 >45 
HT1080 hTRa 0.12 0.66 8.39 2.08 0.11 365.30 2.79   
HeLa 1.2.11a 0.12 0.51 0.98 17.21 <0.0004 >400 22.67   
aLong telomeres/telomerase-positive 
bIC50 (nM) 
            
 
6.2.2. EST cells do not exhibit increased cell death with potential ALT inhibitors or after 
induction of replication stress 
The EST cells have a low level of ALT activity which we hypothesise is preferentially lengthening the 
shortest telomeres, consequently these cells could be sensitive to agents that target the ALT 
mechanism. Arsenic trioxide (ATO; results in PML degradation) and ML216 (BLM helicase inhibitor) have 
been shown to downregulate C-circles in ALT cells (unpublished data). However, neither ALT nor EST 
cells showed greater sensitivity for these agents than telomerase-positive cells (Figure 6.3.A, B; Table 
6.2). Previous work by Flynn and colleagues found that ALT cells are hypersensitive to ATR inhibition 
(Flynn et al., 2015). In this panel of cell lines, the IC50 values for the ATR inhibitor VE-822 ranged from 
0.02-0.53 µM for telomerase-positive cells, 0.02-6.22 µM for ALT cells, and 0.39-3.52 µM for EST cells 
(Figure 6.3.C; Table 6.2), which is consistent with a later report that shows ALT cells are not more 
sensitive to ATR inhibition than telomerase-positive cells (Deeg et al., 2016). There was a slight increase 
in the IC50 doses for EST and ALT cells in response to the ATM inhibitor Ku60019 (Figure 6.3.D; Table 
6.2). Agents that induce replication stress, including mitomycin C, hydroxyurea, and aphidicolin reduce 
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proliferation in all cells; however, the extent of reduction was not related to the telomere biology of the 
cells (Figure 6.3.E, F, G; Table 6.2). Whilst COG-N-291 cells were most sensitive to all three inhibitors, 
the IC50s for LA-N-6 were similar to ALT and telomerase-positive cells, and we found no evidence that 
ALT cells are more sensitive to replication stress than other cell types (Table 6.2). In summary, the 
current study failed to identify any drug that specifically inhibits either ALT or telomerase-positive cells. 
However, we were able to identify the significant sensitivity of EST cells to topoisomerase I inhibitors.   
6.2.3. EST cells have alterations to genes involved in DNA damage repair and replication 
We have previously shown (Chapter 3) that the EST NB cell lines have functional p53 capable of 
activating downstream targets such as p21 and triggering p53-mediated apoptosis in response to DNA 
damage. Mutations to pathways involved in DNA damage repair and replication would prevent the EST 
cells from repairing damage caused by chemotherapeutics leading to apoptosis through the p53 
pathway. Whole genome sequencing data revealed heterozygous alterations of a number of genes 
involved in DNA damage repair and replication in the EST cell lines (Appendix II A2.6). The COG-N-291 
cells have mutations in GEN1 a resolvase that cleaves Holliday junctions (Ip et al., 2008), HLTF which is 
involved in DNA damage repair and replication fork reversal (Achar et al., 2011; Blastyak et al., 2010; 
Kile et al., 2015), and MCM4, a gene involved in the initiation and progression of replication forks (Sheu 
et al., 2014; Sheu et al., 2016). Moreover, LA-N-6 cells have altered EME2 which is involved in the 
cleavage and restart of replication forks (Pepe and West, 2014), and POLM, a polymerase used for gap 
filling in DNA damage repair by NHEJ (Pryor et al., 2015). The effect of heterozygous mutations of these 
genes on DNA damage repair and replication remains to be elucidated.   
6.3. Discussion 
The poor survival rates of NB patients with high-risk disease indicate the need to develop better 
therapies for these patients. Our results, in conjunction with a number of genomic studies (Cheung et 
al., 2012; Kurihara et al., 2014; Molenaar et al., 2012; Peifer et al., 2015; Pugh et al., 2013; Valentijn et 
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Table 6.2. IC50 values for inhibitors that cause replication stress and inhibit factors associated with ALT. 
  
  
IC50 (µM) 
ML216 
Arsenic 
Trioxide VE-822 Ku60019 Mitomycin Ca Hydroxyurea Aphidicolin 
 
LA-N-6  >225 3.24 3.52 >24 0.94 429.24 0.62  
COG-N-291 >225 3.51 0.39 >24 0.05 84.33 0.08  
SK-N-FI >225 2.55 6.22 >24 >3 1199.17 2.38  
CHLA-90 5.04 7.00 0.33 20.91 1.22 257.94 4.45  
GM847 110.53 0.77 0.02 4.97 0.18 193.23 0.51  
U-2 OS 95.98 2.19 0.09 13.37 1.32 731.70 16.13  
SK-N-BE2c >225 4.88 0.07 12.91 0.51 348.27 0.19  
SH-SY5Y >225 3.94 0.53 10.77 0.43 >1600 0.50  
HT1080 26.98 1.26 0.04 3.52 0.52 229.45 0.97  
GM639 95.11 1.26 0.02 11.79 0.49 262.79 0.57  
aIC50 (µg/mL)             
 
al., 2015), suggest that telomere biology may be a target for novel NB therapies. The EST cells are highly 
sensitive to the topoisomerase I inhibitors topotecan and irinotecan. Topotecan and irinotecan are 
derivatives of camptothecin, a topoisomerase I poison that stabilises the topoisomerase I-DNA cleavage 
complex during DNA replication (Hsiang et al., 1985). This results in a dsDNA break when the advancing 
DNA replication fork collides with the topoisomerase I-DNA complex leading to cell cycle arrest and 
apoptosis (Hsiang et al., 1989). The differential response of EST cells to this form of DNA damage 
compared with ALT or telomerase-positive cells was not due to therapy-acquired resistance in the ALT 
or telomerase-positive NB cell lines as neither topotecan nor irinotecan were used to treat NB patients 
from which these cells were derived more than two decades ago (Biedler et al., 1973; Keshelava et al., 
1998; Wada et al., 1993). Whilst COG-N-291 and LA-N-6 have obvious sensitivity to topoisomerase I 
inhibitors the analysis is limited by the number of EST cell lines. The Pediatric Preclinical Testing Program 
(PPTP) identified NB-1643 as acutely sensitive to topotecan in their cell line panel with an IC50 of 0.71 
nM (Carol et al., 2010) and the Reynold’s lab has identified a further four cell lines that are telomerase- 
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Figure 6.3. Telomere biology does not predict the response of cell lines to inhibitors that cause 
replication stress or reduce factors critical to the ALT mechanism.     
Cell lines were treated with increasing concentrations of (A) arsenic trioxide (ATO) which degrades 
PML, (B) the BLM inhibitor ML216, (C) the ATR inhibitor VE-822, (D) the ATM inhibitor KU60019, (E) 
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mitomycin C, (F) hydroxyurea, and (G) aphidicolin for 6 PDs before proliferation was quantified 
using AlamarBlue. U-2 OS and GM847 ALT cell lines, and HT1080 and GM639 telomerase-positive 
cell lines were included as controls. Results are expressed as percentages of growth compared to 
untreated controls and as means of triplicate independent experiments +SD. 
 
negative and lack C-circles (unpublished data). Therefore, further testing is required to establish if any 
of these cell lines have the EST phenotype, with the potential to expand the EST NB cohort for further 
drug screening. Genz-644282 is a recently developed new generation of topoisomerase I inhibitor, not 
derived from camptothecin (Li et al., 2003). According to the PPTP screen, NB cells are generally more 
sensitive to Genz-644282 than topotecan (Houghton et al., 2012), therefore, establishing the acute 
sensitivity of EST cells to Genz-644282 will confirm EST cells are particularly sensitive to topoisomerase 
I inhibitors.  
 One possible explanation for the EST cell sensitivity to topoisomerase inhibitors are the very 
long telomeres of these cells. Telomeres are known to form G-quadruplex structures (Sen and Gilbert, 
1988; Sundquist and Klug, 1989) which need to be removed prior to telomere replication in S. cerevisiae 
(Paeschke et al., 2011). Long telomeres have a greater potential to form such structures which could 
reduce the efficiency of telomeric replication and make complete DNA replication more difficult. 
Furthermore, the replication fork must travel a further distance to fully replicate long telomeres. In this 
study, we found no evidence that telomere length as a single factor was responsible for the EST 
sensitivity to topoisomerase I inhibitors. The cell line U-2 OS has wild type TP53 which can induce p21 
(Bensaad et al., 2006; Cesare et al., 2009) and has similar telomere lengths to EST cell lines however, it 
is not sensitive to treatment with topotecan or irinotecan. Whole genome sequencing identified 
aberrations in DNA damage repair and replication genes in the EST cell lines but further studies are 
required to determine the effect of these heterozygous mutations. The EST cells may be particularly 
sensitive to DNA damage by topoisomerase I inhibitors due to a combination of very long telomeres, 
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wild-type TP53 and impaired DNA repair/replication machinery, which means that the additional DNA 
damage caused by topoisomerase I inhibition during replication, cannot be repaired by the cells leading 
to p53-mediated apoptosis.  
 Topoisomerase levels may predict the response of cells to topoisomerase inhibitors (Burgess et 
al., 2008). We are currently using pressure cycling technology (PCT) and sequential window acquisition 
of all theoretical fragment ion spectra (SWATH) mass spectrometry (Guo et al., 2015) to measure the 
level of proteins in EST, telomerase and ALT NB which will allow us to determine if the level of 
topoisomerase I and II correlates with sensitivity to topoisomerase inhibitors. This study will also allow 
us to determine the effect of heterozygous mutations on the protein expression of GEN1, HLTF, MCM4, 
EME2, and POLM in the EST cells. We will also use the mass spectrometry results to determine a 
proteomic profile of the EST cells compared to ALT and telomerase-positive NB to aid the development 
of targeted therapies based on the telomere biology of NB cells. 
 The use of topoisomerase I inhibitors is a recent development in NB treatment. Topotecan has 
only recently been incorporated into COG clinical trials as a part of induction therapy (Park et al., 2011) 
or to treat relapsed/refractory disease (Garaventa et al., 2003) whilst irinotecan is only used to treat 
relapsed or refractory NB (Kushner et al., 2006). Our results indicate that 11% of high-risk NB, i.e. the 
EST tumours, could be acutely sensitive to upfront treatment with topotecan and irinotecan. Further 
preclinical studies are required to confirm whether topoisomerase I inhibition results in better outcome 
for EST tumours but we have shown that targeting telomere biology may lead to novel treatment 
regimens for high-risk NB.    
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Chapter 7: Discussion 
The acquisition of cellular immortality, via activation of a TLM, is currently considered a hallmark of 
cancer (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). However, studies of some 
cancers including glioblastoma (Hakin-Smith et al., 2003), liposarcoma (Costa et al., 2006; Jeyapalan et 
al., 2008), osteosarcoma (Ulaner et al., 2003), and retinoblastoma (Gupta et al., 1996) have reported 
that a substantial proportion of tumours are TLM-negative, and the widely-held explanation for this has 
been that these are false negatives caused by deficiencies in the standard TLM assays. Our study has 
identified a subset of NB tumours that lack telomerase activity, have very long telomeres, and have such 
low levels of ALT that they are unable to prevent telomere shortening. Cells derived from such tumours 
are capable of long-term proliferation despite ever-shorter telomeres. Subsequent investigations 
showed NB EST cells were acutely sensitive to topoisomerase I inhibitors, indicating TLMs are potential 
targets for novel NB therapies.    
7.1. The ever-shorter telomeres phenotype in human cancer 
Telomerase activity was established as a poor prognostic factor in NB over two decades ago (Poremba 
et al., 2000; Poremba et al., 1999) and recent studies have utilised telomere length (Onitake et al., 2009), 
or ATRX/DAXX mutations (Cheung et al., 2012; Kurihara et al., 2014; Molenaar et al., 2012; Peifer et al., 
2015; Valentijn et al., 2015) to identify ALT tumours. Ours is the first study to utilise C-circles as a 
quantifiable marker of ALT activity to determine the prevalence of ALT in metastatic NB. Using this 
method, we identified 11% of high-risk NB tumours as ALT-negative/TC≥15. These tumours lacked 
telomerase activity, indicating that a subgroup of high-risk NBs lack evidence of a TLM, consistent with 
previous studies (Choi et al., 2000; Krams et al., 2001; Poremba et al., 2000; Poremba et al., 1999; 
Reynolds et al., 1997). These studies were unable to distinguish among the possibilities that the 
apparent lack of significant ALT or telomerase activity was due to: (1) false-negative assays, (2) an as-
yet unidentified ALT mechanism lacking the common phenotypic characteristics of the "classic" ALT 
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mechanism, or (3) a true lack of significant TLM activity in the cells. The only conclusive test to determine 
if cells are TLM-negative is to observe telomere length over time, which cannot be done ethically in 
human tumour samples as it would require serial samples from the same patient over time in the 
absence of treatment. Consequently, cell line models were required to determine which of these 
scenarios was true. We present evidence that human cell lines derived from fatal metastatic disease are 
capable of proliferating for 500 PDs, despite ever-shorter telomeres.   
 The observation of the EST phenotype in high-risk NB provides direct evidence that, as 
previously postulated (Reddel, 2000), immortalisation is not an absolute requirement of oncogenesis. 
Telomerase activity is detectable during the early stages of human embryogenesis however, it is 
downregulated in late embryogenesis resulting in telomerase-negative somatic cells (Ulaner and 
Giudice, 1997; Wright et al., 1996). NB is an embryonal cancer, and we propose that excessive 
telomerase activity during embryogenesis resulted in very long telomeres in the EST progenitor cells 
before telomerase activity was downregulated at the end of embryogenesis. The EST progenitor cells 
would not require significant upregulation of a TLM to allow extensive proliferation to occur in these 
cells although further oncogenic events would be required to form a malignant tumour. Telomere 
trimming is a process that regulates telomere length in cells that have been over-lengthened by 
telomerase (Pickett et al., 2009). The lack of t-circles, a product of telomere trimming, in LA-N-6 cells 
with over-lengthened telomeres due to ectopic telomerase expression suggests that EST cells have a 
failure of telomere trimming. T-circles are also detected in cells that have upregulated ALT (Cesare and 
Griffith, 2004), however we were unable to detect t-circles either in COG-N-291 clone 4, or in the LA-N-
6 MUT p53 clone that spontaneously activated ALT, further confirming that these cells have a failure of 
telomere trimming. This is the first report of a disease that may result from a failure of telomere 
trimming, although the mechanism leading to failure of telomere trimming remains to be elucidated. 
Whole genome sequencing did not identify genetic events unique to the EST cells and further studies 
are required to examine their epigenetic and proteomic profile compared to ALT and telomerase-
positive cells and consequently identify events responsible for the failure of telomere trimming. The 
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failure of telomere trimming in EST cells may be responsible for their sensitivity to topoisomerase I 
inhibitors. If this is the case, knockdown of genes associated with telomere trimming would lead to the 
increased sensitivity of non-EST cells to topoisomerase I inhibitors, providing further evidence that the 
EST cells are a disease resulting from the failure of telomere trimming.   
 Our study did not identify potential EST cell lines in other tumour types although this is likely 
due to the criteria used to identify EST cell lines. The criteria for NB EST may not reflect the phenotype 
of EST cells in other tumour types, as NB is a childhood cancer and consequently the tumour progenitor 
cells have not undergone many cycles of replication induced telomere shortening. In contrast, the 
progenitor cells of adult cancers may have undergone many rounds of cell division, and associated 
telomere shortening, before oncogenesis occurs. Cell lines derived from these tumours may not have 
very long telomere lengths after the PDs required to derive a cell line from the tumour. Indeed, data 
from the Decottignies laboratory, found melanoma cells lacking evidence of a TLM had telomere lengths 
at the upper end of the normal range (Viceconte et al., 2017). Another explanation for the lack of EST 
cell lines in other tumour types may be the difficulty in deriving cell lines from such tumours. The NB 
EST cell lines grow very slowly compared to cell lines with an upregulated TLM and consequently other 
EST cell lines may never have been characterised or grown long term in laboratories due to the bias 
towards with faster growing cell lines for in vitro experiments. Therefore, it is likely that cell line studies 
will underestimate the occurrence of the EST phenotype.      
7.2. Targeting telomere biology in the clinic 
Since the discovery of telomerase, inhibitors have been developed to target the enzyme translating to 
clinical trials in cancers including breast and lung cancer, glioblastoma, and lympho-proliferative 
disorders, although to date there is no evidence of their effectiveness in treating malignancies (Arndt 
and MacKenzie, 2016). In contrast, ALT inhibitors have yet to enter clinical trials and are currently being 
developed in preclinical laboratory models (Deeg et al., 2016; Flynn et al., 2015). High-risk NB patients 
have very poor survival rates and novel targets for therapy need to be identified. Our study, in addition 
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to a number of large scale genomic studies (Cheung et al., 2012; Kurihara et al., 2014; Molenaar et al., 
2012; Peifer et al., 2015; Pugh et al., 2013; Valentijn et al., 2015), indicate that telomere biology plays a 
significant role in NB pathogenesis and may be a target for novel NB therapies. We have shown that NB 
EST cells are highly sensitive to the topoisomerase I inhibitors topotecan and irinotecan and therefore 
11% of high-risk NB could be acutely sensitive to upfront treatment with these agents. The identification 
of further EST NB cell lines, currently underway through expansion of the cell line screen, will aid in the 
identification of other agents that uniquely target these cells. The identification of EST cell lines in other 
cancer types will facilitate further studies to determine if sensitivity to topoisomerase I inhibition is a 
universal feature of EST cells. 
 EST cells provide the first evidence of a disease that may result from a deficiency in telomere 
trimming. This provides a novel area for drug development as there is currently no therapy to target the 
telomere trimming mechanism. The molecular details of the trimming mechanism are still under 
investigation which may lead to the identification of novel therapeutic targets.  
 The development of drugs which target features of telomere biology require appropriate 
biomarkers to predict response to therapy. The discovery of malignant and lethal EST cancer cells 
illustrates the need to assay for TLMs prior to treatment with drugs that target these mechanisms. The 
phenotypic similarity of EST and ALT cells illustrates that care must be taken to correctly define ALT 
tumours: ATRX/DAXX mutations are not a universal feature of ALT cells (Lovejoy et al., 2012), telomere 
length (as measured by telomere qPCR, TRF analysis or telomere FISH) is insufficient to differentiate ALT 
and EST cells, and the presence of low levels of C-circles does not necessarily indicate sufficient ALT 
activity to counter the EST phenotype. Therefore, studies that define a molecular profile for the EST cells 
will be critical in developing accurate clinical assays to differentiate between EST and ALT cells.  
7.3. Conclusion 
In conclusion, this study has provided evidence of lethal, malignant human cancers that can proliferate 
continuously for hundreds of PDs with ever-shorter telomeres. This indicates that the upregulation of a 
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TLM to confer immortalisation is not an absolute requirement for oncogenesis. Patients with high-risk 
NB have a poor survival rate and we need to develop novel therapies to improve the outcome of these 
patients. Our results, indicate that telomere biology is a relevant target for novel NB therapies and EST 
tumours are potentially very susceptible to treatment with topoisomerase I inhibitors. The similarity of 
the EST and ALT phenotypes indicates that rapid and specific assays for TLMs are required to facilitate 
the use of TLM targeting inhibitors as anti-cancer therapeutics.  
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Appendix I: Information Relating to Chapter 2 
ATRX and DAXX sequencing was performed with the primers listed in Table A1.1. and A1.2., respectively. 
The PCR conditions are listed in the subsequent tables.  
 
Table A1.1. Primers used to Sanger sequence ATRX. 
Exon 
PCR 
product 
size 
M13 primer Other primer 
PCR 
Program 
Taq used in 
PCR 
35 552 ATGGTCCTGTGAATGCCATC GGCATTTAAGGGGACCAAAC 1 
Taq Platinum 
(Invitrogen) 
34 339 ACCTTGGGAAATCCCGAATA CAATGACTATCCATCCCTCCA 1 
Taq Platinum 
(Invitrogen) 
33 237 GTTGGCAAATGGAAGGATTC AGTAGGGGGTGGAGGGTACA 2 
Taq Platinum 
(Invitrogen) 
32 353 
GGGTGAAAAGGGTGTTTTGT
T 
GCATAGGGAACCCTCAACAA 3 
HotStar Taq 
(Qiagen) 
31 372 
GGTTTTAGTTTCTAGTACAGT
TGACCA 
GGGGAATGTGTTCCTAAAACC 1 
Taq Platinum 
(Invitrogen) 
30 500 
GCAAAATTGCTGATGAGTTTT
T 
CATTTTATTATCCTTGAAAAAT
TCTGA 
1 
Taq Platinum 
(Invitrogen) 
29 405 
AAGAAATGAATTCTCTGAACT
CTTGA 
CCAACTTTGTTTCCCTCTCTG 1 
Taq Platinum 
(Invitrogen) 
28 329 
TGATGAGCAAGGTGGAAAAT
C 
TGACACTGTTTTGCAACCTGA 1 
Taq Platinum 
(Invitrogen) 
27 313 AAATCCTGCTGGGATTTTTG 
GGGTAGTTTTGTTTCTTTTGTT
GC 
1 
Taq Platinum 
(Invitrogen) 
26 392 CCCCATGGGTAGGTCTTTTT TTGCTTGTATTGGCCTAGCA 1 
Taq Platinum 
(Invitrogen) 
24-25 554 TTCCTCAGTCCTTCCTCAGC CCCCAAATACCAGAGAGCAC 3 
HotStar Taq 
(Qiagen) 
23 289 
GCTTCTCTACACTGCCAAAAG
TG 
TTCTGCTTCCAATAGATGCTTT 1 
Taq Platinum 
(Invitrogen) 
22 387 
TTGTGGGTTTAGAAAGGGTA
AA 
TGCAAAACTGAAAAAGAACA
ACA 
1 
Taq Platinum 
(Invitrogen) 
21 367 TGAGCATTTCATTGGGGAAT TGAAAGAGCGGGAAAGAAAA 1 
Taq Platinum 
(Invitrogen) 
20 449 
TTAACCAAATACGGGAGCAG
A 
TTTCACAGCAGACTAAGATGA
ACC 
1 
Taq Platinum 
(Invitrogen) 
19 576 
GGCAAGAGGGATTAAAAGAT
GA 
TGGCGACATTAAGGGTGATT 1 
Taq Platinum 
(Invitrogen) 
18 387 TTGGAAATTCTGGCCGTTTA 
TTCCCACTGAAATATGCATCA
C 
1 
Taq Platinum 
(Invitrogen) 
17 418 TCTTCAGCCCCTACGACTGT GAAGGAAAGTCCCCCTGTTC 1 
Taq Platinum 
(Invitrogen) 
16 379 CAATTGGATTTGTGGTGTGG CCACCCCACTCACCAATTTA 1 
Taq Platinum 
(Invitrogen) 
194 
 
15 503 TCTTCCACCTTTTCCTGCTG AGGCTGGGTGTGTTGACTC 3 
HotStar Taq 
(Qiagen) 
14 398 
TGGAACAGAGAGGTAACAGC
A 
AACAAACCTCCCCTCAGGAT 1 
Taq Platinum 
(Invitrogen) 
13 245 
TGCTCTGTTTTAATGTCGAGT
CA 
TGAAGGCATGGTCATTCAGA 1 
Taq Platinum 
(Invitrogen) 
12 314 CAGCTTCCCAAAGTGCTAGG CGAGGCATTTTAAAGGCTGA 3 
HotStar Taq 
(Qiagen) 
11 391 TCTATTGGCACATTTATTTCT 
TTGGCCTCCCAAAGTCCTGAG
ATT 
1 
Taq Platinum 
(Invitrogen) 
10 343 
TTTGGAGTCCAGAGTTTAGA
CC 
AACTTGCAGGAAGACTGTGA
GCGA 
1 
Taq Platinum 
(Invitrogen) 
9(g) 493 
CATCTGATGCTGAGGAAAGT
TCTG 
GAGATCCCTGATACTGAATAC
TAGC 
1 
Taq Platinum 
(Invitrogen) 
9(f) 649 
TGAATCTTCATCTGATGGCAC
TGA 
TTTCTGTTCATCGCTGCTTCCC
TC 
2 
Taq Platinum 
(Invitrogen) 
9(e) 640 
AGGAATGGATAATCAAGGGC
ACA 
TCCTTTCCCTGTTGACTTCTCA
GC 
1 
Taq Platinum 
(Invitrogen) 
9(d) 655 
GGATAAGCGTAATTCTTCTGA
CAGTGC 
AGCACTTGCTTGCTGCTTCTTA
GG 
1 
Taq Platinum 
(Invitrogen) 
9(c) 777 
CCGGTGGTGAACATAAGAAA
TCTG 
AACTGTGACTCATCCTGCTCA
CCT 
4 
Taq Platinum 
(Invitrogen) 
9(b) 663 
CTTGTTCAGTTCCACTGCTGC
CAT 
CCTGTTCTGGCTCTGTAACCT
ACT 
1 
Taq Platinum 
(Invitrogen) 
9(a) 742 CCAATGCAAGATGAGCCTTC 
GAGTAAGCAGATGACCTAAA
TTACCAC 
1 
Taq Platinum 
(Invitrogen) 
8 226 
CACACCAGTGTCCTGGAGAT
TT 
AGGAAACACTGAATGTTAGCT
CATCT 
1 
Taq Platinum 
(Invitrogen) 
7 415 
TGCCAAGGTTGTCATGTGCTT
AG 
GAAGTCTTCCAAGGGCAGAT
ACCA 
1 
Taq Platinum 
(Invitrogen) 
6 276 
CCAGCAATGTTGGCTTTATCT
GAACTG 
AAGCACATCCGATTTTCCAA 1 
Taq Platinum 
(Invitrogen) 
5 348 
TTCCTTGTTGAGACCCACTGC
TCA 
GCCATGTTTGGTCGTTTGTAC
ATAGT 
1 
Taq Platinum 
(Invitrogen) 
4 219 
GCTAATTGTAGGGATGCCGT
TTCG 
CTCAGAATAGTGGTTGACATG
AGTTCAG 
1 
Taq Platinum 
(Invitrogen) 
3 259 
AGTGTGAGAATGGGTTTGTG
GAGT 
TGGGTATCAGTAGCCTTCGAC
ACA 
1 
HotStar Taq 
(Qiagen) 
2 424 
GGGCTTCTATAAAGCTTGCTA
ATCTGTC 
ACACCCACAACTGTAACATTT
CCC 
1 
Taq Platinum 
(Invitrogen) 
1 418 
TGTGCTTTGGAGGAGGTAGC
CAAT 
TAAGCAACACACAGGCCTAAC
CCA 
1 
Taq Platinum 
(Invitrogen) 
M13 primer: refers to the addition of the M13 sequence (5’ -GTAAAACGACGGCCAGT- 3’) at the 5’ end of the 
listed primer.  
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Table A1.2. Primers used to Sanger sequence DAXX. 
Exon 
PCR 
product 
size 
M13 primers Other primers 
PCR 
Program 
PCR Master Mix 
8 409 GTGCCACATCCTGTCTCTTCC GGGACAGCTAATGCCAATCTG 5 
Taq Platinum 
(Invitrogen) 
7 404 AAGAGACAGGATGTGGCACG GTCTGCTGGGAGAGACTGGAC 2 
Taq Platinum 
(Invitrogen) 
6(b) 466 TCTCCCAGCAGACTCAGTTCC CAAAGGACGCATAGTGTCACC 2 
Taq Platinum 
(Invitrogen) 
6(a) 534 CAAGGGAACATTCTCCTCACC CGCCTCCATTGAAGGAAGTAG 1 
Taq Platinum 
(Invitrogen) 
5 383 GAGTCCAGGTTGACTGATGGG GAAAGGTTTCAAACAGGTGGC 2 
Taq Platinum 
(Invitrogen) 
4 397 ATGTCAGGTATGAGGCGGATG CATCAGTCAACCTGGACTCCC 2 
Taq Platinum 
(Invitrogen) 
3(d) 576 GTCAGAGCACTCAGCCCTTG GTAAGCTGATCCGCCTCTTTG 2 
Taq Platinum 
(Invitrogen) 
3(c) 543 TAACCCTCCCACACACCTCTC TGGCAGCCAAAGTTGTAGATG 1 
Taq Platinum 
(Invitrogen) 
3(b) 553 CGCCTGTTAACCTCTGGGTAG CATTCCTCTATAACCGGCAGC 1 
Taq Platinum 
(Invitrogen) 
3(a) 502 CAGAGGAAGCAGTAGTTCGGG AGGTGTGTGGGAGGGTTATTC 6 
Taq Platinum 
(Invitrogen) 
2 443 
GGGTTAGTGGGAAAGAAAGG
AC 
GGGCTGGATGTTACTGAAACC 6 
Taq Platinum 
(Invitrogen) 
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Table A1.3. PCR cycling conditions for program 1. 
Number of cycles Step Temperature Time 
1 cycle Taq Hot start 94°C 2 mins 
3 cycles Denaturation 94°C 30 sec 
 Annealing 64°C 45 sec 
 Extension 70°C 1 min 
41 cycles Denaturation 94°C 30 sec 
 Annealing 57°C 45 sec 
 Extension 70°C 1 min 
1 cycle Extension 72°C 10 mins 
   
 
Table A1.4. PCR cycling conditions for program 2. 
Number of cycles Step Temperature Time 
1 cycle Taq Hot start 94°C 2 mins 
3 cycles Denaturation 94°C 30 sec 
 Annealing 65°C 45 sec 
 Extension 70°C 1 min 
41 cycles Denaturation 94°C 30 sec 
 Annealing 59°C 45 sec 
 Extension 70°C 1 min 
1 cycle Extension 72°C 10 mins 
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Table A1.5. PCR cycling conditions for program 3. 
Number of cycles Step Temperature Time 
1 cycle Taq Hot start 94°C 2 mins 
20 cycles Denaturation 94°C 30 sec 
 Annealing 
58.5°C 
-0.5°C from 
annealing temp 
every 3 cycles 
45 sec 
 Extension 72°C 1 min 
30 cycles Denaturation 94°C 30 sec 
 Annealing 55°C 45 sec 
 Extension 72°C 1 min 
1 cycle Extension 72°C 10 mins 
 
Table A1.6. PCR cycling conditions for program 4. 
Number of cycles Step Temperature Time 
1 cycle Taq Hot start 94°C 2 mins 
3 cycles Denaturation 94°C 30 sec 
 Annealing 67°C 45 sec 
 Extension 70°C 1 min 
41 cycles Denaturation 94°C 30 sec 
 Annealing 60°C 45 sec 
 Extension 70°C 1 min 
1 cycle Extension 72°C 10 mins 
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Table A1.7. PCR cycling conditions for program 5. 
Number of cycles Step Temperature Time 
1 cycle Taq Hot start 94°C 2 mins 
3 cycles Denaturation 94°C 30 sec 
 Annealing 63°C 45 sec 
 Extension 70°C 1 min 
41 cycles Denaturation 94°C 30 sec 
 Annealing 55°C 45 sec 
 Extension 70°C 1 min 
1 cycle Extension 72°C 10 mins 
 
 
Table A1.8. PCR cycling conditions for program 6. 
Number of cycles Step Temperature Time 
1 cycle Taq Hot start 94°C 2 mins 
3 cycles Denaturation 94°C 30 sec 
 Annealing 62°C 45 sec 
 Extension 70°C 1 min 
41 cycles Denaturation 94°C 30 sec 
 Annealing 55°C 45 sec 
 Extension 70°C 1 min 
1 cycle Extension 72°C 10 mins 
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Appendix II: Data Pertaining to Chapter 4 
Table A2.1. Characteristics of high-risk NB ALT tumours (n=36). 
Sample 
ID 
G
en
d
er
 
MYCN 
Age 
Dx 
(Yr) 
Outcome 
(Yr) 
Telomere 
Content 
(Arbitrary 
Unit) 
Telomere 
Content 
Group 
C-circle 
Assay 
Product 
(Arbitrary 
Unit) 
C-circle 
Assay 
Classification 
TRF 
(kb) 
Telomerase 
Activity 
CHW 21 F NA 4.49 
DOD 
(2.96yr) 68.7 long 106 + ND - 
 
 
CHW 27 F NA 4.04 
DOD 
(2.1yr) 19.1 long 43.0 + ND + 
 
 
CHW 3 F NA 3.65 
DOD 
(2.62yr) 16.7 long 41.0 + 28.3 ND 
 
 
NB 157 M NA 4.24 
DOD 
(3.6yr) 72.1 long 134 + ND ND 
 
 
NB 31 F NA 2.78 
DOD 
(4.24yr) 60.5 long 1311 + ND ND 
 
 
NB 71 M NA 4.08 
DOD 
(1.32yr) 43.5 long 38.7 + ND ND 
 
 
NB 74 F NA 3.44 
OS 
(2.77yr) 27.9 long 666 + ND ND 
 
 
NB 8 F NA 5.41 
DOD 
(1.63yr) 20.2 long 249 + ND ND 
 
 
NB 92 F NA 4.49 
DOD 
(2.96yr) 75.7 long 54.7 + ND ND 
 
 
PAHSVL M NA 6.7 
DOD 
(7.62yr) 16.02 long 111 + 11.0 - 
 
 
PAIHWT F NA 4.2 
DOD 
(4.27yr) 28.27 long 129 + 11.1 + 
 
 
PAISZV M NA 5.1 
OS 
(5.35yr) 65.89 long 125 + 22.0 - 
 
 
PAIUTE M NA 5.5 
DOD 
(4.01yr) 75.32 long 14.8 + 22.0 + 
 
 
PAPKXS M NA 6.98 
OS 
 (5.4yr) 17.57 long 15.1 + 18.4 + 
 
 
PAPNHR M NA 3.6 
OS 
(5.08yr) 15.92 long 36.0 + 1.9 - 
 
 
PAPTAN F NA 4.0 
OS 
(5.61yr) 26.45 long 141 + 19.9 - 
 
 
PAPUWY 
 
 
M 
 
 
NA 
 
 
5.4 
 
 
DOD 
(2.98yr) 
 
 
23.85 
 
 
long 
 
 
16.0 
 
 
+ 
 
 
19.3 
 
 
+ 
 
 
PARACS F NA 3.2 
OS 
(3.61yr) 15.03 long 341 + ND ND 
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PARASL M NA 4.4 
DOD 
(0.53yr) 34.04 long 25.0 + 24.1 + 
 
 
 
PARBGT F NA 2.6 
DOD 
(2.74yr) 29.58 long 14.0 + ND ND 
 
 
PARKNP M NA 8.8 
DOD 
(1.75yr) 20.87 long 1149 + 20.2 - 
 
 
PARYM
N M NA 4.4 
DOD 
(2.95yr) 42.07 long 462 + ND ND 
 
 
PASAAN F NA 4.2 
OS 
(3.76yr) 16.39 long 348 + 24.8 + 
 
 
PASJRH F NA 7.04 
DOD 
(3.33yr) 21.82 long 26.3 + 23.1 + 
 
 
PASPIJ F NA 8.2 
OS 
(2.81yr) 18.86 long 11.2 + 29.2 - 
 
 
PASRTR F NA 4.4 
OS  
(2.6yr) 18.08 long 7.6 + ND ND 
 
 
PASVYG M NA 5.1 
OS  
(2.3yr) 23.94 long 45.8 + ND ND 
 
 
CHW 24 F NA 2.69 
DOD 
(5.03yr) 14.1 short 249 + ND + 
 
 
CHW 25 F NA 3.59 
OS 
(11.72yr) 12.7 short 111 + ND - 
 
 
PALRGK M NA 5.4 
DOD 
(2.52yr) 13.84 short 104 + 17.0 + 
 
 
PAMHM
K M NA 5.7 
DOD 
(3.18yr) 13.61 short 47.5 + 18.3 - 
 
 
PANLET M NA 5.4 
DOD 
(3.32yr) 8.07 short 29.5 + 9.0 + 
 
 
PANRVJ F NA 13.1 
OS 
(6.19yr) 5.30 short 41.7 + 9.8 - 
 
 
PANUIF M NA 6.1 
OS 
(6.22yr) 7.21 short 14.5 + ND ND 
 
 
PARVLK M NA 16.5 
DOD 
(2.36yr) 7.91 short 219 + 12.7 - 
 
 
PASWLY F NA 2.7 
OS 
(2.72yr) 12.17 short 166 + 14.6 + 
 
F = female    NA = Not Amplified   DOD = Died of Disease       
M = male  Yr = year OS = Overall survival        
 
A= Amplified 
 
 ND = not determined 
  
DX = Diagnosis  
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Table A2.2. Characteristics of high-risk MYCN amplified NB tumours (n=55). 
Sample 
ID G
en
d
er
 
MYCN  
Age 
Dx 
(yr) 
Outcome 
(yr) 
Telomere 
Content 
(Arbitrary 
Unit) 
Telomere 
Content 
Group 
C-circle 
Assay 
Product 
(Arbitrary 
Unit) 
C-circle 
Assay 
Classification 
TRF 
(kb) 
Telomerase 
Activity 
CHW 7 F A 1.71 
OS 
(7.33yr) 18.2 long 1.4 - ND ND 
 
 
NB 114 M A 1.73 
DOD 
(1.28yr) 18.1 long 0.0 - ND ND 
 
 
NB 195 M A 2.27 
DOD 
(1.28yr) 23.6 long 0.0 - ND ND 
 
 
NB 45 F A 3.75 
DOD 
(1.56yr) 20.4 long 0.0 - ND ND 
 
 
PAKPHB M A 0.4 
OS 
(4.25yr) 35.25 long 0.0 - ND ND 
 
 
PAPWFY F A 2.1 
DOD 
(2.75yr) 25.55 long 0.0 - ND ND 
 
 
PARYXW F A 6.0 
DOD 
(1.17yr) 43.20 long 1.5 - ND ND 
 
 
CHW 12 M A 1.78 
DOD 
(1.64yr) 10.8 short 0.0 - 14.9 ND 
 
 
CHW 13 M A 0.78 
DOD 
(0.44yr) 6.5 short 0.0 - 10.4 ND 
 
 
CHW 15 F A 1.96 
DOD 
(0.87yr) 4.7 short 0.0 - 8.6 ND 
 
 
CHW 16 F A 2.19 
OS 
(5.54yr) 7.3 short 0.1 - 11.4 ND 
 
 
CHW 2 F A 1.59 
OS 
(7.41yr) 9.1 short 1.3 - 11.9 ND 
 
 
CHW 20 F A 2.51 
OS 
(4.98yr) 11.1 short 0.0 - ND ND 
 
 
CHW 8 F A 1.32 
OS 
(5.62yr) 3.4 short 0.0 - 11.7 ND 
 
 
NB 149 F A 1.11 
OS 
(8.33yr) 2.5 short 0.6 - ND ND 
 
 
NB 166 F A 5.43 
DOD 
(1.09yr) 13.4 short 0.0 - ND ND 
 
 
NB 169 F A 0.44 
DOD 
(0.66yr) 13.2 short 0.0 - ND ND 
 
 
NB 171 M A 2.93 
DOD 
(0.61yr) 7.6 short 0.0 - ND ND 
 
 
NB 172 F A 2.39 
DOD 
(0.65yr) 3.4 short 0.0 - ND ND 
 
 
NB 23 
 
 
F 
 
 
A 
 
 
2.01 
 
OS 
(9.33yr) 
 
 
7.3 
 
 
short 
 
 
0.3 
 
 
- 
 
 
ND 
 
 
ND 
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NB 40 F A 0.64 
DOD 
(0.05yr) 2.9 short 1.6 - ND ND 
 
 
NB 43 F A 5.81 
DOD 
(0.86yr) 12.3 short 0.5 - ND ND 
 
 
NB 44 F A 1.55 
OS 
(6.76yr) 3.3 short 0.0 - ND ND 
 
 
NB 48 F A 0.73 
DOD 
(0.69yr) 9.7 short 0.0 - ND ND 
 
 
NB 51 M A 1.22 
DOD 
(0.95yr) 2.5 short 0.0 - ND ND 
 
 
NB 53 F A 1.51 
DOD 
(2.15yr) 3.0 short 0.3 - ND ND 
 
 
NB 56 M A 1.38 
DOD 
(1.26yr) 8.0 short 0.0 - ND ND 
 
 
NB 6 F A 1.41 
DOD 
(0.5yr) 14.0 short 0.0 - ND ND 
 
 
NB 98 M A 0.91 
DOD 
(0.63yr) 10.0 short 0.0 - ND ND 
 
 
PAKNYZ F A 1.7 
DOD 
(0.41yr) 4.44 short 0.0 - ND ND 
 
 
PAKPXS M A 3.0 
DOD 
(0.07yr) 2.53 short 0.12 - ND ND 
 
 
PALHHT F A 1.6 
OS 
(9.97yr) 2.09 short 0.27 - ND ND 
 
 
PALUVT F A 2.4 
DOD 
(3.18yr) 4.17 short 0.72 - ND ND 
 
 
PALZMB F A 0.8 
DOD 
(0.53yr) 2.29 short 0.18 - ND ND 
 
 
PAMRAA F A 0.4 
DOD 
(0.5yr) 5.04 short 0.0 - ND ND 
 
 
PANHRZ 1 A 4.1 
OS 
(6.86yr) 1.82 short 0.42 - ND ND 
 
 
PANLTR F A 1.2 
DOD 
(0.41yr) 9.62 short 1.5 - ND ND 
 
 
PAPRHX F A 10.1 
DOD 
(1.01yr) 5.30 short 0.82 - ND ND 
 
 
PAPRPR M A 1.7 
DOD 
(4.32yr) 2.31 short 0.19 - ND ND 
 
 
PAPRXW F A 2.4 
OS 
(5.62yr) 2.03 short 0.0 - ND ND 
 
 
PARELJ F A 0.3 
OS 
(4.3yr) 6.75 short 0.26 - ND ND 
 
 
 
PARETE 
 
 
 
F 
 
 
 
A 
 
 
 
1.9 
 
 
DOD 
(0.7yr) 
 
 
 
4.47 
 
 
 
short 
 
 
 
0.02 
 
 
 
- 
 
 
 
ND 
 
 
 
ND 
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F = female    NA = Not Amplified   DOD = Died of Disease       
M = male  Yr = year OS = Overall survival        
 
A= Amplified 
 
 ND = not determined 
  
DX = Diagnosis  
       
 
 
  
 
 
PARHDE F A 2.3 
DOD 
(1.3yr) 5.79 short 0.41 - ND ND 
 
 
PARSCY M A 1.4 
DOD 
(0.64yr) 9.62 short 1.1 - ND ND 
 
 
PARSUF F A 1.3 
DOD 
(1.02yr) 1.51 short 0.07 - ND ND 
 
 
PARVVM F A 0.9 
DOD 
(0.83yr) 4.89 short 0.0 - ND ND 
 
 
PARXBV M A 3.6 
DOD 
(1.32yr) 8.25 short 0.0 - ND ND 
 
 
PARYRE M A 3.2 
OS 
(4.11yr) 4.38 short 0.29 - ND ND 
 
 
PASBTL F A 1.3 
DOD 
(0.61yr) 3.80 short 0.42 - ND ND 
 
 
PASFKX F A 0.7 
OS 
(3.01yr) 2.10 short 0.23 - ND ND 
 
 
PASLXS M A 2.4 
DOD 
(0.33yr) 2.38 short 0.24 - ND ND 
 
 
PASTGD F A 2.5 
DOD 
(1.5yr) 4.12 short 0.43 - ND ND 
 
 
PASWFB M A 2.0 
DOD 
(0.2yr) 2.10 short 0.54 - ND ND 
 
 
PASYIP F A 2.3 
DOD 
(0.6yr) 3.07 short 0.86 - ND ND 
 
 
PASZPI F A 1.8 
OS 
(2.3yr) 9.61 short 0.32 - ND ND 
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Table A2.3. Characteristics of high-risk ALT-negative/long telomere NB tumours (n=17). 
Sample 
ID G
en
d
er
 
MYCN  
Age 
Dx 
(yr) 
Outcome 
(yr) 
Telomere 
Content 
(Arbitrary 
Unit) 
Telomere 
Content 
Group 
C-circle 
Assay 
Product 
(Arbitrary 
Unit) 
C-circle 
Assay 
Classification 
TRF 
(kb) 
Telomerase 
Activity 
CHW 11 F NA 3.81 
OS 
(14.54yr) 22.3 long 3.8 - 24.3 - 
 
 
CHW 9 F NA 4.67 
DOD 
(2.78yr) 21.1 long 2.3 - 36.3 - 
 
 
NB 128 F NA 4.45 
DOD 
(1.74yr) 27.3 long 0.0 - ND ND 
 
 
NB 19 F NA 3.29 
OS 
(11.98yr) 16.1 long 0.0 - ND ND 
 
 
NB 3 F NA 3.05 
DOD 
(1.27yr) 19.4 long 0.0 - ND ND 
 
 
NB 36 F NA 5.65 
OS 
(9.49yr) 15.2 long 0.0 - ND ND 
 
 
NB 4 F NA 3.83 
OS 
(10.63yr) 73.5 long 0.0 - ND ND 
 
 
NB 60 F NA 1.26 
OS 
(7.38yr) 18.3 long 0.5 - ND ND 
 
 
NB 70 F NA 2.43 
DOD 
(3.71yr) 36.8 long 0.0 - ND ND 
 
 
NB 95 M NA 5.30 
OS 
(12.5yr) 17.8 long 1.4 - ND ND 
 
 
PAIDDG F NA 9.4 
DOD 
(2.5yr) 31.64 long 5.7 - ND ND 
 
 
PAIFXV M NA 5.5 
DOD 
(3.04yr) 20.68 long 1.5 - 18.7 - 
 
 
PALPYT F NA 5.8 
OS 
(9.75yr) 50.67 long 0.0 - ND ND 
 
 
PAMFUX M NA 3.6 
DOD 
(4.52yr) 24.22 long 2.7 - ND ND 
 
 
PAMTPS F NA 11.2 
DOD 
(5.23yr) 18.08 long 4.0 - ND ND 
 
 
PARXFT F NA 5.1 
OS 
(2.05yr) 69.95 long 6.6 - 24.5 - 
 
 
PATHVK M NA 5.8 
OS 
(2.0yr) 52.55 long 0.0 - ND ND 
 
F = female    NA = Not Amplified   DOD = Died of Disease   
M = male  Yr = year OS = Overall survival     
 
A= Amplified 
 
 ND = not determined 
  
DX = Diagnosis 
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Table A2.4. Characteristics of high-risk MYCN non-amplified/short telomere NB tumours (n=41). 
Sample 
ID G
en
d
er
 
MYCN  
Age 
Dx 
(yr) 
Outcome 
(yr) 
Telomere 
Content 
(Arbitrary 
Unit) 
Telomere 
Content 
Group 
C-circle 
Assay 
Product 
(Arbitrary 
Unit) 
C-circle 
Assay 
Classification 
TRF 
(kb) 
Telomerase 
Activity 
 
 
CHW 22 M NA 2.00 
OS 
(15.93yr) 2.9 short 1.5 - ND + 
 
 
CHW 23 F NA 1.47 
OS 
(11.06yr) 2.5 short 0.2 - ND + 
 
 
CHW 26 F NA 1.25 
OS 
(9.7yr) 4.2 short 0.0 - ND + 
 
 
CHW 4 F NA 3.69 
DOD 
(2.47yr) 7.1 short 1.0 - 13.2 ND 
 
 
NB 112 M NA 1.99 
OS 
(5.48yr) 7.4 short 5.0 - ND ND 
 
 
NB 12 F NA 2.12 
OS 
(3.67yr) 9.4 short 0.5 - ND ND 
 
 
NB 140 F NA 3.46 
DOD 
(0.78yr) 6.6 short 1.4 - ND ND 
 
 
NB 17 M NA 3.59 
DOD 
(0.6yr) 5.7 short 1.4 - ND ND 
 
 
NB 174 F NA 3.44 
DOD 
(1.07yr) 13.8 short 0.8 - ND ND 
 
 
NB 198 F NA 4.18 
DOD 
(0.37yr) 2.7 short 0.0 - ND ND 
 
 
NB 216 F NA 1.97 
OS 
(4.65yr) 6.1 short 0.0 - ND ND 
 
 
NB 217 F NA 2.88 
DOD 
(0.97yr) 9.4 short 0.0 - ND ND 
 
 
NB 226 M NA 3.99 
DOD 
(3.2yr) 5.9 short 1.3 - ND ND 
 
 
NB 24 M NA 2.41 
DOD 
(1.68yr) 9.1 short 1.5 - ND ND 
 
 
NB 25 M NA 6.63 
DOD 
(0.67yr) 5.4 short 0.0 - ND ND 
 
 
NB 65 M NA 2.72 
DOD 
(5.71yr) 6.2 short 0.8 - ND ND 
 
 
NB 77 F NA 1.55 
DOD 
(2.42yr) 6.3 short 1.8 - ND ND 
 
 
NB 78 F NA 1.78 
OS 
(3.17yr) 4.6 short 0.0 - ND ND 
 
 
PAHVCS M NA 1.2 
OS 
(5.52yr) 7.17 short 1.1 - 8.5 + 
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PAHXUD 
 
 
M 
 
NA 
 
 
1.4 
DOD 
(3.24yr) 5.10 short 0.0 - 6.6 + 
 
 
PAILRI M NA 1.2 
OS 
(8.25yr) 3.70 short 0.0 - 9.5 + 
 
 
PALKNC M NA 1.0 
OS 
(1.77yr) 3.26 short 0.0 - 9.1 + 
 
 
PALSRF F NA 1.0 
OS 
(8.96yr) 3.44 short 0.0 - 10.2 - 
 
 
PAMHFI F NA 1.1 
OS 
(5.91yr) 6.20 short 0.0 - 8.7 - 
 
 
PAMPXA F NA 1.9 
OS 
(7.39yr) 3.64 short 0.20 - ND ND 
 
 
PAMRTG F NA 1.4 
OS 
(7.65yr) 8.86 short 1.5 - ND ND 
 
 
PAMYBA F NA 12.6 
DOD 
(1.48yr) 3.63 short 0.34 - ND ND 
 
 
PANHVF F NA 6.6 
DOD 
(3.56yr) 0.93 short 0.0 - 4.1 + 
 
 
PAPFSL M NA 6.0 
DOD 
(0.61yr) 2.87 short 0.0 - 9.4 + 
 
 
PAPMUT F NA 2.7 
OS 
(5.25yr) 5.30 short 1.1 - ND ND 
 
 
PAPRGH M NA 1.2 
OS 
(5.14yr) 4.60 short 0.0 - 6.5 - 
 
 
PAPZFW F NA 3.7 
OS 
(4.61yr) 2.13 short 0.80 - ND ND 
 
 
PARADX F NA 4.4 
DOD 
(0.5yr) 5.39 short 0.32 - ND ND 
 
 
PARGIW F NA 3.2 
OS 
(4.69yr) 2.37 short 0.56 - 9.1 + 
 
 
PARNNG F NA 3.7 
OS 
(4.65yr) 3.69 short 0.0 - ND ND 
 
 
PARRLH M NA 3.6 
DOD 
(1.48yr) 4.27 short 0.06 - ND ND 
 
 
PASHVB M NA 5.1 
OS 
(3.17yr) 7.28 short 0.0 - 12.1 + 
 
 
PASJNY M NA 3.4 
DOD 
(1.22yr) 5.41 short 0.0 - 7.9 + 
 
 
PASLUP M NA 4.5 
DOD 
(2.53yr) 2.28 short 0.01 - 5.5 + 
 
 
PASRII M NA 2.3 
DOD 
(1.8yr) 5.04 short 0.59 - ND ND 
 
 
PASUCB F NA 2.8 
OS 
(2.45yr) 2.98 short 0.0 - 13.8 - 
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F = female    NA = Not Amplified   DOD = Died of Disease   
M = male  Yr = year OS = Overall survival   
 
A= Amplified 
 
 ND = not determined 
  
DX = Diagnosis 
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Table A2.5. Genes examined by whole genome sequencing.  
Name Entrez ID Summary Synonym 
ABL1 25 
Protein tyrosine kinase involved in a 
variety of cellular processes, including 
cell division, DNA damage response, 
adhesion, differentiation, and response 
to stress, SWI/SNF complex JTK7, P150 
ACD 65057 Shelterin protein TINT1, TPP1 
ACTL6A  86 
Required for SMARCA4/BRG1/BAF190A 
containing remodelling complex BAF 
with chromatin/nuclear matrix. BAF53A, INO80K 
ACTL6B 51412 Role in remodelling mononucleosomes BAF53B 
AIM2 9447 
Recognises cytosolic dsDNA, putative 
role in tumorigenic reversion and may 
control cell proliferation. PYHIN4 
AKT1 207 
Regulates many processes including 
metabolism, proliferation, cell survival, 
growth and angiogenesis. 
 
ALKBH 8846 DNA repair gene 
 
ALKBH2 121642 DNA repair gene 
 
APEX1 328 
Role in the cellular response to 
oxidative stress. 
 
APITD1 378708 
Involved in DNA damage and repair 
(involved in Fanconi anaemia) 
 
APTX  54840 Editing and processing nucleases aprataxin 
ARID1A  8289 SWI/SNF complex SMARCF, C1orf4 
ARID1B 57492 Involved in chromatin remodelling 
 
ARID3A 1820 Transcription factor 
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ASF1A 25842 Histone chaperone HAsf1, HCIA, HSPC146 
ASF1B 55723 
Member of the H3/H4 family of histone 
chaperone proteins HAsf1b 
ASH1L 55870 Histone methyltransferase 
ASH1, KMT2H, 
KIAA1420 
ASH2L 9070 
Component of the Set1/Ash2 histone 
methyltransferase (HMT) complex ASH2L1, Bre2 
ASXL1 171023 
Transcription coactivator activity, 
chromatin modifier KIAA0978, MDS, BOPS 
ATM 472 DNA damage response ATA, ATDC, ATC, ATD 
ATP5C1 509 Subunit of mitochondrial ATP synthase. ATP5CL1, ATP5C 
ATR 545 Conserved DNA damage response gene MEC1, FRP1 
ATRIP 84126 Conserved DNA damage response gene AGS1 
ATRX 546 
Chromatin Modifier/epigenetic 
remodeller RAD54, JMS, MRX52 
BARD1 580 
DNA damage repair, ubiquitination and 
transcriptional regulation 
 
BAZ1A 11177 
Chromatin Modifier/epigenetic 
remodeller WCRF18, HACF10 
BAZ1B 9031 
Chromatin Modifier/epigenetic 
remodeller 
WSTF, WBSCR10, 
WBSCR9 
BCCIP 56647 DNA repair and cell cycle TOK1 
BCL2 596 Apoptosis Bcl-2, PPP1R50 
BLM 641 DNA helicase RECQL3, RECQ2 
BMI1 648 
Chromatin Modifier/epigenetic 
remodeller PCGF4, RNF51 
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BRCA1 672 
Role in maintaining genomic stability, 
and it also acts as a tumour suppressor. FANCS 
BRCA2 675 
Involved in double-strand break repair 
and/or homologous recombination. FANCD1 
BRD2 6046 
Chromatin Modifier, transcriptional 
regulator KIAA9001, RING3 
BRD4  23476 Chromatin/epigenetic remodeller HUNKI, MCAP 
BRINP1 1620 
Involved in cell cycle and cell death 
pathways 
DBC1, DBCCR1, 
FAM5A 
BRIP1   83990 DNA-dependent ATPase FANCJ 
BTAF1 9044 Regulates transcription MOT1 
CABIN1 23523 
Involved in replication-independent 
chromatin assembly. PPP3IN, KIAA0330 
CARM1  10498 Chromatin regulation PRMT4 
CBX1  10951 Component of heterochromatin. CBX, M31, HP1Hsbeta 
CBX2 84733 Involved in chromatin regulation CDCA6, SRXY5 
CBX3 11335 
Binds DNA and is a component of 
heterochromatin. 
 
CBX5  23468 Component of heterochromatin HP1A 
CCAR2  23468 
Protein is enriched in the 
heterochromatin and associated with 
centromeres. HEL25 
CCNH  902 Transcription P34, P37, CycH, CAK 
CCNO  10309 Cell cycle CCNU, UDG2, CILD29 
CCNT1  904 Transcription HIVE1, CCNT, CYCT1 
CDC25A  993 Cell cycle CDC25A2 
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CDC25B 994 Cell cycle CDC25HU2 
CDK2  1017 Cell cycle P33(CDK2) 
CDK7  1022 
Cell cycle, transcription initiating, DNA 
repair gene CAK, STK1 
CDKN1A  1026 Cell cycle, DNA repair gene 
CDKN1, P21, WAF1, 
MDA-6, CAP20 
CENPA  1058 Chromatin CENP-A 
CENPT  80152 Chromatin C16orf56, ICEN22 
CEP164  22897 
Involved in microtubule organization, 
DNA damage response, and 
chromosome segregation. 
Cep164, 
NPHP15, KIAA1052 
CHAF1A   10036 
Involved in DNA replication and DNA 
repair. CAF1 
CHD1  1105 
Chromatin Modifier/epigenetic 
remodeller CHD-1 
CHD2  1106 
Chromatin Modifier/epigenetic 
remodeller CHD-2, EEOC 
CHD3  1107 
NuRD (nucleosome remodelling and 
histone deacetylation) 
Mi2-ALPHA, ZFH, CHD-
3 
CHD4  1108 
NuRD (nucleosome remodelling and 
histone deacetylation) Mi2-BETA, CHD-4 
CHD7  55636 
Chromatin regulator, transcription 
regulator CRG, KAL5 
CHD8  57680 Chromatin remodeller HELSNF1, AUTS18 
CHEK1 1111 Conserved DNA damage response gene CHK1 
CHEK2  11200 Conserved DNA damage response gene RAD53, CHK2 
CHFR  55743 Cell Cycle RNF116, RNF196 
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CHTF18  63922 Cell replication 
C16orf41, RUVBL, 
CHL12 
CLK2  1196 Transcription 
 
CLOCK  9575 Transcription KAT13D, KIAA0334 
CLSPN  63967 Cell cycle, DNA damage 
 
CREBBP 1387 
Chromatin regulator, transcription 
factor RSTS, KAT3A 
CTBP1 1487 Transcription regulator BARS 
CTCF 10664 Chromatin regulator MRD21 
CTCFL 140690 DNA binding protein CT27, HMGB1L1 
CTDP1  9150 Involved in initiation of translation CCFDN, FCP1 
CTR9  9646 Chromatin regulation SH2BP1, TSBP, P150 
DAXX 1616 Chromatin remodeller DAP6, EAP1, BING2 
DBF4B 80174 Roll in DNA replication and proliferation 
ASKL1, DRF1, CHIFB, 
ZDBF1B 
DCLRE1A  9937 
Required for DNA inter-strand cross-link 
repair and cell cycle arrest 
SNM1, PSO2, HSNM1, 
HSNM1A, KIAA0086 
DCLRE1B  64858 
Involved in t-loop formation, telomere 
replication and DNA damage 
SNM1B, APOLLO, 
HSNM1B 
DCLRE1C 64421 Involved in DNA damage repair 
SCIDA, ARTEMIS, 
HSNM1C, DCLREC1C 
DDB1 1642 
Required for DNA repair 
DDBA, XPCE, XAP1, 
UV-DDB1 
DDB2 1643 Required for DNA repair DDBB, XPE, UV-DDB2 
DHX29 54505 
RNA helicase involved in translation 
initiation. DDX29 
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DHX36 170506 
Role in transcriptional regulation and 
mRNA stability. 
DDX36, MLEL1, G4R1, 
RHAU, KIAA1488 
DHX58 79132 Recognises ssRNA, dsRNA LGP2, RLR 
DDX60 55601 Binds ssRNA, dsRNA and dsDNA 
 
DHX9 1660 Functions as a transcriptional activator. DDX9, LKP, RHA, NDH2 
DKC1 1736 Component of telomerase 
DKC, NOLA4, CBF5, 
NAP57, Dyskerin 
DNMT1 1786 
Chromatin regulator, methylates CpG 
residues. 
DNMT, MCMT, AIM, 
ADCADN, HSN1E 
DNMT3A 1788 
DNA methyltransferase, NuRD 
associated TBRS 
DNMT3B  1789 
DNA methyltransferase, NuRD 
associated M.HsaIIIB, ICF1 
DNTT 1791 DNA polymerase TDT 
DR1 1810 Chromatin regulator NC2B 
E2F1 1869 Transcription activator RBBP3, RBAP1, E2F-1 
E2F2 1870 Transcription factor, cell cycle 
 
E2F3 1871 
Transcription factor, also involved in cell 
cycle and DNA repair KIAA0075 
E2F4 1874 
Transcription factor, also involved in cell 
cycle and DNA repair 
P107/P130-Binding 
Protein 
ECT2 1894 Involved in cell cycle ARHGEF31 
EGF 1950 Involved in cell growth and proliferation HOMG4, URG 
EHMT2 10919 
Methyltransferase that methylates 
lysine residues of histone H3. C6orf30, BAT8 
EID3 493861 
Involved in repair of DNA double-strand 
breaks by homologous recombination NSE4B 
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ELP3 55140 Chromatin remodelling/regulation HELP3, KAT9 
EME1 146956 
Homologous recombination, interacts 
with MUS81 to form a DNA structure-
specific endonuclease SLX2A, MMS4 
EME2 197342 
Homologous recombination, interacts 
with MUS81 to form a DNA structure-
specific endonuclease SLX2B, Gs125 
ENDOV 284131 Editing and processing RNAs 
 
EP300 2033 histone acetyltransferase, remodeller P300, RSTS2, KAT3B 
ERCC1 2067 Involved in DNA repair RAD10, UV20, COFS4 
ERCC2 2068 
Transcription factor also involved in 
DNA repair 
XPD, TTD1, COFS2, 
EM9 
ERCC3 2071 
DNA helicase and transcription factor 
also involved in DNA repair 
RAD25, GTF2H, BTF2, 
TTD2, XPB 
ERCC4 2072 Involved in DNA repair 
XPF, RAD1, FANCQ, 
XFEPS, XPF, ERCC11 
ERCC5 2073 
Involved in DNA repair 
ERCM2, XPGC, COFS3, 
UVDR, XPG 
ERCC6 2074 
Involved in DNA repair 
CKN2, RAD26, ARMD5, 
UVSS1, COFS 
ERCC8 1161 Involved in DNA repair CKN1, UVSS2 
ERI1 90459 
RNA exonuclease, involved in histone 
RNA degradation THEX1, HEXO 
EWSR1 2130 Transcription factor- repressor 
 
EXO1  9156 DNA exonuclease HEX1, EXOI 
EZH2 2146 
Chromatin remodeller and transcription 
repressor 
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FAAP20  199990 Involved in DNA damage repair C1orf86, FP7162 
FAAP24  91442 Involved in DNA damage repair C19orf40 
FAAP100   80233 
Involved in Fanconi anaemia DNA 
damage response C17orf70 
FAN1  22909 Editing and processing nucleases MTMR15 
FANCA 2175 Involved in DNA repair FACA, FANCH 
FANCB 2187 Involved in DNA repair 
 
FANCC 2176 Involved in DNA repair FACC 
FANCD2 2177 Involved in DNA repair FACD, FANCD 
FANCE 2178 Involved in DNA repair FACE 
FANCF 2188 Involved in DNA repair 
 
FANCG  2189 Involved in DNA repair XRCC9 
FANCI  55215 Involved in DNA repair KIAA1794 
FANCL 55120 Involved in DNA repair PHF9, POG 
FANCM 57697 Involved in DNA repair KIAA1596, FAAP250 
FBL 2091 
Methyltransferase that has the ability to 
methylate both RNAs and proteins. RNU3IP1 
FBXO18 84893 Involved in homologous recombination HFBH1 
FEN1  2237 Involved in DNA repair DNase IV, RAD2 
Foxp1 27086 NuRD associated, transcription 
HSPC215, 
QRF1, 12CC4, HFKH1B 
Foxp2 93986 NuRD associated, transcription 
TNRC10, 
SPCH1, CAGH44 
Foxp4 116113 
NuRD associated, transcriptional 
repressor HFKHLA, FKHLA 
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FSBP 100861412 Transcriptional repressor 
 
FUS 2521 Chromatin regulator 
ALS6, ETM4, FUS1, 
POMP75, TLS 
GAR1 54433 Involved in telomerase NOLA1 
GEN1 48654 
Homologous recombination, 
Endonuclease which resolves Holliday 
junctions 
 
GET4 51608 Post translational trafficking C7orf20 
GMNN  51053 Involved in cell cycle regulation MGORS6 
GNL3  26354 Involved in cell proliferation 
E2IG3, NNP47, NS, 
C77032 
GTF2B  2959 Transcription factor S300-II, TFIIB, TF2B 
GTF2F1 2962 
Transcription initiation factor that binds 
to RNA polymerase II 
RAP74, TF2F1, TFIIF, 
BTF4 
GTF2H1 2965 Transcription factor BTF2, TFIIH, TFB1, P62 
GTF2H2 2966 Transcription factor 
T-BTF2P44, TFIIH, 
BTF2, P44 
GTF2H3  2967 Transcription factor TFB4, TFIIH, BTF2, P34 
GTF2H4 2968 Transcription factor TFB2, TFIIH, P52 
H2AFX  3014 Chromatin Structure H2AX 
H2AFY 9555 Chromatin Structure H2AF12M, MH2A1 
H2AFZ 3015 Chromatin Structure H2AZ 
HAT1 8520 Involved in nucleosome assembly KAT1 
HDAC1 3065 
Responsible for the deacetylation of 
lysine residues on the N-terminal part 
of the core histones RPD3L1, GON-10, HD1 
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HDAC10 83933 
Responsible for the deacetylation of 
lysine residues on the N-terminal part 
of the core histones 
 
HDAC2 3066 
Responsible for the deacetylation of 
lysine residues on the N-terminal part 
of the core histones 
YAF1, HD2, RPD3, YY1-
Associated Factor 1 
HDAC3 8841 
Responsible for the deacetylation of 
lysine residues on the N-terminal part 
of the core histones 
 
HDAC4 9759 
Responsible for the deacetylation of 
lysine residues on the N-terminal part 
of the core histones 
 
HDAC5 10014 
Responsible for the deacetylation of 
lysine residues on the N-terminal part 
of the core histones 
HD5, KIAA0600, NY-
CO-9 
HDAC6 10013 
Responsible for the deacetylation of 
lysine residues on the N-terminal part 
of the core histones 
 
HDAC7 51564 
Responsible for the deacetylation of 
lysine residues on the N-terminal part 
of the core histones 
 
HELLS 3070 Chromatin regulation LSH, ICF4 
HELQ  113510 
DNA-dependent ATPase and 5 to 3 DNA 
helicase. HEL308 
HELZ 9931 
Helicase that plays a role in RNA 
metabolism 
KIAA0054, 
DHRC, HUMORF5 
HES1 3280 Transcriptional repressor HRY, HL, HES-1 
218 
 
HEXIM1 10614 
Transcriptional regulator which 
functions as a general RNA polymerase 
II transcription inhibitor. HIS1, EDG1, CLP1 
HIC1 3090 Transcriptional repressor ZNF901, ZBTB29 
HIRA  7290 
Chromatin Modifier/epigenetic 
remodeller TUPLE1, DGCR1, HIR 
HIST1H1A 3024 Replication Dependent Histone H1F1, H1.1, H1a 
HIST1H1B 3009 
Replication Dependent Histone H1F5, H1.5, H1b, H1s-
3 
HIST1H1C 3006 Replication Dependent Histone H1F2, H1.2, H1s-1, H1c 
HIST1H1D 3007 
Replication Dependent Histone H1F3, H1.3, H1d, H1s-
2 
HIST1H1E 3008 
Replication Dependent Histone H1F4, H1.4, H1e, H1s-
4 
HIST1H1PS1 387325 Replication Dependent Histone DJ34B20.16, H1F6P 
HIST1H1PS2 10338 Replication Dependent Histone H3FEP, PH3/e 
HIST1H1T 3010 Replication Dependent Histone H1FT, H1t 
HIST1H2AA 221613 
Replication Dependent Histone BA317E16.2, H2AFR, 
H2AA, TH2A 
HIST1H2AB  8335 Replication Dependent Histone H2AFM, H2A/m 
HIST1H2AC  8334 Replication Dependent Histone H2AFL 
HIST1H2AD 3013 Replication Dependent Histone H2AFG, H2A/g, H2A.3 
HIST1H2AE 3012 Replication Dependent Histone H2AFA, H2A/a, H2A.1 
HIST1H2AG 8969 
Replication Dependent Histone H2AFP, pH2A/f, 
H2A/p, H2A.1b 
HIST1H2AH 85235 
Replication Dependent Histone H2AFALii, dJ86C11.1, 
H2A/S 
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HIST1H2AI  8329 Replication Dependent Histone H2AFC, H2A/c 
HIST1H2AJ 8331 Replication Dependent Histone H2AFE, H2A/E 
HIST1H2AK 8330 Replication Dependent Histone H2AFD, H2A/d 
HIST1H2AL 8332 
Replication Dependent Histone H2AFI, H2A/I, 
dJ193B12.9 
HIST1H2AM 8336 Replication Dependent Histone H2AFN, H2A/n, H2A.1 
HIST1H2BA 255626 
Replication Dependent Histone bA317E16.3, STBP, 
TSH2B, H2BFU 
HIST1H2BB 3018 Replication Dependent Histone H2BFF, H2B/f 
HIST1H2BC  8347 Replication Dependent Histone H2BFL, H2B/l, H2B.1 
HIST1H2BD 8347 Replication Dependent Histone H2BFB, H2B/b 
HIST1H2BE 8344 Replication Dependent Histone H2BFH, H2B/h, H2B.h 
HIST1H2BF 8343 Replication Dependent Histone H2BFG, H2B/g 
HIST1H2BG 8339 Replication Dependent Histone H2BFA, H2B/a, H2B.1A 
HIST1H2BH 8345 Replication Dependent Histone H2BFJ, H2B/j 
HIST1H2BI 8346 Replication Dependent Histone H2BFK, H2B/k 
HIST1H2BJ 8970 Replication Dependent Histone H2BFR, H2B/r 
HIST1H2BK 85236 Replication Dependent Histone H2BFT, H2BFAiii 
HIST1H2BL 8340 
Replication Dependent Histone H2BFC, H2B/c, 
dJ97D16.4 
HIST1H2BM 8342 
Replication Dependent Histone H2BFE, H2B/e, 
dJ160A22.3 
HIST1H2BN 8341 Replication Dependent Histone H2BFD, H2B/d 
HIST1H2BO 8348 Replication Dependent Histone H2BFN, H2B/n, H2B.2 
HIST1H3A 8350 Replication Dependent Histone H3FA, H3/A 
220 
 
HIST1H3B 8358 Replication Dependent Histone H3FL, H3/l 
HIST1H3C 8352 Replication Dependent Histone H3FC, H3/c, H3.1 
HIST1H3D 8351 Replication Dependent Histone H3FB, H3/b, 
HIST1H3E 8353 Replication Dependent Histone H3FD, H3/d, H3.1 
HIST1H3F 8968 Replication Dependent Histone H3FI, H3/i 
HIST1H3G 8355 Replication Dependent Histone H3FH, H3/h 
HIST1H3H 8357 Replication Dependent Histone H3FK, H3/k, H3F1K 
HIST1H3I 8354 Replication Dependent Histone H3FF, H3/f, H3.f 
HIST1H3J 8356 Replication Dependent Histone H3FJ, H3/j 
HIST1H4A 8359 Replication Dependent Histone H4FA 
HIST1H4B 8366 Replication Dependent Histone H4FI, H4/I 
HIST1H4C 8364 
Replication Dependent Histone H4FG, H4/g, 
dJ221C16.1 
HIST1H4D 8360 Replication Dependent Histone H4FB, H4/b 
HIST1H4E 8367 Replication Dependent Histone H4FJ, H4/j 
HIST1H4F 8361 Replication Dependent Histone H4FC, H4/c, H4 
HIST1H4G 8369 Replication Dependent Histone H4FL, H4/l 
HIST1H4H 8365 Replication Dependent Histone H4FH, H4/h 
HIST1H4I 8294 Replication Dependent Histone H4FM, H4/m 
HIST1H4J 8363 Replication Dependent Histone H4FE, H4/e, H4F2iv 
HIST1H4K 8362 
Replication Dependent Histone H4FD, H4/d, H4F2iii, 
dJ160A22.1 
HIST1H4L 8368 Replication Dependent Histone H4FK, H4.k, H4/k 
HIST2H2AA3 8337 
Replication Dependent Histone H2AFO, HIST2H2AA, 
H2A.2, H2A/q 
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HIST2H2AA4 723790 
Replication Dependent Histone H2A/r, H2BFQ, H2B/q, 
H2B.1 
HIST2H2AB 317772 Replication Dependent Histone H2AB 
HIST2H2AC 8338 Replication Dependent Histone H2A, H2AFQ, H2A/q 
HIST2H2BA 337875 Replication Dependent Histone 
 
HIST2H2BB 338391 Replication Dependent Histone 
 
HIST2H2BC 337873 Replication Dependent Histone H2B/t, HIST2H2BD 
HIST2H2BD 337874 Replication Dependent Histone H2BFO, H2B/s, H2B/o 
HIST2H2BE 8349 
Replication Dependent Histone H2B, H2BQ, H2BFQ, 
H2BGL105 
HIST2H2BF 440689 Replication Dependent Histone 
 
HIST2H3A 333932 Replication Dependent Histone H3/N, H3/O 
HIST2H3C 126961 Replication Dependent Histone H3/M, H3, H3.2 
HIST2H3D 653604 Replication Dependent Histone 
 
HIST2H4A  8370 
Replication Dependent Histone H4F2, H4FN, HIST2H4, 
H4/n 
HIST2H4B 554313 Replication Dependent Histone H4/o 
HIST3H2A 92815 Replication Dependent Histone MGC3165 
HIST3H2BA 337872 Replication Dependent Histone 
 
HIST3H2BB 128312 Replication Dependent Histone 
 
HIST3H3  8290 Replication Dependent Histone H3FT, H3t, H3/g, H3.4 
HIST4H4  121504 Replication Dependent Histone MGC24116 
HLTF  6596 
SWI/SNF family, helicase and ubiquitin 
ligase functions SMARCA3 
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HMGA1 3159 Transcription 
HMGIY, HMGA1A, 
HMG-R 
HMGA2 8091 Transcription 
HMGIC, LIPO, BABL, 
STQTL9 
HMGB1 3146 
Involved in transcription and chromatin 
remodelling HMG1, SBP-1, HMG1 
HMGB2 3148 
Involved in transcription and chromatin 
remodelling HMG2 
HMGN1 3150 
Involved in transcription and chromatin 
remodelling HMG14 
HMGN2 3151 
Involved in transcription and chromatin 
remodelling HMG17 
HNRNPA0 10949 RNA processing HNRPA0 
HNRNPA1 3178 RNA processing 
HNRPA1, IBMPFD3, 
ALS19, ALS20, UP 1 
HNRNPA2B1 3181 RNA processing 
HNRPA2B1, IBMPFD2, 
HNRPA2, HNRPB1, 
RNPA2 
HNRNPD 3184 
Involved in RNA processing and DNA 
replication 
AUF1, HNRPD, P37, 
HnRNPD0, HNRPD 
HSP90AA1 3320 
Involved in cell cycle and signal 
transduction 
HSPC1, HSPCA, LAP2, 
EL52, Hsp90 
HSPA1L 3305 Protein stabilization HSP70T 
HUS1 3364 Role in DNA repair 
 
IDH1 3417 
Chromatin regulation 
IDPC, IDCD, HEL-216, 
PICD 
IDH2 3418 
Chromatin regulation 
IDPM, IDHM, D2HGA2, 
IDH 
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IFIH1 64135 RNA helicase 
MDA5, IDDM19, 
IDDM19, RH116, AGS7 
IGF1 3479 Growth factor and replication IGFI, IBP1, IGF-I, MGF 
IKBKAP 8518 
Involved in transcription and chromatin 
remodelling 
DYS, ELP1, IKAP, P150, 
IKI3, DYS, FD 
INO80 54617 
DNA helicase and transcription factor 
also involved in DNA repair INOC1, KIAA1259 
INO80C 125476 
Involved in transcriptional regulation, 
DNA replication and DNA repair. C18orf37 
INO80E 283899 
Involved in transcriptional regulation, 
DNA replication and DNA repair. CCDC95 
ISG20 3669 
Exoribonuclease that acts on single-
stranded RNA CD25, HEM45 
KAT2A 2648 
Histone acetyltransferase that 
promotes transcriptional activation. GCN5L2, STAF97 
KAT2B 8850 
Histone acetyltransferase that 
promotes transcriptional activation. 
PCAF, CAF, Lysine 
Acetyltransferase 2B 
KAT5 10524 Transcriptional activation 
HTATIP, TIP60, 
HTATIP, ESA1, PLIP, 
ZC2HC5 
KDM1A  23028 Histone demethylase, NuRD associated 
lysine (K)-specific 
demethylase 
1A (LSD1) 
KDM3B 51780 Demethylates Lys-9 of histone H3 
C5orf7, JMJD1B, 
KIAA1082, NET22 
KDM4A 9682 
Demethylates Lys-9 and Lys-36 residues 
of histone H3 
JMJD2A, JHDM3A, 
KIAA0677, TDRD14A 
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KDM4B 23030 Demethylates Lys-9 of histone H3 
JMJD2B, KIAA0876, 
TDRD14B, JHDM3B 
KDM4C 23081 
Demethylates Lys-9 and Lys-36 residues 
of histone H3 
JMJD2C, TDRD14C, 
KIAA0780, GASC1, 
JHDM3C 
KDM5A 5927 
Demethylates Lys-4 of histone H3 
RBBP2, JARID1A, 
RBBP2 
KDM5B 10765 
Demethylates Lys-4 of histone H3 
JARID1B, RBP2-H1, 
PLU-1, CT31, PUT1, 
RBBP2H1A, PPP1R98 
KDM5C 8242 Demethylates Lys-4 of histone H3 
SMCX, JARID1C, 
MRX13, MRXJ, 
MRXSCJ, XE169, 
DXS1272E 
KDM6B 23135 
Histone demethylase, demethylates 
Lys-27 of histone H3 
 
KMT2B 
9757 
Methylates Lys-4 of histone H3 
MLL4, MLL1B, CXXC10, 
KIAA0304, TRX2, 
WBP7 
KMT2D 8085 Methylates Lys-4 of histone H3 
(H3K4me). 
MLL2, TNRC21, 
AAD10, KABUK1, 
CAGL114, ALR 
KMT2E 
55904 
Mono- and di-methylates Lys-4 of 
histone H3 (H3K4me1 and H3K4me2) 
MLL5, NKp44L, 
HDCMC04P 
KMT5A 387893 
Monomethylates both histones and 
non-histone proteins, involved in 
mitosis 
SETD8, H4-K20-
Specific Histone 
Methyltransferase 
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KMT5B 51111 Trimethylates Lys-20 of histone H4. 
SUV420H1, Lysine-
Specific 
Methyltransferase 5B 
KTM5C 84787 Histone methyltransferase 
SUV420H2, Lysine (K)-
Specific 
Methyltransferase 5C 
KRAS 3845 Cell proliferation 
 
KRIT1 889 Cell proliferation CCM1, CaM 
LIG1 3978 DNA repair 
 
LIG3 3980 DNA repair LIG2 
LIG4 3981 DNA repair LIG4S 
MAD2L2  10459 Cell cycle and DNA repair REV7, POLZ2, MAD2B 
MAVS 57506 Detect intracellular dsRNA 
VISA, IPS1, KIAA1271, 
CARDIF 
MBD1 4152 
Transcriptional corepressor and 
coactivator, Chromatin 
Modifier/epigenetic remodeller 
 
MBD2  8932 
Transcriptional corepressor and 
coactivator, NuRD complex 
DMTase, NY-CO-41, 
demethylase 
MBD3 53615 
Transcriptional corepressor and 
coactivator, NuRD complex 
 
MBD4 8930 
Transcriptional corepressor and 
coactivator 
 
MCM2 4171 DNA replication 
CCNL1, CDCL1, 
MITOTIN, D3S3194, 
KIAA0030 
MCM3 4172 DNA replication 
RLFB, HCC5, P1-
MCM3, P102 
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MCM4 4173 Initiation of DNA replication CDC21 
MCM5 4174 Cell cycle CDC46 
MCM6 4175 Initiation of DNA replication 
 
MCM7 4176 DNA replication 
MCM2, CDC47, 
P1CDC47, PPP1R104, 
PNAS146, P85MCM 
MCPH1 79648 DNA damage response BRIT1, MCT 
MCRS1 10445 Transcription regulator 
MSP58, P78, ICP22BP, 
INO80Q 
MDC1 9656 Cell cycle and DNA damage response NFBD1, KIAA0170 
MECP2 4204 Mediates transcriptional expression 
RTT, MRX16, MRX79, 
AUTSX3, RTS, MRXSL 
MED12 9968 Transcription 
TNRC11, FGS1, 
ARC240, CAGH45, 
HOPA, MED12S 
MEN1 4221 Transcriptional regulator SCG2, Menin 
MGMT 4255 
Protein catalyses transfer of methyl 
groups from O(6)-alkylguanine and 
other methylated moieties of the DNA 
to its own molecule, which repairs the 
toxic lesions. 
O6-Methylguanine-
DNA 
Methyltransferase 
MKI67 4288 Cell proliferation MIB-1, KIA, PPP1R105 
MLH1 4292 
DNA repair 
FCC2, HMLH1, HNPCC, 
COCA2 
MLLT1 4298 Transcription regulator 
YEATS1, LTG19, ENL, 
CTC-503J8.6 
MNAT1 4331 Transcription regulator 
CAP35, RNF66, MAT1, 
P36, TFB3 
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MPG 4350 DNA repair 
ADPG, AAG, MDG, 
APNG, PIG16, PIG11, 
CRA36.1 
MPLKIP 136647 Cell cycle TTDN1, C7orf11 
MRE11A  4361 
Component of the MRN complex, role 
in double-strand break repair, DNA 
recombination, maintenance of 
telomere integrity and meiosis. MRE11 
MSH2 4436 
Post-replicative DNA mismatch repair 
system 
 
MSH3 4437 DNA repair 
MRP1, DUP, DUC1, 
DUG 
MSH4 4438 Involved in meiotic recombination. 
 
MSH5 4439 Involved in meiotic recombination. MUTSH5, NG23, G7 
MSH6 2956 DNA repair 
GTBP, HNPCC5, 
HMSH6, HSAP, P160, 
GTMBP 
MTA1 9112 
Transcriptional corepressor and 
coactivator, NuRD complex 
p70, MTA1L1, PID, 
KIAA1264 
MTA2 9219 
Transcriptional corepressor and 
coactivator, NuRD complex 
p70, MTA1L1, PID, 
KIAA1265 
MTA3 57504 
Transcriptional corepressor and 
coactivator, NuRD complex 
p70, MTA1L1, PID, 
KIAA1266 
MTF2 22823 Transcriptional activator 
M96, TDRD19A, 
DJ976O13.2, PCL2 
MUS81 80198 
DNA repair and homologous 
recombination SLX3 
MUTYH 4595 DNA repair HMYH 
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MYC 4609 Transcription factor 
C-Myc, MYCC, MRTL, 
BHLHe39 
NAA10 8260 
Catalytic subunit of the N-terminal 
acetyltransferase A (NatA) complex 
ARD1, ARD1A, TE2, 
NATD, OGDNS, 
DXS707, MCOPS1 
NABP1 64859 DNA repair and cell cycle 
SSB2, OBFC2A, SOSS-
B2 
NABP2 79035 DNA repair and cell cycle 
SSB1, OBFC2B, 
LP3587, SOSS-B1 
NBS1 4683 
Component of MRN complex, DNA 
repair NBS, NBN, ATV, P95 
NCAPG 64151 Involved in meiosis 
YCG1, CHCG, HCAP-G, 
NYMEL3, NY-MEL-3, 
CAPG 
NCL 4691 
Chromatin decondensation by binding 
H1 
 
NCOA1 8648 Involved in transcription 
F-SRC-1, BHLHe42, 
KAT13A, NCoA-1, SRC-
1, RIP160 
NCOA3 8202 Chromatin Modifier 
 
NCOR1 9611 Chromatin Modifier 
 
NCOR2 9612 
transcriptional regulator, promoting 
chromatin condensation 
 
Ndc80 10403 Involved in cell cycle 
KNTC2, HEC, KNTC2, 
TID3 
NELFCD 51497 Transcription TH1L, HSPC130, NELFD 
NFRKB 4798 
Involved in transcriptional regulation 
and DNA repair INO80G 
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NHEJ1 79840 DNA repair XLF, XRCC4-Like Factor 
NHP2 55651 Involved in trafficking hTR NOLA2, DKCB2, NHP2P 
NOP10 55505 Involved in trafficking hTR NOLA3, DKCB1 
NSMCE2 286053 
Component of the SMC5-SMC6 
complex, a complex involved in DNA 
double-strand break repair by 
homologous recombination. C8orf36 
NSMCE3 56160 DNA repair 
NDNL2, MAGEG1, 
HCA4, NSE3 
NSMCE4A 54780 DNA repair C10orf86, NSE4A 
NTHL1 4913 DNA repair NTH1, FAP3, OCTS3 
NUTM1 256646 Chromatin regulation 
C15orf55, FAM22H, 
NUT 
OBFC1 79991 DNA replication RPA-32, STN1, AAF44 
OGG1 4968 DNA repair genes 
MMH, HOGG1, OGH1, 
MUTM 
ORC1 4998 DNA replication 
ORC1L, PARC1, 
HSORC1 
ORC2 4999 DNA replication ORC2L 
ORC3 23595 DNA replication ORC3L, LATHEO, LAT 
ORC4 5000 DNA replication ORC4L 
ORC5 5001 DNA replication 
ORC5L, ORC5P, 
ORC5T, PPP1R117 
ORC6 23594 DNA replication ORC6L 
PABPC1 26986 RNA processing 
PAB1, PABPC2, 
PABPL1 
PAF1 54623 Transcription PD2 
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PALB2  79728 DNA repair FANCN, PNCA3 
PAPOLG 64895 
Editing and processing nucleases, 3' 
mRNA polyadenylation PAP2, PAPG 
PARP1  142 DNA damage response 
ADPRT1, PARP, PPOL, 
ARTD1 
PARP2 10038 DNA damage response 
ADPRTL2, ADPRTL3, 
ARTD2, PARP-2, 
PADPRT-2 
PARP4 143 DNA damage response 
ADPRTL1, KIAA0177, 
VAULT3, VWA5C, 
P193, PH5P, PARP-4 
PAX8 7849 Transcription factor 
 
PAXIP1 22976 
Involved in DNA damage response and 
transcriptional regulation 
PAXIP1L, TNRC2, 
PACIP1, CAGF29, 
CAGF28, PAXIP1L 
PCNA 5111 DNA polymerase 
 
PER1 5187 Transcriptional repressor PER, KIAA0482, RIGUI 
PES1 23481 
Involved in cell proliferation and RNA 
processing PES 
PGBD3 267004 Transcription 
 
PHF1 5252 Transcriptional repressor 
HPCl1, PCL1, 
TDRD19C, MTF2L2 
PHF2 5253 Lysine demethylase KIAA0662, JHDM1E 
PHF20 51230 Transcriptional regulator 
C20orf104, GLEA2, 
HCA58, NZF, TZP 
PHF20L1 51105 Involved in chromatin regulation 
URLC1, CGI-72, 
TDRD20B 
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PIF1 80119 DNA helicase C15orf20, PIF 
PINX1 54984 
Involved in chromosome segregation 
and TRF1 and TERT accumulation in 
nucleus 
LPTL, LPTL, 
PIN2/TERF1 
Interacting, 
Telomerase Inhibitor 1 
PKMYT1 9088 Cell cycle PPP1R126, MyT1 
PLK1 5347 Cell cycle PLK, STPK13, EC 2.7.11 
PML 5371 
Involved in tumour suppression, 
transcriptional regulation, apoptosis, 
senescence, DNA damage response, and 
viral defence mechanisms. 
PP8675, TRIM19, 
RNF71, MYL 
PMS1 5378 DNA repair 
PMSL1, HNPCC3, 
HPMS1, MLH2 
PMS2 5395 DNA repair 
PMSL2, HNPCC4, 
PMS2CL, MLH4 
POLA1 5422 DNA polymerase POLA, NSX, P180 
POLA2 23649 DNA replication 
 
POLB 5423 DNA polymerase 
 
POLD1 5424 DNA polymerase 
POLD, CDC2, CRCS10, 
MDPL 
POLD2 5425 Subunit of DNA polymerase 
 
POLD3 10714 Subunit of DNA polymerase 
p66, p68, KIAA0039, 
PPP1R128 
POLD4 57804 Subunit of DNA polymerase P12, POLDS 
POLE 5426 Subunit of DNA polymerase POLE1, FILS, CRCS12 
POLE2 5427 Subunit of DNA polymerase DPE2 
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POLE3 54107 
Role in allowing polymerase epsilon to 
carry out its replication and/or repair 
function- chromatin remodelling P17, YBL1, CHARAC17 
POLE4 56655 
Role in allowing polymerase epsilon to 
carry out its replication and/or repair 
function- chromatin remodelling P12, YHHQ1 
POLG 5428 Mitochondrial DNA polymerase 
POLG1, POLGA, MDP1, 
SANDO, MIRAS, SCAE, 
PEO 
POLH 5429 DNA polymerase RAD30A, XPV 
POLI  11201 DNA polymerase RAD30B, RAD3OB 
POLK  51426 DNA polymerase 
DINB1, POLQ, DINB1, 
DINP 
POLL 27343 DNA polymerase BETAN, POLKAPPA 
POLM 27434 
DNA polymerase, involved in repair of 
DNA double-strand breaks by non-
homologous end joining 
 
POLN  353497 DNA polymerase POL4P 
POLQ 10721 
DNA polymerase that promotes 
microhomology-mediated end-joining 
 
POLR2A 5430 RNA polymerase II 
 
POLR2B 5431 
RNA polymerase subunit 
POL2RB, HRPB140, 
RPB2 
POLR2C 5432 RNA polymerase subunit RPB3, HRPB33 
POLR2D 5433 RNA polymerase subunit HSRBP4, RPB16, RBP4 
POLR2F 5435 RNA polymerase subunit 
POLRF, RPABC2, RPB6, 
RPC15 
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POLR2G 5436 RNA polymerase subunit 
RPB19, RPB7, HRPB19, 
HsRPB7 
POLR2H 5437 RNA polymerase subunit RPB17, RPABC3 
POLR2I 5438 RNA polymerase subunit RPB9, RPB14.5 
POLR2J 5439 RNA polymerase subunit 
RPB11, HRPB14, 
POLR2J1 
POLR2K 5440 Subunit of RNA polymerase II RPB12, RPABC4 
POLR2L 5441 RNA polymerase subunit RPB10, RPABC5 
POLR3A 11128 
Catalytic component of RNA 
polymerase III 
RPC1, HLD7, RPC155, 
ADDH 
POT1 25913 Shelterin complex GLM9, CMM10 
PPARG 5468 Transcription factor NR1C3, GLM1, CIMT1 
PPP1CA 5499 Involved in cell division PPP1A 
PPP1CB  5500 Involved in cell division PP1B 
PPP1CC 5501 Involved in cell division PP1C 
PPP1R10  5514 
Involved in cell cycle progression, DNA 
repair and apoptosis 
CAT53, PP1R10, 
PNUTS, FB19, P99 
PPP2R1A 5518 
Involved in the negative control of cell 
growth and division. MRD36, PR65A 
PPP2R1B 5519 
Involved in the negative control of cell 
growth and division. PR65B 
PPP2R2A 5520 Cell division and growth 
 
PRDM16 63976 
Transcriptional regulator 
PFM13, MEL1, 
KIAA1675, CMD1LL, 
LVNC8 
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PRDM2  7799 
Histone methyltransferase that 
specifically methylates Lys-9 of histone 
H3 
 
PRIM1 5557 
Polymerase that synthesizes small RNA 
primers for the Okazaki fragments 
made during discontinuous DNA 
replication. 
P49, DNA Primase 
Subunit 48 
PRIM2 5558 
Polymerase that synthesizes small RNA 
primers for the Okazaki fragments 
made during discontinuous DNA 
replication. PRIM2A, P58 
PRKCA  5578 
Involved in cell cycle checkpoint and 
transcription regulation PKCA, AAG6 
PRKCB 5579 
Involved in cell cycle checkpoint and 
transcription regulation 
PRKCB2, PKCB, 
PRKCB1 
PRKDC 5591 
DNA-dependent protein kinase involved 
in DNA repair 
HYRC, HYRC1, XRCC7, 
DNAPK 
PRMT1 3276 Arginine methyltransferase 
HRMT1L2, IR1B4, 
ANM1, HCP1 
PRMT2 3275 Methylates H4 HRMT1L1 
PRMT3 10196 
Methylates (mono and asymmetric 
dimethylation) the guanidino nitrogens 
of arginyl residues in some proteins. HRMT1L3 
PRMT5 10419 Chromatin regulator SKB1, HRMT1L5 
PRMT6 55170 Methyltransferase activity HRMT1L6 
PRPF19  27339 
Involved in pre-mRNA splicing and DNA 
repair. 
PSO4, PRP19, 
NMP200, UBOX4 
PSIP1 11168 Transcriptional coactivator 
PSIP2, DFS70, LEDGF, 
P75, P52 
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PTGES3 10728 Involved in transcriptional regulation CPGES, TEBP, P23 
PURA  5813 Transcriptional activator 
MRD31, PUR1, PUR-
ALPHA 
PYGO1 26108 
Involved in signal transduction through 
the Wnt pathway. 
 
RAD1 5810 Involved in DNA damage response REC1, HRAD1 
RAD17   5884 
Involved in cell growth, maintenance of 
chromosomal stability, and ATR-
dependent checkpoint activation upon 
DNA damage. RAD24, CCYC, R24L 
RAD18 56852 
Involved in ubiquitination and DNA 
damage repair RNF73 
RAD21 5885 
Involved in cell cycle, DNA repair and 
apoptosis. 
CDLS4, SCC1, MCD, 
NXP1 1 
RAD23B  5887 DNA repair gene P58 
RAD50 10111 
Component of the MRN complex, which 
plays a central role in double-strand 
break (DSB) repair, DNA recombination, 
maintenance of telomere integrity and 
meiosis. NBSLD 
RAD51 5888 
Homologous recombination DNA 
damage response 
RAD51A, RECA, BRCC5, 
FANCR, HsT16930, 
MRMV2 
RAD51AP1 10635 Involved in DNA damage response PIR51 
RAD51B 5890 
Involved in DNA damage repair via 
homologous recombination RAD51L1, REC2 
RAD51C  5889 
Involved in DNA damage repair via 
homologous recombination FANCO, BROVCA3 
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RAD51D 5892 
Involved in DNA damage repair via 
homologous recombination 
RAD51L3, BROVCA4, 
TRAD, R51H3 
RAD52 5893 
Involved in double-stranded break 
repair. 
 
RAD54B 25788 
Involved in DNA repair and mitotic 
recombination. 
RDH54 
RAD54L 8438 
Involved in DNA repair and mitotic 
recombination. 
RAD54A, HR54 
RAD9A 5883 Involved in DNA damage response RAD9 
RAP1A 5906 
Regulates signalling pathways that 
affect cell proliferation and adhesion RAP1 
RAPGEF1 2889 
Involved in signalling cascade that 
induces apoptosis GRF2, C3G 
RASSF1 11186 
Involved in cell cycle and cell death 
pathways 
RDA32,123F2, 
NORE2A, REH3P21 
RB1  5925 
Involved in chromatin regulation, cell 
cycle and is a tumour suppressor gene OSRC 
RBBP4 5928 
Involved in histone acetylation and 
chromatin assembly. Component NuRD RbAp48 
RBBP5 5929 
Involved in regulating gene induction 
and H3 Lys-4 methylation RBQ3, SWD 
RBBP7  5931 
Core histone-binding subunit, NuRD 
complex RbAp46 
RBBP8   5932 DNA damage repair CtIP, SCKL2 
RBL1  5933 
Involved in cell division and 
heterochromatin formation 
 
RBL2 5934 
Involved in cell division and 
heterochromatin formation 
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RDM1  201299 
May confer resistance to the antitumor 
agent cisplatin. Binds to DNA and RNA. RAD52B 
RECQL  5965 DNA helicase RECQ1 
RECQL4 9401 DNA-dependent ATPase 
 
RECQL5  9400 
DNA helicase, role in DNA replication, 
transcription and repair. 
 
RELA 5970 Chromatin remodeller NFKB3 
REV1 51455 
Deoxycytidyl transferase involved in 
DNA repair. REV1L 
REV3L  5980 
Interacts with MAD2L2 to form the 
error prone DNA polymerase zeta 
involved in translesion DNA synthesis. POLZ 
RFC1 5981 
Component of a complex that possesses 
DNA-dependent ATPase activity 
 
RFC2 5982 
Component of a complex that possesses 
DNA-dependent ATPase activity 
 
RFC3 5983 
Component of a complex that possesses 
DNA-dependent ATPase activity 
 
RFC4 5984 
Component of a complex that possesses 
DNA-dependent ATPase activity 
 
RFC5 5985 
Component of a complex that possesses 
DNA-dependent ATPase activity 
 
RIF1 55183 Conserved DNA damage response gene 
 
RARRES3 5920 Tumour suppressor or growth regulator. RIG1, TIG3 
RING1 6015 Involved in chromatin regulation 
 
RMI1 80010 
Involved in the dissolution of double 
Holliday junctions 
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RMI2 116028 Involved in homologous recombination C16orf75 
RNF168 165918 
Involved in ubiquitination and DNA 
damage repair 
 
RNF2 6045 Chromatin modifier 
 
RNF20 56254 Chromatin modifier 
 
RNF4 6047 
Chromatin modifier, regulates 
degradation of PML 
 
RNF40 9810 Chromatin modifier 
 
RNF8 9025 Involved in DNA damage response 
 
RPA1 6117 
Involved in DNA replication and damage 
response 
 
RPA2 6118 
Involved in DNA replication and damage 
response 
 
RPA3 6119 
Involved in DNA replication and damage 
response 
 
RPA4 29935 
Binds ssDNA and probably plays a role 
in DNA repair. 
 
RPAIN 84268 Participates in DNA metabolism RIP, HRIP 
RRP8 23378 Chromatin regulator KIAA0409, NML 
RTEL1 51750 
TP-dependent DNA helicase implicated 
in telomere-length regulation, DNA 
repair and the maintenance of genomic 
stability. 
C20orf41, NHL, 
DKCA4, DKCB5, 
PFBMFT3 
RUVBL1 8607 
DNA-dependent ATPase and DNA 
helicase activities, involved in chromatin 
modification 
TIP49, PONTIN, ECP54, 
TIH1 
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RUVBL2 10856 
DNA-dependent ATPase and DNA 
helicase activities, involved in chromatin 
modification 
TIP48, REPTIN, ECP51, 
TIH2 
SART1 9092 Role in mRNA splicing 
HOMS1, Snu66, 
SNRNP110, Ara1 
SATB1 6304 Chromatin remodeller 
 
SETD7 80854 
Histone methyltransferase that 
specifically monomethylates Lys-4 of 
histone H3 SET9, SET7, KMT7 
SETDB1  9869 
Regulates histone methylation, gene 
silencing, and transcriptional 
repression-trimethylates Lys-9 of 
histone H3 
 
SETMAR  6419 DNA repair METNASE, Mar1 
SFR1 119392 
Required for double-strand break repair 
via homologous recombination C10orf78, MEIR5 
SGO1 151648 
Role in chromosome cohesion during 
mitosis 
SGOL1, CAID, NY-BR-
85, SGO 
SHFM1 7979 Involved in DNA damage response 
SHFD1, DSS1, SHSF1, 
SEM1, ECD 
SHPRH 257218 
E3 ubiquitin-protein ligase involved in 
DNA repair. 
 
SIN3A 25942 Acts as a transcriptional repressor. 
 
SIN3B 23309 
Acts as a transcriptional repressor, 
NuRD associated 
 
SIRT1 23411 
Transcriptional regulator involved in cell 
cycle, response to DNA damage, 
metabolism, apoptosis and autophagy. Sirtuin 1 
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SIRT2 22933 NAD-dependent protein deacetylase SIR2L 
SIRT3 23410 NAD-dependent protein deacetylase 
 
SIRT5 23408 
NAD-dependent lysine demalonylase, 
desuccinylase and deglutarylase 
 
SIRT6 51548 NAD-dependent protein deacetylase. 
 
SIRT7 51547 
AD-dependent protein deacetylase that 
specifically mediates deacetylation of 
histone H3 at Lys-18 
 
SLX1A  548593 Involved in DNA damage repair GIYD1 
SLX1B  79008 Involved in DNA damage repair GIYD2 
SLX4 84464 
Structure-specific endonuclease 
subunit. 
MUS312, FANCP, 
BTBD12 
SMAD3 4088 Transcription factor 
 
SMARCA1 6594 Involved in chromatin remodelling. 
SNF2L1, SNF2L, SNF2-
Like 1 
SMARCA2 6595 
SWI/SNF complex, transcription 
activator 
SNF2L2, SNF2-Alpha, 
BAF190B 
SMARCA4 6597 
SWI/SNF complex, transcription 
activator 
 
SMARCAD1 56916 SNF protein, required for DNA repair 
and heterochromatin organization. 
HEL1, ETL1, ADERM, 
ATP-Dependent 
Helicase 1 
SMARCB1 6598 
SWI/SNF complex, chromatin 
remodeller 
SNF5L1, INI1, SNF5, 
HSNF5, BAF47 
SMARCC1 6599 
Involved in chromatin remodelling. 
CRACC1, BAF155, 
SWI3 
SMARCC2 6601 Involved in chromatin remodelling. CRACC2, BAF170 
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SMARCD1 6602 Involved in chromatin remodelling. CRACD1, BAF60A 
SMARCD2 6603 Involved in chromatin remodelling. CRACD2, BAF60B 
SMARCD3 6604 Involved in chromatin remodelling. CRACD3, BAF60C 
SMC1A 8243 
Involved in chromosome cohesion 
during cell cycle and in DNA repair. 
SMC1L1, CDLS2, 
DXS423E 
SMC2 10592 
Cell cycle, DNA replication and DNA 
repair SMC2L1, CAP-E 
SMC3 9126 
Cell cycle, DNA replication and DNA 
repair CSPG6 
SMC4 10051 
Cell cycle, DNA replication and DNA 
repair SMC4L1, CAP-C 
SMC5 23137 
Involved in DNA double-strand breaks 
by homologous recombination. SMC5L1 
SMC6 79677 
Involved in DNA double-strand breaks 
by homologous recombination. SMC6L1 
SMG1 23049 
RNA degradation and DNA damage 
response 
 
SMG5 23381 
Involved in nonsense-mediated mRNA 
decay, telomerase associated protein Est1p-Like Protein B 
SMG6 23293 
Involved in nonsense-mediated mRNA 
decay 
C17orf31, EST1-Like 
Protein A 
SMG7 9887 
Plays a role in nonsense-mediated 
mRNA decay. 
C1orf16, EST1-Like 
Protein C 
SMUG1 23583 DNA repair gene FDG 
SMYD2 56950 
Methylates both histones and non-
histone proteins, including p53/TP53 
and RB1. 
KMT3C, ZMYND14, 
HSKM-B 
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SP1 6667 
Chromatin regulator, DNA damage 
response 
 
SP100 6672 Component of PML body 
 
SP110 3431 Transcription factor IFI41, IFI75, VODI 
SPO11 23626 
Required for meiotic recombination 
SPATA43, TOPVIA, 
CT35 
SPRTN 83932 
DNA repair 
c1orf124, PRO4323, 
DVC1 
SRCAP 10847 Chromatin regulator 
 
SSB 6741 Involved in RNA metabolism LARP3 
SSBP1 6742 
involved in mitochondrial DNA 
replication, binds ssDNA SSBP, SOSS-B1, MtSSB 
SSRP1 6749 Chromatin remodeller 
FACT, T160, SSRP1, 
T160 
SSU72 29101 Role in RNA processing and termination. HSPC182, PNAS-120 
STAG1 10274 DNA replication SCC3A, SA1 
STAG2 10735 
Chromatin Modifier/epigenetic 
remodeller SCC3B, SA2 
STRA13 201254 
Involved in DNA damage repair and 
genome maintenance. CENPX, MHF2, MHF2 
SUN1 23353 
Involved in telomere attachment to 
nuclear envelope and gametogenesis. UNC84A, KIAA0810 
SUPT16H 11198 Chromatin remodeller 
CDC68, SPT16, SPT16, 
FACTP140 
SUPT5H 6829 
Involved in mRNA processing and 
transcription elongation SPT5H 
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SUV39H1 6839 Chromatin remodeller 
SUV39H, HTDG, 
KMT1A, MG44, 
Histone H3-K9 
Methyltransferase 1 
SUV39H2 79723 Chromatin remodeller 
KMT1B, Histone H3-K9 
Methyltransferase 2 
SUZ12 23512 Chromatin remodeller CHET9, JJAZ1 
SWI5 375757 Involved in homologous recombination C9orf119, SAE3 
SYMPK 8189 
Involved in histone mRNA 3-end 
processing. SYM, SPK 
TAF1  6872 Transcription and phosphorylation 
DYT3, CCGS, CCG1, 
BA2R, TAF2A 
TBK1 29110 Ubiquitination NAK, T2K 
TBP 6908 Transcription TF2D, GTF2D, SCA17 
TCEA1 6917 
Assembly of RNA Polymerase-II 
Initiation Complex TFIIS, GTF2S 
TCEB3 6924 Transcription TCEB3A 
TDG 6996 Chromatin Structure and Modification 
 
TDP1 55775 DNA repair gene 
 
TDRD1 56165 piRNA metabolic process 
 
TDRD10 126668 
Nucleic acid binding and nucleotide 
binding. 
 
TDRD12  91646 ATP-dependent RNA helicase activity. ECAT8 
TDRD3 81550 
poly(A) RNA binding and chromatin 
binding. 
 
TDRD5 163589 Involved in DNA integrity TUDOR3 
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TDRD6 221400 
Involved in proper precursor and 
mature miRNA expression 
SPATA36, TDR2, 
BA446F17.4 
TDRD7 23424 Post-transcriptional regulation CATC4, TRAP 
TDRD9 122402 
Nucleic acid binding and helicase 
activity. C14orf75, NET54 
TDRKH 11022 Nucleic acid binding and RNA binding. TDRD2 
TELO2 9894 Regulator of the DNA damage response TEL2, CLK2, HCLK2 
TEP1 7011 Telomerase TP1, TLP1, P240 
TERC 7012 Telomerase TRC3, DKCA1, TR 
TERF1 7013 Shelterin complex TRF1, TRBF1, PIN2 
TERF2 7014 Shelterin complex TRF2, TRBF2 
TERF2IP 54386 
Shelterin complex and as a transcription 
regulator. 
RAP1, TERF2 
Interacting Protein 
TERT 7015 Telomerase 
TCS1, EST2, TP2, 
DKCA2, TRT 
TET1 80312 
Chromatin Modifier/epigenetic 
remodeller, DNA demethylation CXXC6 
TET2 54790 
Chromatin Modifier/epigenetic 
remodeller, DNA demethylation KIAA1546 
TFAM 
7019 
Mitochondrial transcription regulation, 
replication and repair. TCF6, TCF6L2 
TGFB1 7040 
Controls proliferation, differentiation, 
adhesion, migration and other functions TGFB, DPD1 
TIAL1 7073 
RNA binding protein involved in 
translational control, splicing and 
apoptosis. TIAR, TCBP 
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TICAM1 148022 
Protein kinase binding and signal 
transducer activity. TRIF 
TINF2 26277 Shelterin complex 
TIN2, DKCA3, TERF1 
(TRF1)-Interacting 
Nuclear Factor 2 
TMEM173 340061 
Sensor of cytosolic DNA from bacteria 
and viruses 
STING, ERIS, HMITA, 
MITA, SAVI, NET23 
TMEM201 199953 Mitosis SAMP1, NET5 
TMPO 7112 
Nuclear organisation and DNA 
replication LAP2 
TNKS  8658 
Wnt signalling pathway, telomerase and 
vesicle trafficking. TIN1, TANK1, PARP5A 
TNKS2 80351 
Wnt signalling pathway, telomerase and 
vesicle trafficking. 
TNKS-2, TANK2, 
PARP5B 
TOP1 7150 Involved in DNA transcription TOPI 
TOP2A 7153 
Involved in DNA replication and 
transcription TOP2 
TOP2B 7155 
Involved in DNA replication and 
transcription Topo II Beta 
TOP3A 7156 Involved in DNA replication Topo III-Alpha 
TOP3B 8940 
Involved in DNA replication and 
transcription TOP3B1 
TOPBP1 11073 Conserved DNA damage response gene TOP2BP1 
TP53 7157 
Conserved DNA damage response gene, 
induces growth arrest or apoptosis 
 
TP53BP1  7158 Conserved DNA damage response gene 53BP1 
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TP53I13 90313 Tumour suppressor 
TP53 INDUCED 
PROTEIN 13 
TP53I3 9540 Member of TP53 signalling pathway 
TP53 INDUCED 
PROTEIN 
TREX1 11277 Editing and processing nucleases DNase III 
TREX2 11219 Editing and processing nucleases 
 
TRIM28 10155 
Chromatin Modifier/epigenetic 
remodeller RNF96, KAP1, TIF1B 
TRIM32 22954 E3 ubiquitin ligase activity. HT2A, LGMD2H 
TRIM33 51592 E3 ubiquitin-protein ligase. TIF1G, RFG7 
TRIM56  81844 
poly(A) RNA binding and ubiquitin-
protein transferase activity. RNF109 
TRIP13 9319 
Chromatin Modifier/epigenetic 
remodeller 
 
TRRAP 8295 
Chromatin Modifier/epigenetic 
remodeller TRA1, STAF40, PAF400 
TTI1 9675 Regulator of the DNA damage response. 
SMG10, KIAA0406, 
TELO2 Interacting 
Protein 1 
TTI2 80185 Regulator of the DNA damage response. 
C8orf41, MRT39, 
TELO2 Interacting 
Protein 2 
TUBA1B 10376 Chromatin, cell cycle, apoptosis Tubulin 
TYMP 1890 
Chromatin Modifier/epigenetic 
remodeller 
 
UBA52 7311 
Ubiquitin gene, Ubiquitin A-52 Residue 
Ribosomal Protein Fusion Product 1 RPL40 
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UBB 7314 Ubiquitin gene, ubiquitin B HEL-S-50 
UBC 7316 Ubiquitin gene, ubiquitin C HMG20 
UBE2A 7319 Ubiquitination and modification RAD6A 
UBE2B 7320 Ubiquitination and modification RAD6B 
UBE2N  7334 Ubiquitination and modification UBC13 
UBE2T 29089 
DNA damage repair and Fanconi 
anaemia FANCT 
UBE2V2 7336 Ubiquitination and modification MMS2 
UBR5 51366 Transcriptional regulation 
 
UHRF1 29128 
Chromatin Modifier/epigenetic 
remodeller 
 
UIMC1 51720 DNA repair 
RAP80, X2HRIP110, 
RXRIP110 
UPF1 5976 
RNA-dependent helicase, involved in 
decay of mRNA containing premature 
stop codons RENT1, NORF1 
USP1 7398 
Negative regulator of DNA damage 
repair HUBP 
VCP 7415 
Related to cell cycle and DNA damage 
repair 
 
WDR48 57599 
Regulator of deubiquitinating 
complexes. UAF1, P80 
WDR77 79084 
Chromatin Modifier/epigenetic 
remodeller MEP50, P44 
WEE1 7465 Cell cycle 
 
WRAP53 55135 Telomerase and Cajal bodies TCAB1, DKCB3 
WRN 7486 DNA helicase RECQL2, RECQ3 
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WRNIP1 56897 DNA synthesis 
 
XAB2 56949 DNA repair gene HCNP, SYF1 
XPA 7507 DNA repair gene XP1, XPAC 
XPC 7508 
DNA repair gene 
XPCC, P125, RAD4, 
XP3 
XRCC1 7515 DNA repair gene RCC 
XRCC2 7516 Homologous recombination RAD51-Like 
XRCC3 7517 Homologous recombination RAD51-Like, CMM6 
XRCC4 7518 DNA repair gene 
 
XRCC5 7520 DNA repair gene 
KU80, KUB2, Ku86, 
NFIV, KARP1 
XRCC6  2547 
Single-stranded DNA-dependent ATP-
dependent helicase, involved in DNA 
non-homologous end joining. G22P1, KU70 
XRCC6P2 389901 DNA repair gene 
 
ZBTB32 27033 
Transcription regulation and DNA 
binding (involved in Fanconi anaemia) ZNF538 
ZBTB44 29068 Transcription regulation ZNF851 
ZBTB48 3104 
Nucleic acid binding and transcription 
factor activity HKR3, ZNF855, TZAP 
ZCCHC7 84186 RNA degradation 
 
ZMYM2 7750 Transcription factor ZNF198 
ZNHIT4 83444 
Involved in transcriptional regulation, 
DNA replication and probably DNA 
repair. 
INO80B 
ZSWIM7 125150 Involved in homologous recombination SWS1 
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Table A2.6. Genetic events identified by whole genome sequencing.  
Sample 
ID 
Gene 
Symbol C
h
ro
m
o
so
m
e
 
Variation 
Type 
Gene 
Region Start site End site 
Refer-
ence 
Allele 
Alter-
native 
Allele 
Allelic 
Fracti-
on 
Protein 
Variant 
LA-N-6 AIM2 1 SNV:DEL Exon 
chr1: 
159032486 
chr1: 
159032486   65.38  
CHLA-90 ATRX X SV:DEL  
chrx: 
76935119 
chrx: 
76959029     
PARKNP ATRX X SV:DEL  
chrx: 
76924445 
chrx: 
77028694     
PAISZV ATRX X SV:DEL  
chrx: 
76937155 
chrx: 
76983145     
PAPTAN BARD1 2 SNV:DEL Exon 
chr2: 
215645502 
chr2: 
215645522   42.86  
PARXFT BARD1 2 SNV:DEL Exon 
chr2: 
215645502 
chr2: 
215645522   45.45  
PARGIW BRIP1 17 SV:TRA Intron 
chr17: 
59796638 
chr2: 
14401098     
SK-N-BE2c CARM1 19 SNV Exon 
chr19: 
11031414 
chr19: 
11031414 C A 46.67 P472T 
PAIFXV CCNT1 12 SV:DEL  
chr2: 
25957192 
chr12: 
104379378     
SH-SY5Y CHEK2 22 SNV:DEL Exon 
chr22: 
29091856 
chr22: 
29091856   75  
CHLA-90 CREBBP 16 SV:DUP Intron 
chr16: 
3885945 
chr16: 
3919341     
COG-N-291 DDX60 7 SV:TRA Intron 
chr7: 
116809191      
COG-N-291 E2F2 1 SV:DEL  
chr1: 
3801505 
chr1: 
30723742     
LA-N-6 EME2 16 SNV:DEL Exon 
chr16: 
1823389 
chr16: 
1823389   43.48  
PAPTAN FOXP1 3 SNV 
Intron/bas
e before 
exon 
chr3: 
71408396 
chr3: 
71408396 C T 46.67  
COG-N-291 GEN1 2 SV:DEL  
chr2: 
1485200 
chr2: 
27254414     
PARGIW HIST1H1B 6 SNV:DEL Exon 
chr6: 
27834678 
chr6: 
27834692   38.46  
PAISZV HIST2H2BC 1 SV:DEL  
chr1: 
110246334 
chr1: 
181216287     
COG-N-291 HLTF 3 SNV Exon 
chr3: 
148789089 
chr3: 
148789089 C A 61.54 D282Y 
PARXFT IDH1 2 SNV:DEL Promoter 
chr2: 
209120302 
chr2: 
209120302   35  
PARGIW INO80C 18 SNV:DEL 
Promoter; 
5'UTR 
chr18: 
33077852 
chr18: 
33077859   55.56  
PARXFT KDM6B 17 SNV:DEL Exon 
chr17: 
7751858 
chr17: 
7751863   54.55  
SH-SY5Y KRAS 12 SNV Exon 
chr12: 
25398284 
chr12: 
25398284 C A 45.45 G12V 
COG-N-291 MCM4 8 SNV Exon 
chr8: 
48875559 
chr8: 
48875559 T G 45.83 F218V 
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CHW_11 MCM6 2 SNV Exon 
chr2: 
136624255 
chr2: 
136624255 A T 52 I220N 
SH-SY5Y MRE11A 11 SNV Exon 
chr11: 
94226952 
chr11: 
94226952 C G 56.25  
PARKNP MSH2 2 SNV:DEL Exon 
chr2: 
47693814 
chr2: 
47693815   69.23  
SK-N-FI NCL 2 SNV:DEL Exon 
chr2: 
232325414 
chr2: 
232325416   57.89  
COG-N-291 NCL 2 SNV:DEL Exon 
chr2: 
232325414 
chr2: 
232325414   48.15  
PAIFXV NCL 2 SNV:DEL Exon 
chr2: 
232325414 
chr2: 
232325414   100  
PAIFXV NCL 2 SNV:DEL Exon 
chr2: 
232326655 
chr2: 
232326655   39.47  
PAIFXV NCOA3 20 SNV:DEL Exon 
chr20: 
46279814 
chr20: 
46279822   44.44  
PARGIW NCOA3 20 SNV:DEL Exon 
chr20: 
46279863 
chr20: 
46279865   100  
PAISZV NCOR1 17 SV:DEL  
chr17: 
16095144 
chr17: 
16095626     
PAPTAN NCOR2 12 SNV:DEL Exon 
chr12: 
124887058 
chr12: 
124887069   63.64  
PAPFSL NSMCE2 8 SNV:DEL Exon 
chr8: 
126114595 
chr8: 
126114595   66.67  
LA-N-6 POLM 7 SV:DEL  
chr7: 
31199193 
chr7: 
64005420     
PAIFXV POLQ 3 SNV:DEL Exon 
chr3: 
121208703 
chr3: 
121208705   50  
PAIFXV POLR2A 17 SNV Exon 
chr17: 
7405325 
chr17: 
7405325 G A 22.22 S819N 
SK-N-FI PPP2R2A 8 SNV:DEL Intron 
chr8: 
26150637 
chr8: 
26150637   60  
SK-N-FI PRDM2 1 SNV:DEL Intron 
chr1: 
14074949 
chr1: 
14074950   57.14  
SK-N-BE2c PRMT2 21 SNV Intron 
chr21: 
48056789 
chr21: 
48056789 C A 40  
SK-N-BE2c PRMT5 14 SNV Intron 
chr14: 
23393931 
chr14: 
23393931 G T 14.81  
PARKNP RAD17 5 SNV:DEL Intron 
chr5: 
68667048 
chr5: 
68667050   46.67  
PAPFSL RAD23B 9 SNV:DEL Intron 
chr9: 
110046745 
chr9: 
110046747   60  
SH-SY5Y RAD23B 9 SNV:DEL Intron 
chr9: 
110046745 
chr9: 
110046747   100  
SH-SY5Y RAD51B 14 SV:INV Intron 
chr14: 
68907987 
chr14: 
69297996     
PARGIW RB1 13 SNV:DEL Exon 
chr13: 
48878084 
chr13: 
48878092   40  
PARGIW RBBP8 18 SNV:DEL Intron 
chr18: 
20513542 
chr18: 
20513549   64.71  
PARGIW RBL1 20 SV:TRA Intron 
chr20: 
35627929      
PAPFSL RECQL4 8 SNV Exon 
chr8: 
145738660 
chr8: 
145738660 C T 30.77 V802M 
SH-SY5Y RECQL5 17 SNV Exon chr17: chr17: G A 80 R175C 
251 
 
73658807 73658807 
PARGIW RIF1 2 SNV:DEL Exon 
chr2: 
152320880 
chr8: 
152320882   23.08  
PAISZV SETDB1 1 SNV Exon 
chr1: 
150934631 
chr1: 
150934631 C A 29.03 S1052* 
PAPTAN SMAD3 15 SV:DEL Intron 
chr15: 
67404674 
chr15: 
67405604     
PARKNP SMARCA2 9 SV:DEL Intron 
chr9: 
2147643 
chr9: 
2151529     
SH-SY5Y SMARCA4 19 SNV Exon 
chr19: 
11134251 
chr19: 
11134251 C T 44.44 R973W 
SK-N-FI SMARCA4 19 SNV Exon 
chr19: 
11170813 
chr19: 
11170813 C T 100 
R1587*; 
R1590*; 
R1653*; 
R1621*; 
R1588*; 
R1591* 
SH-SY5Y SMC3 10 SNV:DEL 
Splice Site; 
Intron 
chr10: 
112360304 
chr10: 
112360305   60  
SK-N-BE2c SMG1 16 SNV Exon 
chr16: 
18827823 
chr16: 
18827823 C A 36.36 S3368I 
LA-N-6 SP1 12 SNV Exon 
chr12: 
53777044 
chr12: 
53777044 T C 46.15 
L431P; 
L438P; 
L390P 
SK-N-BE2c SRCAP 19 SV:TRA Intron 
chr19: 
2599286      
CHLA-90 STAG1 3 SV:DEL  
chr3: 
135906165 
chr3: 
136313178     
COG-N-291 TCEB3 1 SV:DEL  
chr1: 
30723742      
PARKNP TDRD12 19 SNV Exon 
chr19: 
33222697 
chr19: 
33222697 G A 45.83 D31N 
SH-SY5Y TERT 5 SNV Promoter 
chr5: 
1295228 
chr5: 
1295228 G A 60  
PAPTAN TMEM201 1 SNV Exon 
chr1: 
9671877 
chr1: 
9671877 C G 80 S611C 
CHLA-90 TP53 17 SNV Exon 
chr17: 
7577082 
chr17: 
7577082 C T 100 
E127K; 
E247K; 
E154K; 
E286K 
SK-N-FI TP53 17 SNV Exon 
chr17: 
7577544 
chr17: 
7577544 A C 100 
M246R; 
M114R; 
M207R; 
M87R 
SK-N-BE2c TP53 17 SNV Exon 
chr17: 
7578526 
chr17: 
7578526 C A 100 
C96F; 
C3F; 
C135F 
CHLA-90 TP53 17 SNV:DEL Intron 
chr17: 
7588679 
chr17: 
7588679   100  
SH-SY5Y TRRAP 7 SNV Exon 
chr7: 
98581778 
chr7: 
98581778 G T 28.57 
G3004W; 
G3033W 
SH-SY5Y TTI2 8 SNV Exon 
chr8: 
33364825 
chr8: 
33364825 C A 52.63 L283F 
PAPTAN UIMC1 5 SV:TRA Intron 
chr5: 
176387600      
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SK-N-BE2c VCP 9 SNV Exon 
chr9: 
35064279 
chr9: 
35064279 C A 37.5 E194* 
PAPFSL WRNIP1 6 SNV:DEL Exon 
chr6: 
2766363 
chr6: 
2766374   37.5  
CHW_11 ZMYM2 13 SNV Exon 
chr13: 
20580560 
chr13: 
20580560 G T 32 S449I 
SNV, single nucleotide variation; SNV:DEL, deletion of 1-20 bp; SV:DEL, structural variation: deletion; 
SV:TRA, structural variation: translocation; SV:INV, structural variation: inversion. 
 
 
 
 
